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ABSTRACT 
 
Gene regulatory networks control gene expression levels, and therefore play an essential role 
in mammalian development and function. Regulation of gene expression is the result of a complex 
interplay between DNA regulatory elements and their binding partners, known as transcription factors 
(TFs). Due to their vital role in development, intercellular signalling, cell cycle and disease 
development, elucidating the mechanisms by which TFs regulate gene expression is of crucial 
importance in the vast majority of biological processes. In particular, understanding how each TF 
contributes to the expression output of its respective target gene in space and time will help to 
elucidate how gene regulatory networks (GRNs) behave under different physiological or pathological 
conditions. Although extensive work has been accomplished in characterizing the key TFs involved in 
many biological processes, almost no quantitative information is currently available in the literature. 
To get a deep insight into the complex mechanisms underlying the regulation of gene expression, we 
need to acquire quantitative information, since TF abundance within the cell can be linked to their 
transcriptional capabilities. Such information would be of utmost importance to build accurate in silico 
quantitative DNA binding models that could predict and explain the particular properties of gene 
regulatory mechanisms. The quantification of TFs is a difficult task due their natural low abundance in 
cells, and their reliable detection is therefore very much dependent on the overall sensitivity of  current 
technologies. In recent years, a new MS-based technology termed selected reaction monitoring (SRM) 
has gained popularity due to the targeted nature of its approach that allows the detection and 
quantification of proteins in complex samples with an exceptional sensitivity and specificity.  I will 
show in this thesis, this approach is particularly well suited for targeting low abundant proteins such as 
TFs, which are otherwise difficult to identify with conventional shotgun proteomics experiments.  
Consequently, the main focus of my thesis research project entailed the development of an 
SRM-based platform aimed at quantifying TFs in absolute amounts based on in vitro protein 
expression during the terminal stage of adipogenesis, using the pre-adipocyte 3T3-L1 cell line. 
Interestingly, our initial efforts led to the creation of an atlas of TF-specific peptide data, which could 
be readily used for the design of quantitative assays. In the first phase, abundance measurements in 
terms of copies per cell were derived at precise differentiation time-points for two major adipogenic 
players, PPARγ and RXRα. In the second phase, we expanded the number of adipogenic TFs that can 
be monitored in one assay, allowing for the quantification of up to 10 TFs in one single, integrated 
SRM run. Such upscale increases the practical usefulness of the methodology while reducing the 
associated costs, and ultimately allows for non-negligible time-savings. The availability of absolute 
protein copy number data permitted us ultimately to examine the relationship between the number of 
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genome-wide DNA binding events and TF molecules. We derived a quantitative DNA binding model 
that allowed the prediction of the number of PPARγ ChIP-seq binding events given its nuclear 
abundance, chromatin state, and DNA binding energetics. As such, we were able to explain the 
paradoxical observation of a significant increase in PPARγ binding sites despite a saturation in the 
number of PPARγ molecules. We thus demonstrate how TF abundance data can be modeled in 
conjunction with large-scale DNA occupancy and chromatin state data to further our understanding of 
gene regulatory mechanisms mediating cellular differentiation.  
We are now starting to build on our pioneering work to quantify in absolute terms key players 
of the entire, core adipogenic GRN, as such aiming to provide a quantitative explanation of the 
regulatory mechanisms at play during the terminal phase of adipocyte differentiation. Moreover, to 
increase the explicative power of our methodology and to alleviate the throughput limitation that 
comes with obtaining absolute protein measurements, we decided to perform copy-number estimates 
for a larger set of adipogenic TFs utilizing a modified version of our original approach. At the cost of a 
modest loss of accuracy, we are now aiming to develop a sensitive and robust methodology that will 
allow the quantification of entire GRNs at low cost and in a time-effective manner. This is consistent 
with the overall goal in life sciences or clinical research to improve our ability to accurately and 
reproducibly quantify entire pathways or biological networks to improve our systems understanding of 
biological processes. 
 
 
 
 
 
 
 
 
 
Keywords:  
Mass spectrometry, proteomics, selected reaction monitoring, multiple reaction monitoring, 
multiplexing, absolute quantification, quantitative proteomics, protein copy number, systems biology, 
transcription factor, regulation of gene expression, gene regulatory networks, adipogenesis, terminal 
differentiation, quantitative modeling, binding events.  
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RÉSUMÉ 
 
Les réseaux de régulation de gènes contrôlent l'expression des gènes, et donc jouer un rôle essentiel 
dans le développement des mammifères et dans leur fonctionnement. La régulation de l'expression des 
gènes est le résultat d'une interaction complexe entre les éléments régulateurs de l’ADN et leurs 
partenaires de liaison, qui sont connues sous le nom de facteurs de transcription (FT). En raison de 
leur rôle vital dans le développement, dans la signalisation intercellulaire, dans le cycle cellulaire et 
dans le développement des maladies, l'élucidation des mécanismes par lesquels les FTs régulent 
l'expression génique est d'une importance cruciale dans la grande majorité des processus biologiques. 
En particulier, comprendre comment chaque FTs contribue à l’expression de son gène cible 
respectivement dans l'espace et dans le temps nous aiderait à mieux comprendre comment les réseaux 
de régulation des gènes (GRNs) se comportent dans différentes conditions physiologiques ou 
pathologiques. Bien que d'importants travaux aient été réalisés dans la caractérisation des facteurs de 
transcription impliqués dans de nombreux processus biologiques, presque aucune information 
quantitative n’est actuellement disponible. Pour obtenir un aperçu des mécanismes complexes qui 
sous-tendent la régulation de l'expression des gènes, nous avons besoin d'acquérir des informations 
quantitatives, car l'abondance des FTs dans la cellule est liée à leurs capacités de transcription. Une 
telle information serait d'une importance capitale pour construire des modèles quantitatifs qui 
pourraient prédire et expliquer les propriétés particulières des mécanismes de régulation des gènes. La 
quantification des FTs est une tâche difficile en raison de leur faible abondance naturelle dans les 
cellules, et leur détection est donc dépendante de la sensibilité globale des technologies actuelles. Ces 
dernières années, une nouvelle technologie basée sur la spectrométrie de masse appelée Selected 
reaction monitoring (SRM) a gagné en popularité en raison de la nature ciblée de son approche qui 
permet la détection et la quantification des protéines dans des échantillons complexes avec une 
sensibilité et une spécificité exceptionnelle. Dans cette thèse, je montre que cette approche est 
particulièrement bien adaptée pour cibler des protéines de faible abondance comme les FTs, qui sont 
autrement difficiles à identifier par la voie classique de la protéomique shotgun. 
Par conséquent, l'objectif principal de mon projet de recherche de doctorat concernait le 
développement d'une plate-forme SRM visant à quantifier les FTs de façon absolue en se basant sur 
l'expression de protéines in vitro dans la phase terminale de l'adipogenèse, en utilisant la lignée 
cellulaire de pré-adipocytes 3T3-L1. Il est intéressant de noter que nos efforts initiaux nous ont a 
conduit à la création d'un atlas de données peptidiques FT-spécifiques, qui pourraient être facilement 
utilisés pour la conception d’autre tests quantitatifs. Dans la première phase, les mesures d'abondance 
en termes de copies par cellule ont été dérivées à des temps de différentiation précis pour deux 
régulateurs principaux de l’adipognèse, PPARγ et RXRα. Dans la deuxième phase, nous avons élargi 
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le nombre de FTs adipogéniques, permettant la quantification jusqu'à 10 FTs dans une seule analyse 
SRM intégrée. Cet incrément augmente l'utilité pratique de la méthodologie, tout en réduisant les coûts 
associés, et permet en fin de compte un gain de temps. La disponibilité de données absolues de 
protéines en termes de nombre de copies par cellule nous a permis finalement d’examiner la relation 
entre le nombre de liaison FT-ADN dans le génome entier et le nombre de molécules FT. Nous avons 
établi un modèle de liaison FT-ADN quantitative permettant la prédiction du nombre de liaison de 
PPARγ (par ChIP-seq) en prenant compte de son abondance nucléaire, l'état de la chromatine, et le 
bilan énergétique de liaison à l'ADN. En tant que tel, nous étions en mesure d'expliquer l'observation 
paradoxale d'une augmentation significative dans les sites de liaison PPARγ en dépit d'une saturation 
du nombre de molécules PPARγ. Nous avons donc montré comment les données sur l’abondance des 
FTs peut être modélisé, en collaboration avec l’information sur l'occupation de l'ADN à grande échelle 
et les données sur l’état de la chromatine, afin de faire progresser notre compréhension des 
mécanismes de régulation des gènes qui contrôlent la différenciation cellulaire.  
Nous allons appliquer notre technique pour la quantification en termes absolus des principaux 
acteurs impliqués dans le réseau des gènes adipogénique. Nous visons à fournir une explication 
quantitative des mécanismes de régulation en jeu au cours de la phase terminale de la différenciation 
adipocytaire. Par ailleurs, pour augmenter la puissance explicative de notre méthodologie et pour 
atténuer la limitation de débit et de l'obtention de mesures absolues, nous avons décidé d'effectuer des 
estimations par rapport au nombre de copies par cellule pour un ensemble plus vaste de FTs 
adipogéniques en utilisant une version modifiée de notre approche originale. Au prix d'une perte 
modeste de précision, nous visons maintenant à élaborer une méthodologie sensible et robuste qui 
permettra la quantification de GRN entières à faible coût et de manière efficace. Ceci est cohérent avec 
l'objectif global, en sciences de la vie ou dans la recherche clinique, d’améliorer notre capacité à 
quantifier de façon précise et reproductible des voies de signalisation ou des réseaux biologiques afin 
d'améliorer notre compréhension des systèmes biologiques. 
 
 
 
 
Mots-clés: 
Spectrométrie de masse, protéomique, selected reaction monitoring, multiple reaction monitoring, 
multiplexage, quantification absolue, protéomique quantitative, copies des protéines par cellule, 
biologie des systèmes, facteurs de transcription, régulation de l'expression des gènes, réseaux de 
régulation des gènes, adipogenèse, différenciation terminale, modélisation quantitative, événements de 
liaison de l’ADN . 
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LIST OF ACRONYMS  
 
ChIP: chromatin immuno-precipitation 
ChIP-seq: chromatin immuno-precipitation sequencing 
CV: Coefficient of variation  
GNR: gene regulatory network 
LC: liquid chromatography 
LLOD: lower limit of detection 
NE: nuclear extract 
MS: mass spectrometry 
ORF: open reading frame 
SD: standard deviation 
SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SME: standard error of the mean 
SRM: selected reaction monitoring  
SAX: strong anion exchange 
SCX: strong cation exchange 
TF: transcription factor 
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I.I.  DISSECTING GENE REGULATORY MECHANISMS 
 
Understanding how the expression of large sets of genes is orchestrated at the systems-level is 
a topic of fundamental importance in Systems biology. Its ultimate goal is to integrate different levels 
of information to obtain a global view of how complex biological systems function. In this regard, the 
vast majority of biological processes, from homoeostasis maintenance to development, from cell cycle 
to cell differentiation are tuned by differential gene expression. The latter is under the control of gene 
regulatory networks (GRNs), which consist of physical and functional interactions between DNA-
binding regulatory proteins, transcription factors (TFs), and regulatory elements of their target genes 
(i.e. promoters, enhancers). The key function of these networks is to coordinate the progression of 
distinct transcription regulatory states both in space and time, a sine qua non condition for cell 
survival. Unfortunately, most models of GRNs are incomplete and their players far from being 
completely characterized. In essence, regulation of gene expression, therefore of the proteins that 
genes encode, can be seen as a multi-layered process involving several steps and a vast number of 
participants. The final outcome is the result of the combined effects of the multiple events affecting a 
particular gene, from the early stages of transcription all the way to the modification that may occur on 
the protein once the transcript has been translated. At the transcriptional level, understanding how each 
TF contributes to the expression output of its respective target gene in space and time will help us to 
understand how gene regulatory networks behave.   
Although qualitative information explaining TF interactions and behavior is widely available 
in the literature
1-3
, reliable quantitative proteomic measurements are hardly available. This disparity is 
explained by TF natural low abundance in cells, which make quantitative analyses a substantial 
challenge considering the current state of proteomics technologies. Reliable quantitative data would be 
extremely useful for in silico modelling for computational biologists. In the last decade, quantitative 
models have been generated aiming to predict gene expression levels using as inputs selected TFs, 
whose abundance and hence activity was inferred from mRNA levels. However, the reliability of 
mRNA-protein activity correlations appears to be inadequate, limiting the predictive power of the 
respective models
4-6
. Thus, absolute TF levels need to be experimentally measured to determine how 
much of a binding site will be occupied by a TF in order to assess its regulatory input. Moreover, the 
pivotal role that TFs play in dictating normal development and proper functioning of the organism 
animates an increasing interest for this particular family of proteins to become potential 
pharmaceutical targets in the therapeutics of various diseases, including cancer
7-9
. Transcription-based 
drugs represent a significant percentage of the drugs currently present in the market 
10
. Hence, accurate 
quantitative TF data is of critical importance to effectively understand the role and behaviour of TFs as 
regulatory proteins also from a medical perspective. Aberrations in the fine-tuning mechanisms of 
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regulation could be related to disease processes. This in turn could help in the design of more effective 
medicaments. 
Various techniques are available for the quantification of proteins nowadays, the majority of 
which rely on the use of antibodies (e.g. ELISA, protein microarrays). Quantitative immunoassays are 
widely used because of their accuracy and the fact that they can be implemented even in small 
laboratories due to their low cost and simplicity. Nevertheless, these techniques suffer from a certain 
number of drawbacks, non-linearity in quantitation and formation of unspecific reactions to name a 
few. Moreover, quantitation of different proteins normally necessitates separate experiments, not to 
mention that only a limited number of TF-specific antibodies are commercially available, limiting 
thereby the applicability of these methodologies to small scale studies of several TFs at the time. In 
this regard, there is a strong need for a robust methodology that could bypass such limitations, 
possibly pushing the current limits in terms of sensitivity and specificity even farther. Until recently, 
mass spectrometry-based methodologies simply lacked the necessary sensitivity to be used for the 
identification of low abundant proteins.  
 
I.II THE ADIPOGENIC MODEL 
 
The terminal adipocyte differentiation is the last phase of adipogenesis, during which pre-
adipocytes develop into mature adipocytes through a cascade of gene expression events. It is a natural 
process, consequence of normal cell turnover on one hand, as well as a necessity for fat mass storage 
in case of excessive weight gain. The study of adipogenesis has a clear medical relevance: excess fat 
mass, characterized by an increase in cell size and number, dramatically increases the risk of 
developing series of pathologies, including metabolic syndrome symptoms and cancer
11
. Several 
studies have established a basic framework of the GRN orchestrating the terminal phase of 
adipogenesis
12, 13
. Although substantial effort has been devoted to identify TFs and co-TFs involved in 
adipogenesis
14, 15
, almost no information is available on adipogenic TF levels in the nucleus or in the 
cytoplasm. In this regard, understanding adipogenic TF contribution to target gene expression output 
during adipocyte differentiation may give further insight on how the adipogenic regulatory network 
behaves under different physiological or pathological conditions, opening possibly new venues for 
disease diagnostic and cure. The murine embryonic 3T3-L1 preadipocyte cell line recapitulates most 
of the aspects of terminal adipocyte differentiation observable in vivo
16
. Their homogeneity, 
synchronous development, as well as their availability makes this cell line the perfect model candidate 
for the study of adipogenesis. 
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I.III STATE OF THE ART QUANTITATIVE PROTEOMICS 
 
Noticeable improvements in mass spectrometer detection limits have opened the doors to the 
quantitative analysis of proteins that are expressed at very low levels in cells, such as TFs. The 
majority of these techniques employ metabolic (SILAC), chemical (ICAT, iTRAQ) or enzymatic 
(digestion with 
16
O/
18
O) stable isotope labelling to introduce a predictable mass shift between peptides 
from two or more experimental conditions (each methodology is reviewed in Ong and Mann
17
). 
Relative quantification is achieved by comparing “heavy” to “light” peptide signal intensities. These 
applications allowed capture of temporal changes and comparison among proteomes, and have become 
in the past decade a gold standard in biomedical applied proteomics
18, 19
.  
The increasing need for researchers to obtain accurate protein measurements has spurred an 
increasing interest to develop methodologies aimed at quantifying fractions of the proteome in 
absolute amounts. Despite such efforts, absolute quantification remains rather challenging from a 
technical perspective when compared to relative quantification
20
. Nevertheless, recent improvements 
in sensitivity and throughput have allowed for the routine implementation of absolute quantification 
methodologies. In essence, one can segregate MS-based quantification methodologies into two major 
classes: those requiring stable isotope labelling and those that do not necessitate labelling, so called 
“label-free”. Each of them carries a number of advantages as well as limitations. Label-free strategies 
are proven to provide a rather dynamic range of quantification, are of simple implementation and 
amicable to up-scaling. Unfortunately, this may come at the cost of accuracy and linearity when based 
on spectral counting. Recently, considerable effort has been devoted to overcome such limitations
21
, 
and combine the benefits of label-free with the sensitivity of targeted MS approaches
22
. 
Stable isotope-labelling quantification entails the spiking of “heavy”-labelled peptides, such as 
AQUA
23
, in which selected chemically synthesized isotope-labelled peptides are carefully quantified 
and used as standards. “Heavy”-to-“light” peptide ratios define the amount of the endogenous protein 
present within the biological sample. Issues with the cost of these peptides and with its storage have 
pushed for an amelioration of the technique, in which concatenated peptides (QconCAT)
24
 are utilized. 
One of the criticisms though regarding QconCAT constructs resides in the digestion of its tryptic 
peptides, which does not mirror the digestion of endogenous proteins. For this particular reason, many 
laboratories have oriented their methodologies towards the expression of full-length proteins, 
expressed either in vivo (Absolute SILAC)
25
 or in vitro (PSAQ)
26
, which are spiked at some stage of 
sample preparation within the complex mixture. The main advantage is that all tryptic peptides 
generated from the protein, except the C-teminal one, can be readily monitored. This application tries 
to overcome issue related to peptide detection, because a large fraction of protein-specific peptides 
may not be identifiable due to sample complexity, solubility and ionization issues. Furthermore, by 
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selecting only a small subset of peptides the methodology is more sensitive to post-translational 
modification. Methods based on full-length protein expression allow also for a more accurate 
quantification and a more robust statistical assessment; in addition precipitation issues related to 
peptide storage are systematically bypassed. It is generally agreed that the spiking of the labelled 
standard should be introduced as early as possible within the stages of sample fractionation, as to 
secure that both the standard and its endogenous counterpart are subject to the same artefacts. 
Therefore, sample losses or differential proteolytic treatments that may affect downstream 
measurements are minimized. Recently, a novel implementation of the absolute SILAC methodology, 
named SILAC-PrEST
27
, introduces the use of a solubilisation tag to quantify in absolute terms the 
amount of recombinant PrESTs (Protein Epitope Signature Tags) produced in vivo as to quantify 40 
selected proteins in HeLa cells. One of the benefits of the ABP (albumin binding protein) 
solubilisation tag resides in the fact that most of its tryptic peptides can be used for quantification, 
increasing the overall robustness of the approach. In addition, the experiments have been carried by 
switching the “heavy” versus “light” isotope incorporation of the PrESTs and of the sample, further 
corroborating its robustness. Ultimately, the two steps of quantification of the recombinant PrESTs 
and of their endogenous counterparts have been collapsed in one single experiment, simplifying the 
workflow as a whole.  
To sum up, novel applications in quantitative proteomics and advances in MS technology 
development allowed us to accurately measure protein amounts in a given mixture in absolute terms. 
One particular technique, named Selected Reaction Monitoring (SRM), also known as Multiple 
Reaction Monitoring (MRM), is becoming a benchmark in targeted proteomics approaches, for it 
allows the detection and quantification of predetermined sets of proteins, based on selected peptide 
fragmentation reactions, in complex samples with previously unseen sensitivity and specificity. This in 
turn allows for a more in-depth analysis in the proteome, particularly for those proteins that are 
expressed at such low levels that fail detection with canonical MS approaches. The most important 
aspect of SRM, when it comes to quantification, is the consistency and the uniqueness of the peptides 
selected. Only peptides that uniquely identify a protein of choice, and that are consistently detected in 
different MS runs should be utilized; such peptides are termed “proteotypic” 28. Moreover, when 
selecting such peptides, one has to be careful as to select the highest responding peptides for each 
protein of interest. There is no gold standard for the identification of such peptides. Nevertheless, 
several bioinformatic tools that guide the user in the selection of proteotypic peptide candidates based 
on a set of physico-chemical properties are currently available
29
 (e.g. Pinpoint: Thermo Scientific, 
Waltham, USA). The best responding peptides are usually selected for validation (e.g. ESP 
Predictor
30
). In recent years, SRM coupled to stable-isotope labelling techniques has been adopted for 
estimating cellular protein levels in large-scale proteomic analyses
31, 32
. Most of such efforts were 
aimed at quantifying large fraction of the proteome, covering the largest possible dynamic range. As 
the complexity of the model system studied increases, mainly due to technical limitations, venturing in 
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the lower levels of the dynamic range becomes extremely challenging. Quantitative information 
available on TFs appears to be rather scarce compared to the biological importance of this family of 
DNA-binding proteins. Pioneering work has been accomplished in bacteria and low eukaryotes first
33, 
34
 before measuring copy-numbers per cell in mouse and human
32, 35, 36
. Mann and co-workers were 
able to accurately quantify proto-oncogene c-Fos at approximately 5-6,000 copies per cell, and Zfp828 
at approximately 70-75,000 copies per cell utilizing the SILAC-PrEST methodology in HeLa cells
27
. 
Aebersold and colleagues have estimated of the lowest copy-number per cell of several transcription 
factors including Zfp608, Zfp335, Zbtb40, Zbtb48, and E2F7 at less than 500 copies per cell utilizing 
a stable-isotope labelling SRM-based technique
32
. Thus, although transcription factors are being fished 
out in the context of large-scale efforts aimed at determining copy-numbers for a fraction of an 
organism’s entire proteome, no comprehensive study focused at quantitatively monitoring TFs 
dynamic behaviour in biological process has been carried out.  
The adipogenic regulatory network has been widely studied because it has a clear medical 
relevance. A significant effort has been devoted to establish the basic framework of the GRN 
orchestrating the terminal phase of adipogenesis
12, 13
. In particular, several transcriptomic studies have 
been implemented to understand what are the specific cellular mechanisms that take place during this 
period of time in the cell’s life37, 38. Interestingly, recent genome-wide binding analyses have revealed 
that a few TFs alone are responsible for a wide range of gene expression events in the early stages of 
differentiation as well as in the mature adipocytes
39
. The poor mRNA-protein activity correlations 
experimentally observed have fostered and interest to employ proteomic methodologies to obtain 
protein expression profiles during adipocyte differentiation, tackling thus the problem from a different 
angle. Kim and co-workers examined the changes in protein expression resulting from hypoxia and 
normoxia in a 3T3-L1 murine cell line
40
. Ahmed and colleagues monitored the changes in mRNA and 
protein and profile of adipose tissue in response to drug treatment (rosiglitazone) to identify several 
potential protein targets for insulin sensitization
41
. Using a 5-plexed SILAC-based MS approach 
Pandey and co-workers identified 882 nuclear and secreted proteins at 5 different time-points of 
adipogenesis. For about half of them relative quantitative measurements were obtained
42
. In the above 
mentioned studies, TFs are strongly underrepresented if identified at all. The knowledge of TF levels 
in absolute terms is absolutely needed to effectively understand the dynamics of adipocyte biology.   
Last year, an interesting application, adapted by the developers to the quantification of TFs, 
has been built by the MacCoss laboratory at the University of Washington (U.S.A), which consists of 
a high-throuput, cost-effective methodology for the discovery of optimal precursor- and fragment- 
ions to be utilized in targeted proteomics assays based on the use of in vitro-synthesized full-length 
proteins. Absolute quantification of in vitro-expressed TFs is accomplished via two GST (Glutathione-
S-transferase) signature peptides. Using their approach, MacCoss and colleagues were able to 
experimentally derive optimal transitions for 96 human TFs, which expression and enrichment was 
verified for 44 TFs in total. The utility of the derived ion transitions to quantify endogenous TFs was 
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tested by measuring relative abundances of 6 candidates between 4 human cell lines
43
. To conclude, 
although there is a growing interest in adopting proteomic-based methodology, cost-effective and 
sensitive methodology to achieve absolute TF quantification are currently lacking. Thus, to date, no 
study targeting key regulatory TFs that provides a quantitative analysis of the dynamics of a cellular 
process of interest such as adipocyte differentiation in absolute terms has been published. 
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I.IV DNA-CENTERED APPROACHES TO CHARACTERIZE REGULATORY 
PROTEIN–DNA INTERACTION COMPLEXES 
 
Our capabilities to elucidate the dynamic mechanisms by which TFs regulate the expression of a 
target gene is strongly influenced by the methodology we adopt. Until recently, protein-centered 
methodologies have been widely implemented particularly due to the availability of TF-specific 
antibodies. Recently, there has been a growing consensus in favour of the notion of DNA directly 
influencing DNA-binding protein complex formation. This paradigm shift catalysed the interest 
of understanding how DNA nuclear composition dictates TF recruitment and protein complex 
formation, with the aim of providing a holistic explanation of dynamic gene regulatory 
mechanisms. This review summarizes the state-of-the-art and focuses on novel areas of 
improvement of gene-centered approaches, with a particular attention to the years to come. 
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Gene regulation is mediated by site-specific DNA-binding proteins or transcription factors (TFs), 
which form protein complexes at regulatory loci either to activate or repress the expression of a target 
gene. The study of the dynamic properties of these regulatory DNA-binding complexes has so far been 
dominated by protein-centered methodologies, aiming to characterize the DNA-binding behavior of 
one specific protein at a time. With the emerging evidence for a role of DNA in allosterically 
influencing DNA-binding protein complex formation, there is renewed interest in DNA-centered 
approaches to capture protein complexes on defined regulatory loci and to correlate changes in their 
composition with alterations in target gene expression. In this review, we present the current state-of-
the-art in such DNA-centered approaches and evaluate recent technological improvements in the 
purification as well as in the identification of regulatory DNA-binding protein complexes within or 
outside their biological context. Finally, we suggest possible areas of improvement and assess the 
putative impact of DNA-centered methodologies on the gene regulation field for the forthcoming 
years. 
WHY DNA-CENTERED METHODS?  
Differential gene expression is central to most fundamental biological processes and is controlled by 
site-specific DNA binding protein complexes. The latter transcriptional complexes, of which 
transcription factors (TFs) are the core members, function by integrating extra- and intracellular cues 
through protein–protein or protein–ligand interactions and translating these cues into a gene regulatory 
output by binding to gene regulatory elements.
1
 Signal integration can thereby be directly mediated by 
the TF itself, for example, through post-translational modification (PTM) of TF domains which 
modulates its activity
2
 or cellular location,
3
 or can be controlled indirectly through interaction with co-
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regulators. These higher-order interactions can result in, or can also be the result of PTMs, and can 
then determine whether the TF-containing complex acts as an activator or repressor of gene 
expression. This concept has perhaps been best characterized for nuclear receptor TFs, for which 
multiple PTM-dependent co-activator and co-repressor complexes have been identified (e.g. reviewed 
in ref. 4 and 5). It is currently unclear to what extent these higher-order protein interactions and 
resulting PTMs can affect DNA binding specificities and affinities. Given that TFs have often been 
observed to act both as activators and repressors,
4,6,7
 it is possible that the associated DNA binding 
complex influences DNA binding specificity or affinity, for example to distinguish genes that need to 
be repressed from those that need to be activated. This could occur through modulation not only of the 
TF DNA binding domain,
8
 but also of regions located outside the DNA binding domain that can alter 
DNA recognition and affinity through protein domain intercommunication.
9–11
 In recent years 
however, there has been increasing evidence for the reverse notion of the DNA dictating complex 
formation rather than the DNA binding complex differentiating between gene targets.
12–15
 In other 
words, while the implicated TF(s) is still responsible for target gene identification, the nucleotide 
composition of the respective TF binding site allosterically influences co-regulator recruitment and 
thus whether the resulting DNA binding complex will activate or repress gene expression (Fig. 1). So 
far, this phenomenon has been elucidated for only a couple of TFs, including Oct-1,
15
 NF B
13
 and 
glucocorticoid receptor,
14
 but it is possible that this regulatory principle extends to many, if not most, 
other TFs. To validate this, it will be important to perform a comprehensive analysis of transcriptional 
complexes while bound to DNA, ideally without using protein-specific antibodies as this would 
significantly limit the experimental scope since such antibodies are available for only a low number of 
TFs and co-regulators. This DNA-centered approach to transcriptional regulation would also allow 
assessment of the dynamic properties of these complexes, as the same DNA bait  could be used in 
distinct biological contexts. With the rapidly growing amount of experimentally defined regulatory 
element data (e.g. the Fantom and Encode consortia
16,17
), there is a wealth of suitable DNA bait 
candidates which could provide instrumental insights into gene regulatory mechanisms. The use of 
actual regulatory elements as DNA baits rather than TF binding site-representing double-stranded 
oligonucleotides may thereby be more informative given the often relatively poor correlation between 
in vitro-derived TF binding sites and in vivo-observed binding events.
18
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Fig. 1 Drawing illustrating the complex interplay 
between TF binding site recognition and DNA-
binding protein complex formation at a specific 
regulatory locus. 
 
 
The practical realization of such DNA-centered analyses has so far been difficult, as there are inherent 
difficulties associated with studying TF function such as their low expression and involvement in 
many transient and context-dependent interactions. Nevertheless, in recent years, important 
experimental progress has been made, which promises to significantly improve our ability to study the 
dynamic properties of transcriptional complexes in a DNA-centered fashion. Here, we provide a 
critical overview of these advances by highlighting their technical improvements over previously 
available DNA-centered methods and by pinpointing the remaining limitations. In addition, we briefly 
compare their output against protein-centered DNA binding complex detection methods, and highlight 
the advantages and disadvantages of each strategy. 
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DNA AFFINITY CHROMATOGRAPHY  
 
GENERAL CONCEPT  
The most familiar DNA-centered method is DNA affinity chromatography. This approach to study 
TF-containing complexes is based on DNA bait-mediated protein purification, which is achieved by 
exploiting the inherent capacity of TFs to bind to DNA. DNA is thereby either absorbed or linked 
covalently to a chromatographic support before being used for DNA affinity chromatography. 
Originally, heterogeneous non-specific DNA such as salmon or herring DNA was linked to a cellulose 
or sepharose chromatographic support (reviewed in ref. 19). This approach is not optimal for the 
purification of specific DNA binding complexes because of the abundant prevalence of contaminant 
proteins which non-specifically bind either to the support material or to the DNA. Rather, this 
approach is now commonly used as one of the many steps involved in TF purification as it efficiently 
removes contaminating proteins from complex protein mixtures. To subsequently isolate selected TFs 
or DNA binding complexes, specific DNA sequences are preferred. These are typically double-
stranded oligonucleotides either in single-copy or concatemerized format, which represent TF 
consensus binding sites
20
 or very small DNA regions with known DNA binding function identified, for 
example, through DNAse I footprinting.
21
 Since TFs have an affinity several orders of magnitude 
greater for their consensus binding site sequence compared to non-specific DNA, the use of TF-
specific double-stranded oligonucleotides allows a relatively straightforward purification of the 
respective TF and associated proteins from complex protein mixtures. However, this approach has also 
important limitations. First, while binding site concatemerization has been the preferred format for TF 
purification, it also introduces novel DNA sites, increasing the probability that other proteins will bind 
to the DNA bait and thus reducing purity.
19
 Second, DNA binding and complex assembly occurs in 
vitro and since also stringent washing is required, only proteins that bind with high affinity to the 
respective TF will be retained, making this approach not ideal to study the dynamic properties of DNA 
binding complexes within their endogenous context. Third, it requires prior knowledge of specific TF 
binding sites. For a large number of TFs such corresponding binding sites are still unavailable, 
limiting the scope of this method.
1
 Consequently, the approach is TF-centered, and will therefore not 
provide a comprehensive view of the factors controlling the transcription of your gene of interest. 
Fourth, such DNA bait typically represents just one of the possible binding site possibilities. This is 
important given the in vivo observation in both prokaryotic
22
 and eukaryotic systems
1
 that TFs also 
bind to sub-optimal binding sites. Thus, while the use of high affinity binding sites will provide a 
significant insight into DNA-binding protein complexes involving the respective TF, it will be by no 
means comprehensive. Moreover, it is becoming increasingly clear that multiple binding sites with 
varying TF affinities can cooperate, for example through DNA looping, to stabilize the TF-containing 
28 
 
complex.
23
 Thus, individual sites would fail to capture this complex. Finally, double-stranded 
oligonucleotides or other short DNA fragments usually fail to preserve the same DNA topology as that 
of the endogenously occurring TF binding site, which has also been shown to affect DNA binding. For 
example, p53 binding to DNA was enhanced with increasing negative superhelix density.
24
  
RECENT ADVANCES  
In recent years, there have been attempts to overcome many limitations by considering the use of 
single regulatory elements (or at least short fragments thereof) such as enhancers or promoters as DNA 
baits.
25–28
 This approach does not require a priori knowledge of TF binding site properties, and since 
elements are typically linked to a specific gene, it also provides information of immediate relevance to 
how the respective gene may be transcriptionally controlled. Recent examples of the DNA affinity 
chromatography approach include the isolation of a Drosophila TF, DEAF-1, binding to the enhancer 
of an immunity gene,
26
 as well as several proteins binding to promoter fragments of, respectively, the 
human ESRRA and MTA2 genes.
27
 In both studies, DNA was immobilized onto a solid phase by 
biotin-labelling the DNA and coupling it to either streptavidin-coated columns or magnetic beads. This 
is in contrast with the technique of DNA trapping used by Jiang and co-workers
29
 in which a 250 bp 
region of the human c-jun promoter with a single stranded (GT)5 tail was annealed to single-stranded 
(AC)5-Sepharose. Several pre-initiation components such as RNA polymerase II, TBP, and the TFIF 
subunit RAP 74 were retrieved as well as the TF SP1. DNA trapping typically supports better 
purification as streptavidin-coated supports are known to bind to contaminating proteins (Table 1). In 
addition, DNA trapping allows a non-denaturating elution of bound proteins,
29
 which, because of the 
strength of the interaction, is not possible with DNA immobilization where high temperatures and 
denaturating agents such as SDS are required to elute proteins. On the other hand, DNA 
immobilization is less time consuming and amenable to automatization due to its relatively simple 
workflow, and is therefore often the method of choice. As indicated above, a critical aspect of both 
techniques is the use of competitor DNA such as salmon sperm DNA, poly(dI:dC) or scrambled bait 
DNA to eliminate proteins that have low affinity for the DNA bait but would otherwise be retained 
because of the high concentration of bait DNA. 
 
Table 1 Summary of the strengths (+) and weaknesses (−) of the discussed DNA-centered methods to 
characterize regulatory protein–DNA interaction complexes  
 
 
29 
 
  
 
  
 
  
 
Time-
consu
ming 
 
Unambiguous 
protein 
purification/identi
fication 
 
Unambiguous 
complex 
purification/identi
fication 
 
Prone 
to 
artific
ial 
DNA 
bindi
ng 
 
Unbias
ed 
(truly 
DNA-
centere
d) 
interact
ion 
screen 
 
Protein 
complex 
characteriz
ation in its 
natural 
context 
 
Homogen
eous 
DNA 
  
 
− − − 
 
− 
Heterogen
eous 
DNA 
Short 
DNA 
sequen
ces as 
DNA 
bait 
TF-
specific 
double-
stranded 
oligonucle
otide 
trapping 
− + − 
  
− 
TF-
specific 
double-
stranded 
oligonucle
otide 
immobiliz
ation  
+ − 
  
− 
Concatem
ers  
+ − − 
 
− 
Long 
DNA 
sequen
ces as 
DNA 
bait 
DNA 
trapping 
− + + 
 
+ − 
DNA 
immobiliz
ation  
+ + 
 
+ − 
PICh − + +  + + 
Supershift (Electrophoretic 
Mobility Super Shift Assay) 
− + − − − − 
High-throughput yeast one-
hybrid  
+ − − 
 
− 
 
30 
 
DNA-BINDING PROTEIN IDENTIFICATION 
ANTIBODIES  
The most straightforward and therefore widespread strategy to identify captured TFs or TF-containing 
protein complex members is based on the use of antibodies. Their application is thereby not restricted 
to DNA affinity chromatography,
28
 as other protein–DNA interaction detection approaches also 
benefit greatly from antibody availability. An excellent example is the supershift assay in which the 
identity of a DNA-binding protein is confirmed only when a protein-specific antibody reduces the 
electrophoretic mobility of a protein–DNA interaction complex.30 A significant advantage of such a 
gel shift procedure over other protein–DNA interaction detection methods is its ability to distinguish 
single from multimeric forms of bound protein and to immediately relate this information to the 
respective DNA bait. For example, using supershift assays, Tantin and colleagues
31
 determined that 
DNA baits were more likely to induce di- or multimerization of the TF Oct-4 when they contained at 
least three Oct-4 half sites. Thus, and as discussed already above, binding site cooperativity can 
influence the formation of distinct TF complex configurations, with each possibly having a differential 
impact on how the respective target gene is transcriptionally controlled. Nevertheless, despite their 
utility, antibodies restrict the scope of the assay as only a limited number of highly specific DNA-
binding protein antibodies are currently available. Moreover, antibody implementation requires an a 
priori assumption about the identity of interacting proteins, making this approach protein-centered. 
Thus, while several protein-centered methods have already contributed in significant fashion to our 
understanding of the molecular mechanisms underlying protein–DNA interactions in vitro and in vivo 
(reviewed extensively in ref. 1), we will not discuss them here given this review s focus on DNA-
centered protein–DNA interaction approaches. Instead, we will briefly discuss new efforts to eliminate 
the protein-centered bias of current DNA bait-based techniques such as gel shift and DNA affinity 
chromatography by linking them to de novo protein detection and identification methods such as two-
dimensional gel electrophoresis (2-DE)
32
 and mass spectrometry.
33
 Since it is desirable still to confirm 
the identity of 2-DE-detected proteins using mass spectrometry, we will briefly focus on the latter 
technology. 
MASS SPECTROMETRY  
Traditionally, the detection and identification of DNA-binding proteins or complexes by mass 
spectrometry has always been difficult owing to the low cellular abundance of the majority of these 
types of proteins.
34
 In recent years, mass spectrometry has become increasingly sensitive, driven by 
fast-paced technological advances in instrumentation. This significant increase in mass accuracy and 
resolving power now allows for the first time a more detailed functional analysis of such lowly 
expressed proteins as their spectral peaks become increasingly distinguishable from background noise 
in complex mixtures. Based on overall sensitivity, two mass analyzers stand out. The first is the 
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Fourier transform ion cyclotron resonance mass spectrometer (FT-ICR).
35
 The second is the Orbitrap, 
which also uses an FT-based strategy.
36
 For example, Mann and co-workers
27
 have used an FT-ICR to 
identify sequence-specific DNA-binding proteins in HeLa S3 cells purified by DNA affinity 
chromatography. Interestingly, when comparing the eluted protein SDS-PAGE profiles from the wild-
type and negative control DNA bait, there was virtually no difference and thus no clear bands were 
revealed corresponding to true specific DNA-binding proteins. Nonetheless, because of the sensitivity 
of FT-ICR, candidate DNA-binding proteins that were more abundant in the wild-type versus negative 
control samples were in the end identified (see also below). Protein-centered approaches aiming to 
characterize TF-specific protein interaction partners or complexes are also benefiting greatly from the 
recent sensitivity increase as evidenced by the fact that many of the detected TF interactors were 
themselves TFs.
37,38
 Thus, we are entering an exciting era in which proteins such as TFs that have 
traditionally been for the most part off-limit become increasingly accessible and thus characterizable. 
 
DNA-BINDING DYNAMICS  
To achieve a comprehensive, mechanistic understanding of gene regulation, it is essential to not only 
determine the identity of regulatory DNA-binding complex members, but to also chart compositional 
complex changes in relation to alterations in target gene expression. This need to monitor protein 
complex assembly dynamics either with other proteins or with DNA has prompted the development of 
quantitative proteomics approaches (e.g. reviewed in ref. 39). The latter involve the labelling of 
proteins with isotopically distinguishable tags enabling a protein abundance comparison between two 
or more biological samples. Brand et al.
37
 used isotope-coded affinity tagging (ICAT) to monitor the 
compositional changes of the protein complex involving the TF NF-E2p18/MafK during erythroid 
differentiation. Results uncovered more than 100 potential protein interactors and indicated that MafK 
acts as a dual-function TF, exchanging dimerization partners upon induction of differentiation, leading 
to the replacement of interacting co-repressors with co-activators and up-regulation of the expression 
of its target gene -globin. To answer questions related to the molecular mechanisms underlying this 
protein partner exchange, the next step would be to monitor the compositional changes of only those 
MafK-containing complexes that are bound to DNA. Although this is in principle feasible by 
monitoring the DNA occupation of individual complex members at distinct time points using 
chromatin immunoprecipitation,
37,40
 the unavailability of antibodies for the majority of proteins limits, 
as indicated previously, the scope of such assays and thus prevents a functional analysis of the 
majority of detected protein interaction partners. Moreover, similar to other recent mass spectrometry-
based TF-protein interaction detection techniques such as the streptavidin-mediated isolation of 
biotinylated TF complexes,
38
 the approach used by Brand and colleagues
37
 is again strictly TF or 
protein-centered and may therefore miss crucial factors that may influence MafK complex assembly 
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on the DNA and thus -globin gene regulation in general without physically interacting with MafK, 
but for example by altering DNA accessibility.
41
 With this experimental mindset, Mittler et al.
27
 
combined the stable isotope labelling with amino acids in cell culture  (SILAC) technique with DNA 
affinity chromatography to detect protein–DNA complex assembly differences on wild-type versus 
mutated TF binding sites or short regulatory element fragments. For both types of DNA baits, a 
significant number of putative binding proteins were found. Since most of these were captured in 
approximately equal amounts by the wild-type and negative control bait, they could however be 
eliminated. The identity of the remaining proteins was in line with predictions and proved the value of 
their method. In addition, these researchers were able to identify proteins, many of which were 
previously not described, that preferentially bind to methylated versus non-methylated CpG sites on 
the MTA2 gene promoter. While the latter method clearly increases our ability to determine TF 
binding profiles, it still suffers from the previously mentioned important limitation that DNA binding 
and putative complex assembly occurs in vitro and thus information regarding the complex 
composition at the corresponding endogenous locus is lost. 
 
ALTERNATIVE DNA-CENTERED APPROACHES 
PICH  
To enable the in vivo assessment of regulatory DNA-binding complexes at specific gene loci, Déjardin 
and Kingston
42
 have now developed the PICh (Proteomics of Isolated Chromatin segments) method. 
This method is a drastic departure from previous methods typically based on DNA affinity 
chromatography as it is better described as a reverse chromatin immunoprecipitation, since it uses 
cross-linking to fix protein complexes on DNA, but rather than using a protein-specific antibody to 
identify bound DNA regions, it employs a DNA element-specific probe to pull down the associated 
protein complex (Fig. 2). The probe is an oligonucleotide containing locked nucleic acid (LNA) 
residues. These have an altered backbone that favours base stacking, thereby significantly increasing 
the stability of probe–DNA interactions. After the probe has hybridized to chromatin cross-linked to 
protein complexes, it is captured on streptavidin magnetic beads through a desthiobiotin molecule 
covalently linked to the probe. Desthiobiotin is a biotin analog with weaker affinity for avidin which 
therefore permits a more gentle competitive elution using biotin, limiting the co-elution of non-
specific factors. Thus, by maintaining the DNA-bound protein complex in its natural state and because 
probes can be designed against any locus, PICh provides in principle the possibility to correlate 
protein complex composition changes with alterations in the expression of any target gene. However, 
PICh has so far only been used to detect proteins associated with human telomere sequences, which, 
with around 100 copies per cell, are rather abundant in the genome and therefore compensate for the 
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relatively low protein detection sensitivity of the method. Evolving the method to allow screening of 
less abundant chromatin loci or even unique regulatory elements is now the next challenge and could 
involve a reconsideration of probe design, the use of even more sensitive mass spectrometers, or the 
integration of quantitative proteomics techniques. 
 
 
Fig. 2 Drawing illustrating the protein complex purification 
workflow using DNA affinity chromatography (A) and PICh (B). 
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HIGH-THROUGHPUT YEAST ONE-HYBRID ASSAY  
While PICh has the promise to revolutionize the gene regulation field, it remains to be seen how much 
the method will live up to expectations. Consequently, DNA affinity chromatography as well as other 
alternative methods will remain useful to study the dynamic properties of regulatory DNA-binding 
complexes in DNA-centered fashion. One other alternative method is the high-throughput yeast one-
hybrid system, which allows the screening of regulatory elements of interest for interacting TFs or TF 
dimers.
43–45
 Although the latter technique does not allow the detection of DNA-binding complexes and 
is performed in yeast and thus outside the endogenous context, it provides the unique possibility to 
scan the whole regulatory protein repertoire for binding to a DNA bait of choice depending on the 
completeness of the screened TF library.
46,47
  
 
CONCLUSION  
 
In recent years, there has been renewed interest in obtaining a complete understanding of the complex 
mechanisms underlying gene regulation, driven by recent discoveries illustrating the complex 
interplay between all components involved (DNA, TFs, co-regulators etc.) in guiding the formation of 
functional regulatory complexes, which either activate or repress gene expression. Consequently, there 
are revived efforts to improve current technologies to enable an increasingly more accurate and 
comprehensive study of gene regulatory complex formation. Specifically, there is a significant need to 
monitor the formation of such complexes at defined regulatory loci in distinct biological contexts, 
hence the renewed interest in DNA-centered protein–DNA interaction detection technologies. 
Although progress in this area has been made as discussed in this review, we are still far from the 
complete and functional characterization of DNA-binding protein complexes and from the ability to 
relate changes in their composition to expression changes of their respective target genes. In this 
regard, we are eagerly looking forward to novel developments in the in vivo quantitative proteomics 
field, to improved TF and protein complex purification methods, and to further increases in the 
sensitivity of mass spectrometers, which are quickly becoming the gold standard  in the analysis of 
DNA-binding functional protein complexes. 
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ABBREVIATIONS  
 
TF Transcription Factor 
PTM Post-Translational Modification 
SDS Sodium Dodecyl Sulfate 
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
2-DE Two-dimensional Gel Electrophoresis 
FT Fourier Transform 
FT-ICR Fourier Transform Ion Cyclotron Resonance 
ICAT Isotope-Coded Affinity Tags 
SILAC Stable Isotope Labelling with Amino Acids in Cell Culture 
PICh Proteomics of Isolated Chromatin Segments 
LNA Locked Nucleic Acid 
Co-R Co-regulatory element 
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II. RESULTS 
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II.I DEVELOPMENT OF A GENE-CENTERED PROTEOMIC 
PLATFORM FOR THE SYSTEMATIC IDENTIFICATION OF DNA 
BINDING PROTEINS AND COMPLEXES 
 
The purpose of this project was to adapt a proteomic platform to capture DNA-binding proteins 
or complexes in a systematic and quantitative manner within their functional context in vivo. 
Contrary to most protein-DNA interaction techniques that are used today, the platform is gene-
centered, in that it takes advantage of the growing amount of experimentally defined 
transcriptionally active DNA element data to identify associated DNA binding proteins or 
complexes. By incorporating a stable metabolic labelling technique (SILAC), it thereby aims to 
provide quantitative information regarding the binding behaviour of these DNA binding 
proteins or complexes. The information collected was intended to be used to build a 
comprehensive protein-DNA interaction map that elucidates the dynamic and quantitative 
aspects of gene regulation.  
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Development of a gene-centered proteomic platform for the 
systematic identification of DNA binding proteins and complexes 
 
MOTIVATION 
 
Gene expression is a complex mechanism that requires the input of several signalling cascades 
involving a large number of components. The components of these cascades have been extensively 
characterized, providing valuable information on how living cells are able to respond to their 
environment 
1, 2
. Signalling ultimately results in differential gene expression. The interface between 
these signalling pathways and the protein layer that mediates gene regulation, the so-called gene 
regulatory networks, has however been poorly characterized because many of the implicated 
regulatory proteins such as transcription factors (TFs) and co-regulators tend to be present at very low 
concentrations in cells, making the study of this important class of proteins with today’s technologies 
quite challenging (figure 1). It is our major goal to understand in deeper detail the mechanisms that 
dynamically and quantitatively govern gene expression within their native context. To achieve this 
goal, we need to comprehensively characterize the regulatory protein interface between signalling 
pathways and the genome and therefore intend to develop a technology that enables us to monitor TF 
and co-regulator changes in a systematic manner. 
 
Signalling pathway 1
Signalling pathway 2
TF1
TF2
Co-F1
Co-F3
Co-F2
?
cytoplasm nucleus
DNA
 
 Figure 1. Model of gene regulation emphasizing the relative lack of knowledge regarding the   
composition and dynamic properties of the regulatory protein interface indicated by a question mark. 
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INTRODUCTION 
 
The recent outburst of genomic information has spurred the development of novel methods to analyze 
and characterize the protein and gene components of gene regulatory networks and to understand how 
they interact at the systems level. To date, most of these methods are TF-centered, in that they use TFs 
to retrieve DNA sequences bound by them 
3, 4
. Chromatin immunoprecipitation (ChIP) is a powerful 
technology to assess whether a protein of interest is bound to a given genomic region “in vivo” 5. Yet 
ChIP relies heavily on the use of antibodies and thus is limited to analysis of the factors that have 
previously been tested, and unfortunately does not establish a comprehensive description of protein 
complex composition. Moreover, TF-centered methods do not take advantage of the growing amount 
of experimentally defined regulatory element data that has recently been generated, for example as 
part of the Encyclopedia of DNA elements Project (ENCODE, 
6
), or other genome-wide regulatory 
element mapping projects 
7, 8
.  
To address these limitations and gain insight into locus-specific protein complex composition, 
a gene-centered strategy would be required enabling the purification of an endogenous segment of 
chromatin, e.g. a regulatory element of interest, in sufficient quantity and purity to identify the in vivo 
associated proteins. Such a technology would permit a detailed correlation between composition at a 
locus and phenotype, leading to a deeper understanding of gene regulation mechanisms. Mann and 
colleagues developed an “in vitro” gene-centered quantitative interaction screen that utilizes short 
promoter fragments (wild-type (WT) versus mutated) to analyse sequence specificity for the capture 
of TFs 
9. Since this methodology uses a very short DNA “bait” sequence, it allows for the 
characterization of only a small subset of DNA binding proteins, thereby failing to reflect the 
appropriate cellular endogenous context.  
Recently, a new technique called PICh (Proteomics of Isolated Chromatin segments) was 
developed, in which specific nucleic acid probes are used to target specific sequences within genomic 
DNA 
10
 (figure 2). In doing so, PICh enables the specific isolation of sequence specific DNA binding 
complexes, extracted directly from live cells, thereby maintaining the cellular environment as close as 
possible to the physiological context (“in vivo”). The identification of such complexes is performed by 
mass spectrometry (MS). To date, PICh has only been used to detect proteins associated with telomere 
sequences, which are present in multiple copies within cells. We aim to adapt the technique to the 
much more challenging task of screening individual DNA sequences, such as enhancers or promoters 
for interacting protein complexes. This is challenging because such unique sequences are present only 
twice in diploid cells. We therefore need to increase significantly the sensitivity of PICh to permit the 
characterization of single copy regulatory sequences bound complexes.  
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       (Déjardin & Kingston; Cell, 2009) 
Figure 2.  Workflow of the PICh protocol  
 
In order to understand dynamic aspects of gene regulation, we also aim to monitor protein complex-
DNA interaction phenomena in biological samples showing differential expression of a particular gene 
of interest. To optimize the PICh assay for our purposes, we have chosen a well-studied gene 
regulation model, the β-globin cluster, which will be explained in the next section. 
 
THE MODEL 
 
The β-globin gene family is probably one of the best studied families of genes. Several TFs and 
transcriptional complexes have already been identified as modulators of globin gene expression, 
particularly in mouse and human, and the corresponding gene regulatory elements have been well 
characterized (reviewed in 
11
). In addition, these genes are tissue-specific and developmentally 
regulated. The β-globin gene cluster is located on chromosome 11 and consists of five functional 
genes, arranged from 5' to 3' reflecting their developmental sequential expression. ε-globin is normally 
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expressed in the embryonic yolk sac  while A-gamma and G-gamma globin are expressed only during 
fetal development. Around birth, the production of γ-globin declines whereas the production of β-
globin sharply increases. The combination of two alpha genes and two beta genes comprises the 
normal adult haemoglobin. 
Located 6-20 kb 5´ of the human ε-globin gene, a series of erythroid-specific DNase I 
hypersensitive sites (HSs), each of 200 to 400 bp in size, aid in controlling the expression of 
downstream cis-linked globin genes. These five sites form the globin locus control region (LCR) 
which can up-regulate or down-regulate expression in a cooperative manner. HSII lies some 11 kb 5´ 
of the ε-globin gene, and is well known to stimulate the transcription of embryonic as well as fetal 
globin genes in erythroid cell 
12
. How HSII interacts with distant cis-linked globin promoter sequences 
to stimulate expression at different developmental stage is not fully understood. What has been 
proposed is that complex mechanisms of looping and tracking take place during globin gene 
expression 
13
 
14
. The ε-globin gene is situated 11 kb 3´ of HSII and its transcription is stimulated by the 
enhancing capabilities of this particular site. The core of the ε-globin promoter is about 200 bp long. 
Many TFs and co-factors are known to interact with the HSII element of the LCR (e.g. GATA1, NF-
E2, Sp1) and with the promoter of the embryonic ε-globin gene (e.g. AP1, NF-E1)(figure 3). Figure 3 
shows the overall organization of the human β-globin gene locus, including the LCR and the five 
globin genes, including DNA binding motifs (circles), TFs (squares), and co-factors (triangles). TFs, 
by binding to specific motifs through selective recruitment of co-factors, can either activate or repress 
gene expression 
15, 16
. We therefore aim to identify TFs and co-regulators that are already known to 
bind to β-globin cis-linked regulatory sequences, namely to the 5 sites in the LCR and to β-globin 
promoters, and complement such knowledge with newly identified interactors, including other TFs or 
co-regulators. 
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Figure 3.   Summary of TFs and co-regulators known to interact with the LCR element HSII and with      
the embryonic ε-globin promoter. 
 
Importantly, human cell lines in which globin genes are dynamically expressed are easily available, 
providing a relatively easy-to-use model system to study globin gene regulatory mechanisms (e.g. 
K562 cells, 
17
). The K562 is an immortalized human myelogenous leukaemia cell line that was 
derived from a 53 year old patient in blast crisis 
18, 19
. Being an immortalized myeloid leukemia line, 
K562 cells do not show a classical “erythroid” behaviour; instead they present mixed characteristics of 
early-stage erythrocytes 
20
, granulocytes 
21
 and monocytes 
22
. K562 cells constitutively express 
embryonic and fetal globin genes (epsilon and gamma), but not β-globin 23. Globin expression can be 
increased up to ten fold by exposing K562 cells to inducing agents such as hemin 
24
, hydroxyurea, and 
sodium butyrate. 
Thus, the 5 elements known to mediate globin expression as well as promoter regions will be selected 
and used as baits to capture interacting proteins or complexes in conditions where β-globin like genes 
are expressed (K562) versus silenced (here the HEK293 cell line will be used as a negative control as 
globin genes are not expressed in these cells), revealing specific patterns of regulation. These 
experiments should yield sufficient information to generate crude background protein profiles and thus 
enable the elimination of false positive proteins from the analysis by intelligently discarding those 
proteins that are constantly present throughout different experimental settings. 
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METHODS 
TF COMPLEX CAPTURE USING SPECIFIC PROBES 
 
As mentioned in the introduction, the PICh technique (figure 2) was recently developed to 
characterize protein composition on specific loci within the chromatin in a functional “in vivo” 
context. Interestingly, the PICh technique can be applied on a high-throughput set up, due to the fact 
that the LC (liquid chromatography)-MS steps are amenable to automatization (e.g. MudPIT 
(multidimensional protein identification technology) 
25
). 
For the optimization of hybridization to the target sequences, the chromatin capturing probe 
is composed of mixed LNA/DNA oligonucleotides. Locked nucleic acid (LNA) residues (figure 4) 
have an altered backbone that favors base stacking, thereby significantly increasing the stability of 
probe-chromatin interactions 
26
.  
 
 
Figure 4. Comparison of LNA and RNA nucleotides 
 
A desthiobiotin molecule is covalently linked to the 5´ of the oligonucleotide thorough a long 
spacer. The use of desthiobiotin (a biotin analog with weaker affinity for avidin) is justified by the 
fact that the structure of the molecule permits a competitive gentle elution using biotin 
27
, limiting 
the co-elution of non-specific factors.  
 
 
Figure 5.  The chemical structure of the molecular probe. A desthiobiotin moiety is covalently 
linked to a long phosphoramidate spacer linked to the 5´ end of a 25mer oligo.  
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To minimize the steric hindrance (which is detrimental for yields) observed upon immobilization of 
chromatin 
28, 29
, a very long spacer has to be placed between the immobilization tag and the 
LNA/DNA probe (figure 5). It has been previously shown that tether lengths of at least 40 atoms for 
surface-bound oligonucleotides are crucial for optimum target hybridization. It is also possible to 
make longer linkers by adding spacers one after the other to the end of the oligonucleotide prior to 
adding a terminal desthiobiotin. Excessively long tethers will have the adverse effect of interfering 
with hybridization 
30
.  
Thus, we plan to adapt the PICh technology to target single copy regulatory sequences using the 
above mentioned chromatin capturing probe technology. Those probes have to be highly specific to 
avoid hybridization to other loci in the genome leading to an incorrect interpretation of the results. 
 
TF COMPLEX DETECTION 
One of the larger difficulties associated with protein identification and quantitation is the co-
purification of often abundant “sticky” proteins unrelated to the biological process of study. These 
“false positives” may obscure the correct interpretation of the proteomic data 31. It is possible to 
overcome this problem via the systematic analysis and comparison of protein profiles obtained after 
each DNA affinity chromatography-based purification. Thus, by screening several DNA baits, a 
DNA affinity background protein profile could be generated. Non-specific proteins can then be 
systematically discarded allowing the identification of proteins that are relatively unique to the DNA 
sequence of interest. It is clear that this strategy will only succeed if the protein detection method of 
choice delivers data in a standardized format and therefore supports direct comparison of protein 
profiles between different assays.  
The recent transition to spectrum-based protein identification (in addition to sequence-based 
identification) may in this context be highly beneficial. Indeed, spectral library searching has 
recently shown promising results, in terms of computational time, identification rate and accuracy, 
32
. Therefore, high quality peptide matches obtained from a sequence search approach can be 
extracted from a first set of experiments to build an appropriate spectral library. Run after run, 
tandem mass spectra can be screened against the library, and only spectra with no interpretation 
would be submitted to a sequence search engine. By generating a spectral library “on the fly”, either 
from search results from a previous experiment where a similar sample preparation process was 
employed, or from a fraction of the samples to be analyzed, a significant percentage of the spectra 
can be rapidly and unambiguously identified. As mentioned in the introduction, the low abundance 
of TFs is a crucial limiting factor. Generating a spectral library may not be sufficient to clearly 
identify TF peptides due to the fact that TF peaks may be hidden in the background noise or the 
resulting spectra may be too complicated to be interpreted. To address this issue, we also intend to 
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develop a proteotypic peptide library, in collaboration with the laboratory of Biomolecular Mass 
Spectrometry of Prof. Tsybin, to ease the bioinformatic burden of TF identification by furnishing 
clean spectra belonging to purified TFs. 
Thus,  we plan to detect loci specific protein complexes (captured by PICh) by filtering out non-
specific interactors in a multiple screening process. Spectrum-based protein identification will be 
facilitated by the availability of a TF proteotypic peptide collection of spectra. 
 
COMPARATIVE PROTEOMICS 
An important novel aspect of this project is our goal of monitoring protein expression changes within 
our models. To render our approach quantitative, a biological differential labelling technique named 
SILAC (Stable Isotope Labelling of Amino acids in Cell cultures) will be combined with the PICh 
method 
33
. SILAC will enable relative quantitation of DNA-binding protein complexes between 
different biological states, such as “expressed” versus “non-expressed”. In the simplest version of this 
technique, two cells populations are differentially labelled by growing them separately in a light 
medium versus a medium enriched with heavy, non-radioactive isotopes such as 
13
C and 
15
N (often in 
either arginine or lysine). Proteins obtained from such cultures are then pooled, trypsinized, and 
subjected to LC-MS/MS (figure 6). Metabolic incorporation of heavy amino acids into the proteins 
results in a proportional mass shift of the corresponding peptides. This mass shift can be detected by 
mass spectrometers. Therefore, the relative protein abundance in each experimental condition can then 
be inferred by combining the two samples and comparing their peak intensities.  
 
 
        (Gingras et al.; Nature Reviews; 2007) 
                                     Figure 6.  SILAC metabolic labelling 
 
Thus, based on the differential expression of proteins of interest using SILAC, we will be able to 
better understand the dynamic aspects of gene regulation within specific biological processes. 
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IMPLEMENTATION 
 
As previously described, the major aim of the project is to develop a consistent gene-centered 
proteomic platform to capture TFs and co-factors in the form of functional complexes in a 
systematic manner within their natural environment. The model we decided to use is the β-globin 
gene cluster in the K-562 cell line. 
 
CAPTURE OF HSII AND Ε-GLOBIN PROMOTER BINDING PROTEINS 
As already mentioned, the HSII site and the ε-globin promoter regulatory regions were chosen as a 
basis for the development of the PICh proteomic platform. We believe that exposed DNA sequences 
will facilitate the process of hybridization. However, it is possible that proteins bound to the target 
may render the DNA inaccessible, while tight packing of chromatin in heterochromatin by either 
methylation or acetylation may hinder the accessibility to the target sequence as well. On the other 
hand, the original PICh report targeted core telomere sequences and did obtain good results, 
indicating that it is as yet unclear in how much bound proteins may interfere with probe 
hybridization. Nevertheless, to alleviate potential interference problems, we designed probes to 
regulatory regions where the probability of finding proteins bound to them is relatively low. It 
impossible to ensure “a priori” that the target sequence will be “free of proteins”. Interestingly, the 
likelihood of observing TFs bound to regulatory sequences decreases proportionally to the distance 
from the core region.  Therefore it would be good practice, if TFs DNA-binding pattern are known, 
to target relatively “empty” motifs, with the hope that the hybridization process takes place without 
any interference (figure 7). 
 
 
 
Figure 7.  Schematic representation of the probe-chromatin interaction 
 
50 
 
Once hybridization to chromatin takes place, the complex probe-regulatory (hybrid) sequence will 
be isolated by purification and sonicated. The resulting sequences are expected to have a length of 
400 to 500 bp. The hybrids will be affinity-captured using streptavidin coated magnetic beads, and 
eluted using free biotin as a competitor. Extensive cross-linking with formaldehyde will ensure a 
better preservation of protein-DNA and protein-protein complexes. Consecutively, the process of 
cross-linking will be reversed to allow for the proteins bound to the regulatory sequence to be 
separated and purified before resuming the classical proteomics workflow. 
 
Ε-GLOBIN DIFFERENTIAL EXPRESSION USING SILAC 
The quantitative analysis of ε-globin expression will be implemented using the two cell populations 
(K562 and HEK293) in three different conditions: K562 cells alone, K562 cells grown in the 
presence of hemin (up-regulated), and HEK293 cells. Hemin is used as it increases the expression of 
globin genes up to ten fold (figure 8).  
 
 
 
Figure 8.   Schematic representation of globin concentration in K562 cells (alone, and in presence of 
hemin) and in HEK293 cells. 
 
Here, we are interested in observing differential protein composition at specific regulatory loci, in 
order to understand in a dynamic setting how locus protein composition determines gene expression. 
 
BUILDING A TF PROTEOTYPIC PEPTIDE LIBRARY  
Tandem mass spectrometry (MSMS) is routinely used to identify naturally occurring peptide 
sequences from complex mixtures of proteins. This technique is utilized to obtain structural 
information of proteins by fragmenting the ions produced in the source of a mass spectrometer and 
identifying the resulting ions. Structural information of the intact protein can be obtained by pulling 
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together the collected data through bioinformatics. Another use of tandem mass spectrometry is that 
specific compounds can be detected in complex samples by analysing their fragmentation pattern 
(selected reaction monitoring or SRM). In this technique, the analysers are set to detect a specific ionic 
transition belonging to the protein of interest. The mass of the parent as well as the product ion have to 
be known. SRM is used to confirm unambiguously the presence of a specific protein in a complex 
mixture. The main advantage is its high specificity and sensitivity. In most instances, as few as two to 
three identified peptides are sufficient to positively reveal the presence of a particular protein in a 
sample 
34
. Some peptides are more prone to uniquely identify a protein than others, meaning that they 
are frequently observed. Most mass spectrometers show an identification bias toward analysing 
peptide species with the most intense MS signal.  However, signal intensity often does not relate to 
frequency of observation. These “proteotypic” peptides should possess particular physico-chemical 
properties that allow them to be detected at higher frequency (figure 9).  
 
 
               (J. of Proteome Research; Vol. 6, No. 3; 2007) 
 
Figure 9.  Diagram showing the frequency of peptide observation. 
 
Ideally, by examining the peptides found in experimental data sets collected by multiple screenings, a 
comprehensive proteotypic peptides library can be generated.  
The development of an open source public repository for peptide tandem mass spectrometry data, the 
Global Proteome Machine Database (GPMDB), has made it possible to retrieve a list of proteotypic 
peptides for a limited number of species, based on experimental observations. This repository contains 
more than four million annotated peptide mass spectra, contributed by many laboratories. Other 
proteotypic peptide databases include PeptideAtlas (www.peptideatlas.org), SBEAMS 
(www.sbeams.org), and PRIDE (www.ebi.ac.uk/pride). Until today, no comprehensive TF proteotypic 
peptide database has been developed. Moreover, due to the difficulties in detecting TF peptides, many 
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TF entries in these databases remain empty. As previously explained, building a library of TF 
proteotypic peptides will be a useful tool for the identification and absolute quantification of TFs.  
The high sensitivity needed for the detection of transcription factor peptides will be provided 
by a Fourier Transform Ion Cyclotron Resonance (FT-ICR) analyser (laboratory of Biomolecular 
Mass Spectrometry, EPFL) as it has been known to have the highest sensitivity among mass 
spectrometers. 
Clearly, proteotypic peptides open exciting new avenues not only for improvements in speed and 
accuracy of protein identifications, but also for cross-comparisons of quantitative proteomics data, 
bypassing the use of protein tagging or the use of internal calibrants. The goal is to identify 
proteotypic peptides for our vast collection of transcription factors to be used in a spectrum based 
protein identification methodology. 
  
PRELIMINARY RESULTS 
 
DEVELOPMENT OF A MOUSE TF DATABASE 
In order to study the complex interplay between DNA and its binding transcription factor and co-
factors, our laboratory has cloned already approximately 900 mouse TFs out of the 1,200 planned, 
representing a good majority of TFs encoded by the mouse genome. cDNA sequences were 
retrieved from either Genbank or Riken databases, and used as templates for  the design of  longest 
open reading frames (lORFs). Each lORF, which encode for a TF of interest, was computed by 
means of bioinformatics (due to the large number of TFs). For this purpose, I developed a series of 
object-oriented “perl” scripts in a Linux environment, and subsequently screened the lORFs for the 
presence of DNA binding domains (BDs) using a program developed by Jacques Rougemont 
(Bioinformatics and Biostatistics Core Facility, EPFL). The predicted lORFs were compared to the 
ones present in different databases such as Genbank, Refseq, and Riken. For the majority of TFs, the 
two sequences were exactly the same. In some instances though, the two sequences showed 
variations. Those differences were due either to incomplete gene sequencing or differential intron 
incorporation. Figure 10 shows the decision tree in the choice of the most appropriate sequence to 
be used for TF cloning. The chosen sequences were used for Gateway-compatible amplification of 
the insert using specific Gateway primers (see below).   
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Figure 10.  Diagram showing the lORF decision process. 
 
TF “IN VITRO” EXPRESSION USING “GATEWAY” CLONING 
To simplify cloning procedures, our laboratory has adopted the "Gateway" cloning technology, which 
uses a particular plasmid construction strategy to rapidly clone one DNA sequence into multiple 
destination plasmids. “Gateway” cloning greatly reduces the labour-intensive and time-consuming 
procedures of classical plasmid construction, and bypasses the utilization of restriction enzymes. This 
makes the technology useful in many applications, specifically for protein expression. To be able to 
isolate the proteins, a GST tag was fused to the C-terminus for downstream isolation. We chose the C-
terminus as successful GST-based protein purification then implies that the complete protein is 
expressed.  
TFs of interest were expressed using a cell-free eukaryotic protein expression method (in vitro 
transcription translation system). Basically, in vitro translation is accomplished using a crude lysate 
from a given organism; providing the translational machinery, tRNAs, accessory enzymes and other 
factors. Compared to traditional cell-based expression methods, cell-free “in vitro” protein synthesis 
procedures are extremely rapid, making them suitable for screening expression templates. Reduced 
reaction volumes and short process time as well as improvements in translation efficiency make the 
use of a cell-free system suitable for high-throughput strategies as well. Moreover, even proteins that 
are toxic for cells in high amounts, such as TFs, can be easily expressed. 
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SELECTION OF PROTEOTYPIC PEPTIDES OF PPARΓ 
In the context of discovering proteotypic peptides, peptides that constantly and uniquely identify a 
given protein, PPARγ (peroxisome proliferator-activated receptor) RXRα, and p53 were chosen for 
preliminary testing. PPARγ was cloned and expressed using the methods explained above. GST fused 
PPARγ was expressed using a rabbit reticulocyte lysate and purified using agarose beads coupled to 
protein A first and using streptavidin coated magnetic beads with biotinilated anti-GST IgG antibodies 
in a second series of experiments. Proteins in the lysate were separated by molecular weight with 
SDS-PAGE, and stained with Coomassie Blue (figure 11) and silver nitrate (figure 12). The presence 
of PPARγ was confirmed by Western Blot (figure 13). 
 
                                  
 
 Figure 11.  (on the left) Coomassie Blue stained SDS-PAGE gel of PPARγ, RXRα, and p53 expressed 
in rabbit reticulocytes           
Figure 12.  (on the right) Silver stained SDS-PAGE gel of PPARγ, RXRα, and p53 expressed in rabbit 
reticulocytes 
 
 
 
 
Figure 13.  Western Blot of PPARγ and p53 on a nitricellulose 
membrane using mouse and goat anti-mouse GST abs. 
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The figures show that Coomassie Blue staining is not sensitive enough to detect protein bands 
belonging to the expressed proteins. Silver staining on the other hand appears to be much more 
sensitive, but it is difficult to clearly distinguish bands of interest from the background noise, 
indicating that proteins are expressed but likely at low levels. The three expressed proteins bands were 
excised from the gel in figure 2. Peptides were extracted from the fraction after trypsination, and run 
on an ESI ion-trap with a negative control (blank gel fraction) and a positive control (mouse anti-GST 
IgG heavy chain). Protein identification with Mascot showed no traces of either PPARγ, RXRα or p53.  
The expression yields obtained with the rabbit reticulocyte “in vitro” cell free expression 
system were simply too low. A wheat germ “in vitro” cell free expression system is more appropriate. 
Wheat germ has shown a much higher yield in previous preliminary experiments 
(www.promega.com), and should thus be a better system for the expression of the amount of TF 
protein needed for MS identification. 
 
DESIGN OF THE PROBES 
The gene-centered proteomic approach will firstly be implemented to fish out two regulatory regions 
(HSII and the epsilon-globin promoter) using the specifically design probes presented above (section 
4.a). Two 25mer LNA containing oligonucleotides were designed to have a melting temperature of 
76°C (Déjardin & Kingston; 2009). The relative concentration of LNA bases within the oligo 
determines the melting temperature. The locked nucleic acids provider reported an increase in the Tm 
of the primer of 2 to 6 °C per incorporation of LNA residue (www.exiqon.com) when compared with 
DNA. Such a melting temperature ensures that the probe hybridizes to genomic DNA without 
disrupting the structure of the protein complex bound to the double stranded DNA. 
 
 Sequence  
(LNA residues are capitalized) 
Genomic 
position 
Chromosome Position 
from 
ATG 
Tm 
(°C) 
HSII actCtAggctgaGaacAtctggGca 5,266,142-
5,266,118 
11 N/A 76 
HBE1 
promoter 
gaGagCtaGaaCtggGtgAgatTct 5,248,184-
5,248,208 
11 -457 76 
 
Table1.  Sequence and genomic information of HSII and HBE1. 
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Table 1 shows the sequences and characteristics of the two probes that have been designed to target 
the HSII and HBE1. In order to achieve the desired melting temperature (76°C) LNA residues had to 
be carefully introduced every 3-4 bp.  
 
FUTURE PERSPECTIVES 
 
It was our goal to extend the platform to the study of less characterized models of gene regulation. 
Currently our laboratory is studying the regulatory networks underlying adipogenesis, and our method 
would strongly contribute to the understanding of the dynamic process of differentiation in mouse 
3T3-L1 pre-adipocyte cells. Along the lines of the newly developed proteomic platform, promoters of 
TFs of interest will be screened for interacting proteins or complexes. In later stages, additional up or 
downstream regulatory elements could be included. The goal will be the creation of a list of high-
confidence PDIs, which will consequently be used to generate a gene regulatory network underlying 
adipocyte differentiation. Once the validity of the platform is established for cell cultures, it would be 
very interesting to move a step closer to real “in vivo” models by expanding our methodology to the 
systematic analysis of DNA binding complexes directly in tissue. Recently, Krueger and Mann have 
extended the SILAC technique to enable proteomic quantitative analysis from tissue samples. Mice 
were fed with a 
13
C6-lysine diet, without adverse effects. This “SILAC mouse” can therefore to be 
used as “Wild Type” reference to the analysis of a plethora of knock-out mice. Again, Krueger et al. 
have successfully used different organs from a SILAC mouse to the “in vivo” quantitation proteomic 
study of the integrin pathway 
35
. I am currently exploring the possibility of obtaining specific tissues 
from SILAC mice to be used to validate the results obtained using cells lines, bringing to the table a 
different perspective on “in vivo” proteomic studies. Tissues of interest include mouse adipose 
(namely for the study of the differentiation process of 3T3 cells), and mouse blood (for the dynamic 
developmental study of globin genes).  
The knowledge obtained with our gene-centered proteomic platform can be employed for future 
modelling efforts to make predictions on how gene regulatory networks behave under different 
physiological or pathological conditions in different organisms. Our hope is that this technology will 
serve as a blueprint, and be utilized on a routine basis for the systematic analysis of DNA binding 
protein complexes within their functional context. 
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CONCLUSIONS 
 
Our initial efforts lead us to obtaining promising preliminary results. In particularly, we were able to 
build a comprehensive TF clone library that could be very useful in the context of increasing protein 
identification confidence or serve as a valid resource to promptly generate TF-specific proteotypic 
peptides simply by producing TFs of choice "in vitro". To this end, using three well-studied TF as 
trailblazers, we explored different possibilities to optimize TF expression. It is of crucial importance to 
utilize a transcription/translation system that can produce proteins in very high yields in order to 
obtain enough material for downstream applications. In our case, the rabbit reticulocyte protein 
expression kit we tested did not live up to its expectation. After a careful consideration of "in vitro" 
expression systems commercially available, we decided to adopt one capable of producing proteins in 
large amounts. For this purpose, the high-yield wheat germ-based expression system from Promega 
was selected. However, all things considered, the most crucial aspect of this project is the 
hybridization of the LNA/DNA probes onto their corresponding target regions. Although the two 
probes we had devised did successfully bind to genomic DNA (therefore in the absence of DNA-
binding proteins) proving that the designing of the probes was well conducted, we experienced major 
issues in probe hybridization when we switched to using chromatin. Since protein-complex 
composition as well as chromatin landscape may interfere with probe anchoring, finding accessible 
target regulatory regions might become a rather difficult task. Our several attempts were not sufficient 
to achieve a successful landing of the probes onto their targets. It appears that specifically avoiding 
core regulatory regions, which are often highly occupied, might not be sufficient on its own to increase 
the likelihood of having the probe hybridizing onto its target sequence. Our initial assumption was that 
the DNA-binding protein landscape density decreases as we move away from the core regulatory 
regions, which appears not necessarily always to be the case. Other factors (such as the actual 
chromatin conformation around the specific target site) play an important role in the process. The 
latter are unfortunately rather difficult to predict. One possible way to address this problem would be 
to design several probes targeting different sites within the same regulatory region, hoping that at least 
one hybridization event takes place. Unfortunately, such a procedure may be impractical and rather 
uneconomical, due to the high cost of the single probes. If we consider the original development of the 
PICh technique, which entailed the targeting of telomeric repeat sequences, one probe was used to 
target multiple genomic loci. A human cell contains 92 telomeres (23 pairs of chromosomes), 
therefore one probe could hypothetically hybridize onto 92 different genomic sites. In the current 
work, we aimed at selecting regulatory regions that are present in two copies in diploid cells, 
representing thereby an increase in sensitivity of a factor 50. In this regard, as to not loose sensitivity 
we were obliged to start with large amounts of cells to obtain enough material for the subsequent 
analysis, and planned to use the most sensitive MS-based technology available to tackle the issue of 
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TF-complex composition identification and subsequent quantification. To sum up, the major 
bottleneck encountered in the development of this project related to the successful hybridization of the 
LNA/DNA probes onto their target sequences. After several unsuccessful attempts, we deemed that 
utilizing one probe only per regulatory region was simply not enough to warrant probe-DNA binding. 
In essence, the attractiveness of the methodology as a whole is drastically reduced if multiple probes 
per regulatory element have to be utilized. Moreover, the difficulties we encountered in the 
implementation of the PICh approach seemed to be shared and acknowledged by many colleagues 
(thus raising doubts about the reproducible nature of the PICh method). In the light of these facts, we 
decided to abandon the project and concentrate our efforts on the quantification of TF.   
59 
 
REFERENCES 
 
1. Kim MO, Si Q, Zhou JN, Pestell RG, Brosnan CF, Locker J, Lee SC: Interferon-beta 
activates multiple signaling cascades in primary human microglia. J Neurochem 2002, 
81(6):1361-1371. 
2. Roberts RE: The role of Rho kinase and extracellular regulated kinase-mitogen-activated 
protein kinase in alpha2-adrenoceptor-mediated vasoconstriction in the porcine palmar 
lateral vein. J Pharmacol Exp Ther 2004, 311(2):742-747. 
3. Blais A, Dynlacht BD: Constructing transcriptional regulatory networks. Genes Dev 2005, 
19(13):1499-1511. 
4. Mak HC, Pillus L, Ideker T: Dynamic reprogramming of transcription factors to and from 
the subtelomere. Genome Res 2009. 
5. Pillai S, Dasgupta P, Chellappan SP: Chromatin immunoprecipitation assays: analyzing 
transcription factor binding and histone modifications in vivo. Methods Mol Biol 2009, 
523:323-339. 
6. Encode Consortium: Identification and analysis of functional elements in 1% of the 
human genome by the ENCODE pilot project. Nature 2007, 447(7146):799-816. 
7. Fantom Consortium: The Transcriptional Landscape of the Mammalian Genome. Science 
2005, 309(5740):1559-1563. 
8. Pennacchio LA, Ahituv N, Moses AM, Prabhakar S, Nobrega MA, Shoukry M, Minovitsky S, 
Dubchak I, Holt A, Lewis KD et al: In vivo enhancer analysis of human conserved non-
coding sequences. Nature 2006, 444(7118):499-502. 
9. Mittler G, Butter F, Mann M: A SILAC-based DNA protein interaction screen that 
identifies candidate binding proteins to functional DNA elements. Genome Res 2009, 
19(2):284-293. 
10. Dejardin J, Kingston RE: Purification of proteins associated with specific genomic Loci. 
Cell 2009, 136(1):175-186. 
11. Dean A: Chromatin remodelling and the interaction between enhancers and promoters 
in the {beta}-globin locus. Brief Funct Genomic Proteomic 2004, 2(4):344-354. 
12. Bouhassira EE, Krishnamoorthy R, Ragusa A, Driscoll C, Labie D, Nagel RL: The enhancer-
like sequence 3' to the A gamma gene is polymorphic in human populations. Blood 1989, 
73(4):1050-1053. 
13. Ptashne M: Gene regulation by proteins acting nearby and at a distance. Nature 1986, 
322(6081):697-701. 
14. Chakalova L, Carter D, Debrand E, Goyenechea B, Horton A, Miles J, Osborne C, Fraser P: 
Developmental regulation of the beta-globin gene locus. Prog Mol Subcell Biol 2005, 
38:183-206. 
15. Gusev VD, Nemytikova LA, Chuzhanova NA: [A rapid method for detecting 
interconnections between functionally and/or evolutionary close biological sequences]. 
Mol Biol (Mosk) 2001, 35(6):1015-1022. 
60 
 
16. Muchardt C, Seeler JS, Nirula A, Gong S, Gaynor R: Transcription factor AP-2 activates 
gene expression of HTLV-I. Embo J 1992, 11(7):2573-2581. 
17. Vakoc CR, Letting DL, Gheldof N, Sawado T, Bender MA, Groudine M, Weiss MJ, Dekker J, 
Blobel GA: Proximity among Distant Regulatory Elements at the [beta]-Globin Locus 
Requires GATA-1 and FOG-1. Molecular Cell 2005, 17(3):453-462. 
18. Lozzio CB, Lozzio BB: Human chronic myelogenous leukemia cell-line with positive 
Philadelphia chromosome. Blood 1975, 45(3):321-334. 
19. Drexler HG, Matsuo Y: Malignant hematopoietic cell lines: in vitro models for the study 
of natural killer cell leukemia-lymphoma. Leukemia 2000, 14(5):777-782. 
20. Gahmberg CG, Jokinen M, Andersson LC: Expression of the major red cell 
sialoglycoprotein, glycophorin A, in the human leukemic cell line K562. J Biol Chem 
1979, 254(15):7442-7448. 
21. Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, Polliack A, Vanky F: Properties of 
the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 
1976, 18(4):421-431. 
22. Lozzio BB, Lozzio CB, Bamberger EG, Feliu AS: A multipotential leukemia cell line (K-
562) of human origin. Proc Soc Exp Biol Med 1981, 166(4):546-550. 
23. Wada-Kiyama Y, Peters B, Noguchi CT: The epsilon-globin gene silencer. 
Characterization by in vitro transcription. J Biol Chem 1992, 267(16):11532-11538. 
24. Mookerjee B, Arcasoy MO, Atweh GF: Spontaneous delta- to beta-globin switching in 
K562 human leukemia cells. Blood 1992, 79(3):820-825. 
25. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, Garvik BM, Yates JR, 3rd: 
Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 1999, 
17(7):676-682. 
26. Vester B, Wengel J: LNA (locked nucleic acid): high-affinity targeting of complementary 
RNA and DNA. Biochemistry 2004, 43(42):13233-13241. 
27. Hirsch JD, Eslamizar L, Filanoski BJ, Malekzadeh N, Haugland RP, Beechem JM, Haugland 
RP: Easily reversible desthiobiotin binding to streptavidin, avidin, and other biotin-
binding proteins: uses for protein labeling, detection, and isolation. Anal Biochem 2002, 
308(2):343-357. 
28. Griesenbeck J, Boeger H, Strattan JS, Kornberg RD: Affinity purification of specific 
chromatin segments from chromosomal loci in yeast. Mol Cell Biol 2003, 23(24):9275-
9282. 
29. Sandaltzopoulos R, Blank T, Becker PB: Transcriptional repression by nucleosomes but 
not H1 in reconstituted preblastoderm Drosophila chromatin. Embo J 1994, 13(2):373-
379. 
30. Morocho AM, Karamyshev V, Shcherbinina O, Polushin N: Biotin-labeled oligonucleotides 
with extraordinarily long tethering arms. Methods Mol Biol 2005, 288:225-240. 
31. Ranish JA, Yi EC, Leslie DM, Purvine SO, Goodlett DR, Eng J, Aebersold R: The study of 
macromolecular complexes by quantitative proteomics. Nat Genet 2003, 33(3):349-355. 
61 
 
32. Lam H, Deutsch EW, Eddes JS, Eng JK, King N, Stein SE, Aebersold R: Development and 
validation of a spectral library searching method for peptide identification from MS/MS. 
Proteomics 2007, 7(5):655-667. 
33. Ong SE, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, Mann M: Stable 
isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate 
approach to expression proteomics. Mol Cell Proteomics 2002, 1(5):376-386. 
34. Mallick P, Schirle M, Chen SS, Flory MR, Lee H, Martin D, Ranish J, Raught B, Schmitt R, 
Werner T et al: Computational prediction of proteotypic peptides for quantitative 
proteomics. Nat Biotechnol 2007, 25(1):125-131. 
35. Kruger M, Moser M, Ussar S, Thievessen I, Luber CA, Forner F, Schmidt S, Zanivan S, 
Fassler R, Mann M: SILAC mouse for quantitative proteomics uncovers kindlin-3 as an 
essential factor for red blood cell function. Cell 2008, 134(2):353-364. 
 
 
 
 
 
  
62 
 
II.II ABSOLUTE COPY NUMBER ANALYSIS OF TRANSCRIPTION 
FACTORS DURING CELLULAR DIFFERENTIATION USING A 
MULTIPLEX, TARGETED PROTEOMICS APPROACH 
 
The main goal of the research project is the development of an MS-based quantitative assay 
aimed at monitoring the dynamic changes in TF abundance underlying biological processes of 
interest. We intend to establish a multi-layered system for the efficient development of a 
sensitive medium-throughput SRM assay based on the use of TF proteins expressed in vitro for 
optimal transition selection. Absolute quantification of endogenous TFs is achieved by spiking 
heavy labeled TF proteins expressed extemporaneously in a cell-free system. Labeled proteins 
are quantified in situ via a unique engineered light reference-peptide tag. A faster 
implementation of this technology utilizes additional reference-peptide variants to expand the 
number of TFs that can be simultaneously analyzed. We ultimately focus on generating a 
quantitative model of gene regulation during terminal adipogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The supplementary tables and the supplementary note can be found in the Annex 
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ABSTRACT 
 
The regulatory properties of transcription factors (TFs) are largely dictated by their cellular 
abundance. Thus, deriving absolute TF copy numbers is crucial to understand how these proteins 
control gene expression. Here, we present a novel and sensitive selected reaction monitoring (SRM)-
based mass spectrometry assay, allowing us to simultaneously determine the absolute copy numbers of 
up to 10 proteins. We apply this approach to profile the levels of key TFs during adipogenesis, 
revealing that their abundance differs dramatically (from 250 to >300,000 copies per nucleus), but that 
their dynamic range during differentiation varies at most five-fold. We also formulate a genome-wide 
TF DNA binding model to explain the significant increase in PPARγ binding sites during the final 
differentiation stage, despite a concurrent saturation in PPARγ copy number. This model provides 
unique, quantitative insights into the relative contributions of binding energetics, copy number, and 
chromatin state in dictating TF DNA occupancy profiles.  
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Introduction 
 
Understanding how the expression of large sets of genes is orchestrated at a systems level is a topic of 
fundamental importance in biology. Differential gene expression is controlled by gene regulatory 
networks, which consist of functional interactions between regulatory state (e.g. transcription factors 
(TFs)) and genomic (e.g. gene promoters, enhancers) components
1
. A major current interest is to 
derive models of gene regulatory networks that elucidate or predict the dynamic transcriptional 
mechanisms underlying complex gene expression programs
2-4
. An important drawback of existing 
models is that relatively little quantitative data has so far been used in their calibration. In particular, 
accurate measurements on the absolute, molecular abundance of most TFs are still very sparse
2, 5
, even 
though such information is key to understand most biochemical and regulatory processes involving 
this type of proteins
6, 7
. This conundrum can be explained by the relatively low expression of TFs in 
cells
8
, which make their direct quantification by mass spectrometry (MS) or other assays a substantial 
challenge. Consequently, only a few MS-based studies have to date been able to provide TF copy 
numbers in higher eukaryotes
9, 10
. However, since these studies were not specifically designed to target 
TFs, they did not tackle the difficult task of tracking the expression of TFs of interest over the course 
of specific biological processes.  
Newly emerging proteomic approaches combining selected reaction monitoring (SRM) with 
isotope dilution quantification strategies now promise to alleviate this scarcity in absolute copy 
number data as they enable targeted, quantitative analyses
10-13
. These approaches all share the same 
principle of targeting a subset of detectable peptides which are specific to the protein of interest (i.e. 
proteotypic peptides). Quantification is thereby achieved by comparing their extracted MS signals to 
those of accurately quantified, isotopically-labeled peptides (usually having the same sequences), 
which are utilized as internal standards. Two recently published quantification strategies introduced 
the use of a single reference peptide serving as a cost-effective surrogate and allowing the accurate 
measurement of synthetically produced, full-length proteins
14, 15
. This intermediate information is 
crucial in the following step, where the complete set of protein-specific peptides can in turn be used to 
accurately quantify the endogenous protein within a complex sample. This has the advantage that both 
the endogenous and the synthetically produced counterpart are enzymatically digested together, 
leading to a more accurate and reproducible quantification
16, 17
. However, while powerful, this entire 
workflow currently only permits the direct quantification of one protein per assay, making it a costly 
and time-consuming exercise. This is because quantifying more than one protein at a time necessitates 
that the standards are quantified in a separate step. Moreover, precipitation and resolubilization issues 
inherently linked to protein/peptide storage may interfere with the overall accuracy of the 
methodology. Together, these considerations prompted us to develop an SRM-based assay in which 
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the internal protein standard quantification step is performed in situ (i.e. both the protein standard and 
its endogenous counterpart are simultaneously quantified within the same assay). In addition, we 
managed to multiplex this procedure, an important step towards addressing the need for assay 
upscaling, which remains one of the main limitations in current SRM-based assays as recently 
highlighted by Picotti and Aebersold
18
. As such, our assay is capable of monitoring and determining 
absolute amounts of pre-determined sets of up to 10 TFs (or other lowly abundant proteins of interest) 
per single, analytical run. 
Here, we applied this workflow to assess the dynamic changes in absolute TF levels during the 
terminal phase of adipogenesis. While quantitative proteomic studies have been performed to explore 
the adipogenic proteome, these lacked the required sensitivity to detect and quantify core adipogenic 
TFs
19-21
. Adipogenesis is in part orchestrated by two master regulators, PPARγ and RXRα, and can to 
a reasonable extent be mimicked in vitro using the mouse pre-adipocyte 3T3-L1 cell line
22, 23
. We were 
able to successfully monitor the temporal changes in nuclear PPARγ and RXRα abundance during 
3T3-L1 differentiation, thereby obtaining values on absolute copy numbers per cell. This first 
accomplishment prompted us to apply the multiplex variant of our methodology to derive absolute 
measurements for 10 TFs within this cellular system in one single run. Herein, we demonstrate that the 
monitoring and quantification of sets of lowly abundant proteins can be achieved without 
compromising detection sensitivity. Finally, we provide a first insight into how TF abundance data can 
be modeled in conjunction with large-scale DNA occupancy and chromatin state data to further our 
understanding of gene regulatory mechanisms mediating cellular differentiation. Specifically, our 
model reveals how the DNA binding profile of PPARγ is in large part influenced by its own copy 
number and local chromatin state, thus underwriting the importance of both protein levels and 
chromatin remodeling in dictating TF DNA binding behavior. 
 
RESULTS 
 
SELECTION OF TF-SPECIFIC PROTEOTYPIC PEPTIDES AND CORRESPONDING 
FRAGMENT-IONS FOR TARGETED SRM ASSAYS 
 
We initially turned to fragmentation spectra databases such as the NIST (http://www.nist.gov/nvl/) and 
PeptideAtlas
24
 to select the ideal pool of peptide candidates for the design of our SRM-based assay, 
aiming to monitor nuclear PPARγ and RXRα abundance during terminal adipogenesis. However, only 
a limited amount of information regarding TF-specific peptides could be retrieved. We therefore had 
to devise a strategy that did not rely on the use of publicly available information to discover 
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proteotypic peptides of TFs. To alleviate concerns regarding the detectability of TFs, we implemented 
three different bi-dimensional peptide fractionation pipelines on 3T3-L1 total nuclear protein extracts 
at day four of differentiation (a time point at which the adipogenic master regulators PPARγ and 
RXRα are known to be highly expressed25, 26) with the precise aim of discovering TF-specific peptide 
candidates that could be utilized in downstream quantitative analyses. However, only two peptides for 
each TF were retrieved in spite of the higher resolving power provided by the extensive fractionation 
and the consecutive higher sensitivity expected in mass spectrometry (Supplementary Fig. 1). Thus, 
despite recent increases in overall sensitivity 
27
, MS-based shotgun data-dependent methodologies are 
still lacking the combination of acquisition speed and sensitivity necessary to directly analyze lowly 
abundant proteins such as TFs within complex matrices derived from mammalian cells. The results of 
these preliminary experiments partly explain the scarcity of TF-specific peptides that we initially 
observed in databases. In response, we and others
28
 are currently undertaking significant efforts to 
address this TF data paucity, but it is clear that current TF-specific peptide repositories are still far 
from being complete. An alternative strategy based on the combined use of proteotypic peptide 
prediction tools and crude peptides synthesis
29
 did also not improve the quality of our acquired data. In 
fact, the majority of the synthetic peptides were either hardly detectable or not consistently detectable 
over the time course of the experiment. We attribute this behavior to peptide solubility and ionisability 
issues. We therefore searched for a more direct route to access detectable TF peptides, opting for a 
full-length protein expression-based strategy, which allows for a better accounting of the local 
environment surrounding the peptide cleavage sites. The enhanced wheat germ in vitro transcription-
translation system proved to be straight-forward to use and led to the highest protein production yield 
(Online Methods and data not shown). Ten TFs (including PPARγ and RXRα) that exhibit gene 
expression at some point during terminal adipogenesis were retained for downstream applications 
based on their high yields upon in vitro expression. Importantly, this expression system also tags 
proteins with an in frame C-terminal glutathione S-transferase (GST) sequence for full-length 
expression validation and efficient purification (Supplementary Table 1). Highly enriched GST-
tagged proteins with the correct, expected molecular weight were successfully obtained after 
optimization of the synthesis, capture, wash and recovery conditions as exemplified in 
Supplementary Figure 2. In-gel digestion followed by high resolution LC-MS/MS subsequently 
enabled us to generate a collection of experimentally detected TF-specific tryptic peptides for the 10 
TFs (Supplementary Table 2). The pool of peptides identified in the preliminary screen was 
submitted to a series of manual curation steps to ensure maximum sensitivity and selectivity, which 
was subsequently validated by SRM (Online Methods). Specifically, we selected peptides that exhibit 
reliable detectability, digestability, homogeneity, stability and uniqueness (whenever possible).  
 
 
68 
 
IMPLEMENTATION OF THE SRM-BASED METHODOLOGY 
 
In SRM, the quantification of proteins is generally achieved by spiking a set of pre-determined, 
isotopically-labelled proteotypic peptides into a complex sample at known concentrations to serve as 
standards
30
. It would thereby be optimal to dispose of the complete set of protein-specific peptides, as 
peptide behavior in the mass spectrometer is rather difficult to predict, but the cost associated with 
accurate quantification of synthetic peptides makes this difficult to implement (e.g.
31
). Moreover and 
perhaps more importantly, the differences in physicochemical behavior between peptides makes the 
use of individual peptides less attractive, since peptide solubility will affect the measurement 
accuracy
32
. Building on pioneering work
14, 15, 33
, we therefore set out to utilize full-length, isotopically-
labelled, in vitro-expressed TFs directly as standards for quantification of endogenous TFs utilizing a 
modified version of the same workflow that we have adopted for transition selection. For this purpose, 
we added an in-frame proteotypic reference-peptide tag previously employed for quantitative 
interaction studies, SH-Quant
15
, at the N-terminus of the protein constructs. This tag is utilized for the 
in situ quantification of heavy TFs utilizing a synthetic and accurately quantified light SH-Quant 
counterpart. In this manner, one single peptide only (the SH-Quant) is used for the absolute 
quantification of a heavy, in vitro-expressed standard TF, thus simplifying and reducing the cost of the 
assays even further. In turn, quantification of the endogenous TF in absolute amounts is achieved by 
utilizing TF-specific peptides (Fig. 1 and Fig. 2a). 
 
ABSOLUTE QUANTIFICATION OF TWO ADIPOGENIC MASTER REGULATORS: 
PPARΓ AND RXRΑ 
 
To evaluate PPARγ and RXRα peptide transitions, two separate pilot SRM assays were implemented 
as depicted in Figure 1 and exemplified in Figure 2b (details in Supplementary Figs. 3-5).  
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Figure 1: Workflow for the absolute quantification of TFs in 3T3-L1 cells. 
The left panel shows the preparation of 3T3-L1 total nuclear protein extract. Cells are lysed at each 
differentiation time point (0h or Day 0 (D0), 2h, Day 1 (D1), Day 2 (D2), Day 4 (D4), and Day 6 (D6)) after 
which nuclear proteins are extracted. The resulting protein mixture is separated by SDS-PAGE, stained with 
Coomassie Blue, and bands where selected TFs (RXRα here) are expected to be located are excised from the gel. 
The right panel shows the preparation of in vitro-expressed SH-tagged TFs. The constructs are expressed in their 
heavy-labeled version (*) using a wheat germ-based in vitro transcription-translation kit, purified by GST 
affinity, separated by SDS-PAGE, and stained with Coomassie Blue. Bands containing the heavy-labeled 
constructs (SH-RXRα-GST* here) are excised from the gel and sliced. Each nuclear extract band to be 
quantified is then mixed with one gel slice of the in vitro-expressed TF construct, spiked after dehydration with 
known amounts of light SH-Quant tag and in-gel digested together. The resulting peptide mixtures are then 
quantified by SRM using validated proteotypic peptides selected from information previously collected on each 
in vitro-expressed TF via shotgun-MS runs. Each TF quantification requires a separate experiment in this 
configuration. 
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Figure 2. In situ protein quantification procedure and SRM-based monitoring of light and heavy 
RXRα peptides with their corresponding quantification tag (SH-Quant) spiked together into a 
nuclear extract sample. 
(a) The scheme outlines the two step procedure used for the SRM-based quantification strategy (RXRα is used 
here as an example). In step 1, the amount of heavy-labeled, in vitro-expressed SH-RXRα-GST is quantified by 
isotope dilution using a pre-determined amount of light, accurately quantified SH-Quant reference-peptide (SH-
tag). Specifically, quantification of the in vitro- expressed heavy construct is achieved based on the ratio of the 
light versus the heavy SH-tag peptide. Hence, the calculation of the heavy SH-tag reveals the amount of total 
heavy RXRα found in the assay. In step 2, RXRα-specific heavy signature peptides are used to accurately 
determine the amounts of endogenous RXRα present within the 3T3-L1 nuclear extract by comparing heavy 
versus light (endogenous) peptides. The two steps are accomplished at the same time to further simplify the 
assay and to limit measurement variations that may occur during differential treatment of the samples. Typical 
peptide fragmentation signatures, as well as the LC co-elution of the heavy TF-specific peptides serve as strong 
identification criteria in SRM-based mass spectrometry. (b) Subpanel 1: Positioning of the five proteotypic-
selected peptides within RXRα. For the sake of clarity, their sequences are color-coded (peptides ending with a 
lysine in red, peptides ending with an arginine in green). Subpanel 2: Total ion extraction of five proteotypic 
peptides of the light (endogenous) and heavy forms as well as the SH-Quant tag. Clear separation of all peptides 
was achieved using a short LC gradient. Subpanel 3: raw file showing a zoom-in of the SH-Quant tag 
(AADITSLYK) in its light and heavy forms (colored in red and black respectively) and the calculated peak area 
using Pinpoint (subpanel 4). The calculated peak intensities of selected fragment ions of the light and heavy tag 
are also presented. 
 
Subsequently, the complete workflow was applied to monitor the absolute, nuclear abundance of 
PPARγ and RXRα during terminal adipogenesis. The technical robustness of the whole workflow is 
highlighted by the low coefficient of variation (CV) obtained within one biological sample 
(Supplementary Fig. 6). The resulting data, as summarized in Figure 3 and Supplementary Table 3, 
provide unique insights into the dynamic protein copy number per cell (nucleus) profiles of PPARγ 
and RXRα. We found that there are approximately two- to six-fold more RXRα than PPARγ protein 
copies in the nucleus depending on the differentiation time point. Prior to the induction of 
differentiation, nuclear TF copy numbers are at their lowest with ~2,000 for PPARγ and ~10,000 for 
RXRα. The number of RXRα molecules then peaks two days after differentiation (~32,000) after 
which it declines from ~23,000 at day four to ~13,000 at day six. In contrast, the greatest number of 
nuclear PPARγ molecules was found at day four (~8,500) with a small decline at day six (~7,500).  
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Figure 3. Summary of RXRα and PPARγ levels quantified by SRM. 
(a) A graphical summary of the concentration (expressed as fmol/µg nuclear extract (NE)) of RXRα (left) and 
PPARγ (right) in three individual biological replicates (bars represent the mean ± SD of three technical 
replicates). (b) Absolute RXRα and PPARγ levels visualized as copies per cell (bars represent the mean ± SEM 
of three biological replicates). 
 
To validate our results, we performed Western blot analysis utilizing anti-PPARγ and anti-RXRα 
antibodies for each time-point (Supplementary Fig. 7). The detected TF copy number profiles mirror 
those observed by our SRM-based quantification approach, although it is clear that only relative 
changes can be assessed using immunoblotting and that this technique appears to inflate (PPARγ) or 
deflate (RXRα) the actual, dynamic changes. Together, our results indicate that nuclear PPARγ and 
RXRα protein copy numbers change substantially over the course of adipogenesis. In addition, they 
illustrate both the accuracy and sensitivity of our targeted proteomics approach.  
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A QUANTITATIVE MODEL OF GENOME-WIDE TF DNA BINDING 
 
The availability of absolute protein copy number data allowed us to examine the relationship between 
the number of genome-wide DNA binding events and TF molecules. Using RXRα and PPARγ ChIP-
seq data from Nielsen et al.
34
, we found that, until the fourth differentiation day, the number of TF 
molecules and corresponding binding events correlate well (R
2
 = 0.96 for PPARγ; R2 = 0.85 for 
RXRα; Supplementary Fig. 8), and that in general, there are substantially more RXRα than PPARγ 
binding events consistent with their corresponding TF copy numbers. The slightly lower correlation 
between the number of RXRα binding events and protein copies compared to that for PPARγ may 
reflect the ability of RXRα to bind DNA as a homodimer, which may reduce the binding site count per 
RXRα molecule. Nevertheless, the high correlations indicate that ChIP-seq occupancy data likely 
reflect endogenous conditions rather than being the result of differences in antibody-mediated protein 
recoveries as previously hypothesized
34
. A striking discrepancy was however observed for day six as, 
compared to previous days, the number of RXRα and PPARγ binding events significantly increases 
(>three-fold for both TFs), whereas the number of TF molecules saturates or even decreases 
(Supplementary Fig. 8). To reconcile these findings and to possibly provide a mechanistic 
explanation for this phenomenon, we generated a quantitative model to predict the number of PPARγ 
binding events in the genome given a number of TF molecules, ChIP detection threshold, and genome 
accessibility maps (Supplementary Note, the document can be found in the Annex). The chromatin 
mark histone three lysine 27 mono-acetylation (H3K27Ac) was recently found to be a good indicator 
of active or accessible regulatory regions given its substantial overlap with FAIRE (open chromatin) 
sites
35
 and its utility in identifying active promoters and enhancers
36
. In addition, more than 80% of 
PPARγ binding sites are located within H3K27Ac-enriched regions37, further strengthening the 
observation that the H3K27Ac mark is a reasonable proxy for chromatin accessibility. Consequently, 
we formulated the model to account for the distribution of specific and non-specific sites for PPARγ in 
H3K27Ac-enriched regions, as derived from recent genome-wide enrichment data for differentiation 
days zero, two, and six
37
 (Fig. 4a). To assess the DNA binding events at thermodynamic equilibrium, 
we assumed that all the PPARγ proteins were on the DNA at either specific or non-specific sites, 
consistent with the consensus in the field that TFs tend to mostly reside on DNA in vivo
7
. For the sake 
of simplicity, we did not consider interactions with other TFs, or hindrance due to other proteins 
sitting on DNA (for a discussion on these topics, see Supplementary Note). The resulting model 
predicts the number of binding events given the number of PPARγ copies per cell (nucleus) for each 
time point as a function of the ChIP detection threshold expressed as percentage occupancy (or 
residency time) (Fig. 4b). While it is difficult to precisely estimate the latter threshold, a survey of our 
own and published ChIP data revealed that the signal associated with DNA binding is typically 
considered as positive from around 1% (as compared to input)
26, 38
. Interestingly, when we used ~1% 
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as detection threshold, our model predicts binding event numbers which closely mimic the 
experimentally derived data (Fig. 4c).  
 
 
 
Figure 4. Quantitative modeling of genome-wide PPARγ DNA binding. 
(a) Cumulative number of genomic sites in H3K27Ac regions at Day 0 (gray line), Day 2 (dashed line), and Day 
6 (black line). The axis runs from the strongest (1000-fold stronger than non-specific sites) to medium affinity 
sites (60-fold stronger). While the numbers for Day 0 and Day 2 are comparable, Day 6 shows a 35% increase in 
this range. (b) Number of detected bound loci at Day 0 (gray line), Day 2 (dashed line), and Day 6 (black line) 
during 3T3-L1 terminal differentiation in function of the detection threshold on the expected occupancy. The 
model takes into account the measured PPARγ copies per cell (nucleus) and the distribution of accessible high 
affinity sites. Matching with the number of measured ChIP-seq sites predicts an occupancy threshold of 1.35%. 
(c) Temporal pattern for the prediction on the number of detected PPARγ-bound sites (dashed line), the actual 
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number of measured sites (black line), and the protein copy number (grey line). Note that the number of sites 
shows an exponential-like increase, while the protein copy number graph reflects saturation. 
 
Thus, the model correctly predicts the temporal pattern in the number of binding sites over the course 
of terminal adipogenesis. A closer look into the determining factors revealed that the sharp increase in 
binding events at day six as compared to days zero and two is in part driven by the increase in PPARγ 
copy number between days two and six. However, we found that an equally important factor relates to 
shifts in the relative distributions of higher versus lower affinity sites in accessible genomic regions at 
the different differentiation time points (Fig 4a). Specifically, whereas the overall size of accessible 
regions is similar across all days, we found that cells undergo important chromatin remodeling 
between days six as compared to zero and two such that more medium-to-high affinity sites for 
PPARγ become available. This in turn allows for a substantial increase in detectable DNA binding 
events even though the TF copy number increase is relatively modest. Together, these analyses show 
the value of accurately quantifying TF copy numbers to generate quantitative DNA binding models 
from which emergent properties regarding gene regulatory mechanisms underlying a specific 
biological process can be derived. 
 
MULTIPLEXING THE SRM ASSAY 
 
Although our approach now enables us to monitor absolute protein copy numbers over time in a 
sensitive and reproducible manner, we sought to overcome the current limitation of quantifying only 
one protein per assay. For this purpose, we designed 9 quantotypic SH-Quant tag variants that, along 
with the original SH-Quant tag, allow the quantification of up to 10 proteins or TFs in one single 
integrated SRM assay, thereby increasing the practical usefulness of the methodology. This required 
changing one or two amino acids within the parent SH-Quant sequence for each variant, while 
retaining the best transitions for tag quantification and creating distinct peptide fragment signatures for 
tag identification purposes.  
We subsequently generated 10 expression vectors enabling the coupling of each tag variant to 
a distinct, adipogenic TF. Our list includes: RXRα, NFIB, PIAS3, PIAS4, FOSL2, RARg, PPARγ, 
ARID3a, NR2C1 and SMAD22 (we included PPARγ and RXRα as validation). Corresponding 
transitions as well as the retention time of the parent ions are presented in Figure 5a. The performance 
as well as chromatographic separation of the nine, newly designed candidates and their parent SH-
Quant sequence was tested in a series of SRM runs (Fig. 5b). Two SH-Quant tag-variants 
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“AADITSLYK” and “AAEVTSLYK” are isobaric and yet could be clearly distinguished by their 
chromatographic profile and by their distinct transitions (Fig. 5c,d,e).  
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Figure 5. Properties of the SH-Quant tag variants. 
(a) The table provides a detailed summary of the different tags designed for the multiplex assay. The sequences 
of tags 2 to 10 derive from the original SH-Quant tag 1, and were designed with the intent of conserving intense 
y” fragment ions at positions y2 to y5 for quantification purposes. The fragmentation fingerprint of ions y6 to y8 
allow for improved tag identification especially in the case of isobaric peptides. Overall, this targeted design 
resulted in a clear LC separation of isobaric tags 3 and 7 (m/z = 470.2; green) or tags 1 and 9 (m/z = 491.2; red). 
(b) LC-SRM spectrum of a multiplexed nuclear extract sample using a 120 minute gradient. (c) 
Chromatographic separation of all ten SH-Quant tags. Near complete chromatographic separation was achieved 
for most tags using a short LC gradient of 60 min. (d) Zoom-in view of the area highlighted in panel c, showing 
the extracted ion current (EIC) of isobaric SH-Quant tags 1 and 9 in a multiplex sample (peak 1: m/z = 491.2, 
peak 2: 491.2) and the calculation (e) of the peak areas of the light and heavy versions using Pinpoint. The above 
outlined sequence design resulted in a clear difference in physicochemical properties of two isobaric SH-Quant 
tags, as seen by their different elution times at 30.7min (AAEVTSLYK) and 35min (AADITSLYK) respectively 
in a complex sample. Identical elution times were observed for both light and heavy versions of all 10 SH-Quant 
tags. 
 
A standard curve was established for each SH-Quant tag variant by spiking them separately within the 
same 3T3-L1 nuclear extract preparation that was next used for TF abundance measurements 
(Supplementary Figs. 9-10). This allowed us to determine the lower limit of quantification (LLOQ) 
for each tag (the original SH-Quant tag is presented as an example in Supplementary Fig. 11). The 
increased sample complexity also required optimization of the hardware setup for LC separation. 
Applying the multiplex version of our methodology, we were able to monitor endogenous levels of 10 
TFs in 3T3-L1 nuclear extracts derived from three terminal differentiation time points (Day 0, Day 2, 
and Day 6) (Figs. 6a,b). As summarized in Figure 6c and Supplementary Figure 12, we found that 
the majority of the additionally analyzed TFs (e.g. PIAS4, NFIB, SMAD2, RARg, FOSL2) are 
expressed within approximately the same absolute copy number range as PPARγ or RXRα 
(Supplementary Table 3).  
Importantly, measurements of PPARγ and RXRα copy numbers were coherent with data obtained with 
the non-multiplex approach, indicating that the up-scaling of the SRM assay does not interfere with 
measurement precision. The abundance of other TFs such as PIAS3, NR2C1, and ARID3a fell below 
the quantification threshold. Nevertheless, the overall quality of the fragment ions monitored for the 
heavy and light peptides (Fig. 6d) clearly allows for the unambiguous identification of these TFs.  
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Figure 6. Simultaneous monitoring of the nuclear abundance of ten TFs during terminal 
adipogenesis. 
(a) Multiplex SRM transition profiles of selected best responding tryptic peptides from all ten TFs during a 120 
minute LC-SRM run. (b) Zoom-in (minutes 29-36) of the highlighted region in spectrum (a), illustrating the 
complexity of the mixture and the separation quality achieved with the multiplex SRM assay on nuclear extract 
sample. (c) Calculated endogenous levels of all ten TFs detected at Day 0, Day 2, and Day 4 (bars represent the 
mean ± SEM of 4-6 technical replicates). (d) Calculated peak areas of ten proteotypic peptides in their light and 
heavy versions. 
 
DISCUSSION  
 
In this study, we describe the development of a sensitive and multiplex, targeted MS assay, which 
uniquely allowed us to monitor the absolute copy number fluctuations of specific TFs of interest 
during a cellular differentiation process. Determining the copy number of this type of proteins has 
been of longstanding interest given that the DNA binding ability of a TF and hence its regulatory 
capacity strongly depends on its cellular concentration
6, 7, 39
. However, despite the fundamental 
importance of TFs in most biological processes, a recent comprehensive survey showed that only a 
handful of studies have so far provided estimates on the abundance of animal TFs
7
. These analyses 
were mostly achieved with indirect immuno-based measuring methods (e.g. 
40
), whose additional 
drawback is the dependence on antibodies which are available for only a limited number of TFs. 
Nevertheless, these studies estimated TFs to be expressed in the range of 5,000 to several hundred 
thousand copies per nucleus
7
, which is in line with our results. 
Driven by this lack of accurate TF measurements and aided by recent improvements in 
analytical capacities of MS, we built an SRM-based workflow that combines high sensitivity and 
technological innovation to generate quantitative data in absolute terms. This workflow, which 
significantly extends recent efforts to specifically tailor MS methodologies to quantify lowly abundant 
proteins such as TFs (albeit so far only in relative terms)
28
, offers several advantages. First, the only 
requisite of our SRM-based assay is the in vitro expression of the protein candidate, which, except for 
certain types of proteins, becomes relatively trivial given the availability of efficient cloning and 
expression systems and Open-Reading Frame (ORF) clone libraries
41, 42
. Thus, the assay capitalizes on 
the well-appreciated advantages of in vitro full-length protein expression, including the quick and 
economical production of nearly any protein of choice (isotopically labeled or not), as well as the 
ability to limit the accuracy loss linked to the use of single or concatenated peptides
18
. In addition, the 
ability to nearly extemporaneously produce heavy-labeled full-length protein standards, and to 
simultaneously quantify both these protein standards and their endogenous counterparts within the 
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same assay bypasses the necessity for protein/peptide storage, another significant source of variability 
in any quantitative assay
18
. Finally, the elution profiles and ion intensities of the protein standard-
specific heavy peptides are compared to those of their non-labeled counterparts, further increasing the 
protein identification confidence. This is of great importance when dealing with peptide signals of 
lowly abundant proteins such as TFs. Second, the SH-Quant tag used in our assay allows for a robust, 
sensitive, and reproducible in situ quantification of the internal standard protein and by extension 
allows for accurate dynamic monitoring of endogenous protein copy number fluctuations. Third, the 
introduction of variations in this reference tag enables the analysis of multiple proteins in one single 
assay. These quantotypic tag variants differ from the original tag at the most by one or two amino 
acids, thereby minimizing the putatively adverse impact on measurement accuracy which may arise 
due to significant differences in physico-chemical properties of the peptides. Indeed, the results 
obtained with the multiplex pipeline demonstrate that the overall accuracy and sensitivity compared to 
the “one protein at a time” approach is maintained, thus providing a cost-effective, relatively quick, 
and sensitive strategy to simultaneously quantify several proteins or even entire pathways. Our 
quantification strategy therefore constitutes a powerful and even cost-effective alternative to 
quantitative immunoassays (immunoblotting
43
 or ELISA) to determine fluctuations in protein 
abundance over a wide concentration range with the additional advantage of being able to multiplex 
the assay, something that is much more difficult to do with ELISA
31
. This multiplex capacity should 
be of great value to those interested in examining or modeling absolute, dynamic changes of entire 
pathways or sets of biomarkers of interest in wildtype versus clinical, disease, or perturbation settings. 
Here, we illustrate the importance of deriving this type of data by building a quantitative 
model aiming to clarify an intriguing discrepancy between TF binding site and copy number data. As 
such, we provide a quantitative explanation for the common observation that many TFs, including 
PPARγ, bind to significantly fewer sites in the genome than predicted based on the presence of their 
respective consensus motifs
37, 44, 45
. Whereas it was suggested that other factors may contribute to this 
binding site selectivity, here, we demonstrate that, at least for PPARγ, its DNA binding profile can be 
closely modeled by simply considering its own copy number, simple thermodynamic principles, and 
chromatin accessibility. The functional consequence of our findings is that the chromatin state 
constitutes a landing map for PPARγ DNA binding, consistent with the emerging notion of the 
importance of chromatin structure in shaping TF DNA binding patterns
45
. This raises the question as 
to which other factors may control the chromatin state over the course of terminal adipogenesis. One 
possible candidate is the adipogenic TF C/EBPβ, which was recently shown to mediate chromatin 
accessibility in this terminal differentiation process
46
. However, several other TFs may also qualify 
based on the differential enrichment of their respective motifs in adipocyte- compared to pre-
adipocyte-specific H3K27Ac sites
37
 and thus the precise identity of the responsible TF(s) remains to 
be elucidated. 
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In summary, our work represents an important effort to expand the analytical and practical 
capabilities of targeted proteomics approaches while safeguarding measurement accuracy. In a next 
phase, we look forward to further expanding the number of reference-peptide variants to boost the 
assay’s multiplex capacity as part of the overall aim to elucidate and model the dynamic properties of 
entire biological processes or networks under different experimental conditions. 
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METHODS 
 
3T3-L1 cell culture, differentiation, and protein extraction 
3T3-L1 cells were cultured and differentiated into adipocytes as detailed in Raghav et al.,
23
 
(Supplementary Methods).  
 
Cloning and plasmids 
Mouse TF ORFs were cloned in Gateway format essentially as described earlier
42
. To make the wheat 
germ (WG) in vitro transcription-translation expression system (Promega) compatible with the mouse 
TF ORF clones and to allow the purification of TFs, we modified the SP6 pF3A WG (BYDV) Flexi 
vector (Promega) to accommodate the Gateway reading frame A cassette (Invitrogen). A glutathione-
S-transferase (GST) coding sequence containing a stop codon was subsequently incorporated in frame 
at the 3’-end of the second (i.e. 3’) Gateway site using standard cloning techniques. TFs were then 
subcloned from the Gateway entry clone level into this “in house” modified pF3A-GST destination 
vector by standard Gateway cloning (Supplementary Methods).  
 
In vitro protein expression and purification, gel staining, and immunoblotting 
For selection of optimal TF transitions: the 10 selected TFs containing a GST tag at their C-terminus 
were expressed in vitro via the TnT SP6 High Yield Wheat Germ Protein Expression System 
(Promega) according to the manufacturer’s protocol. GST-labeled TFs were subsequently purified via 
glutathione sepharose 4B beads (GE Healthcare) according to the manufacturer’s protocol 
(Supplementary Methods). Purified proteins were separated by SDS-PAGE in a 10% resolving gel 
(Tris-Glycine) and stained either with silver nitrate or with Coomassie blue (SimplyBlue Safestain, 
Invitrogen) for band visualization. Validation of in vitro-expressed proteins was performed by 
Western blot (Supplementary Methods). 
For TF quantification: the 10 selected TFs were expressed in vitro via the TnT SP6 Wheat Germ High 
Yield Master Mix Minus Amino Acids (Promega) in their isotopically-labeled version. 18 amino acids 
were mixed to reach a 80µM final concentration and added to the reaction together with isotopically-
labeled Arginine (
13
C,
15
N-Arg) and Lysine (
13
C,
15
N-Lys)(Cambridge Isotope Laboratories) to a 1mM 
final concentration prior to resorting to the conventional expression protocol. Depending on the 
analyzed TF, 3X reactions were utilized (or 4X for TFs with low expression yields). Subsequently, the 
purification and fractionation techniques described above were applied.   
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Reference peptide tag incorporation 
The SH-Quant peptide (AADITSLYK)-coding sequence along with the segment of the 5’ Gateway 
site comprised between the PvuI and PvuII restriction sites was synthesized by Geneart-Life 
Technologies. An SpeI restriction site was added at the 3’ of the tag-coding sequence to simplify the 
insertion of tag variants. The SH-Quant insert was introduced in the PvuI and PvuII restriction sites at 
the 5’ Gateway site of the pF3A-GST vector by double digestion with the two restriction enzymes and 
subsequently ligated to obtain the SH-pF3A-GST destination vector.  
 
Reference peptide tag variants design for multiplexing 
The additional tags 2 to 5 described in Fig. 5 were designed by a first permutation of Ile residue 4 
from the original SH-Quant tag sequence with amino acids of different hydrophobicity and size (G, A, 
V, F) to introduce molecular weight and/or retention time differences while not altering the 
fragmentation pattern. Additional tags 6 to 10 were generated by a second permutation conservative of 
the charge by replacing Asp residue 3 by Glu in the 5 sequences generated as above. Hydrophilic 
residues Thr 5 and Tyr 8 which produce intense y” fragment ions were kept constant to maintain 
solubility and sensitivity. The IN VITRO expression vector SH-pF3A-GST was modified via site-
directed mutagenesis (QuikChange Lightning, Stratagene) according to the manufacturer’s protocol to 
generate the SH-quant peptide variant-incorporating vectors (SHi-pF3A-GST). The I4G, I4A, I4V, 
I4F, D3E, D3E- I4G, D3E-I4A, D3E-I4V, and D3E-I4F substitutions were introduced into SH-pF3A-
GST using the forward and reverse primers presented in Supplementary Table 4, and sequence-
verified. Proteotypicity of the newly designed tags was confirmed with Blast-P against the mouse 
protein database (http://blast.ncbi.nlm.nih.gov). 
 
In vitro-expressed TF identification 
In vitro-expressed proteins were in-gel digested using trypsin as follows: the samples were reduced in 
10 mmol/l dithioerythritol (DTE) and alkylated in 55 mmol/l iodoacetamide (IAA) before being dried. 
The samples were then incubated with 12.5 ng/ml of trypsin overnight at 37°C. The resulting tryptic 
peptides were extracted from the gel slices, dried, and resuspended in 2% acetonitrile (ACN): 0.1% 
formic acid (FA) for LC-MS/MS analysis. A mass spectrometer (LTQ Orbitrap XL (Thermo Fisher 
Scientific) equipped with an ultraperformance LC (UPLC) system (nanoACQUITY; Waters) was used 
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(Supplementary Methods). Data search was performed using Mascot software (v. 2.3; Matrix 
Science) and Proteome Discoverer (v.1.3; Thermo Fisher Scientific) (Supplementary Methods). 
 
Proteotypic peptide selection 
The procedure to select optimal TF proteotypic peptide candidates is explained in the Supplementary 
Methods. 
 
Nuclear extract sample preparation and spiking of SH-Quant reference tags 
Typically, 400 µg (quantified using the BSA assay) of total protein nuclear extract (differentiation 
times: Day 0 to Day 6) were separated and fractionated by SDS-PAGE using 10% Tris-Glycine gels. 
Gel bands were excised around the migration height of the selected proteins: 50-60 kDa for RXRα and 
PPARγ, 30-40 kDa and 45-70 kDa for the multiplex analysis (all 10 TFs). Gel fractions were first 
reduced and alkylated using 10 mM dithioerythritol and 55mM iodoacetamide, followed by gel drying 
using speed vacuum. Gel fractions were re-suspended in 50 mM ammonium bicarbonate (pH 8.3) 
digestion buffer, containing trypsin (Trypsin-Gold, Promega) at a final concentration of 12 ng/µl. The 
accurately quantified SH-Quant tags (JPT Peptide Technologies) were added to each tube (200 
fmol/tag) immediately after re-suspension in the digestion buffer. Digestion was performed overnight 
at 37 °C. Following digestion, peptides were extracted from gels and accurately aliquoted into four 
equal volumes (4x 100 µl) followed by sample drying using speed vacuum and stored at -20°C prior to 
analysis. 
 
Liquid chromatography-mass spectrometry (LC-MS) analysis 
Dried aliquots (theoretical concentration: 100 μg) were re-suspended in 20 μl LC-MS loading solvent 
(2% acetonitrile, 0.1% formic acid) yielding a final, theoretical concentration of nuclear extract of 5 
μg/μl. Following re-suspension, samples were allowed to settle for 1h to increase overall peptide 
solubility prior to analysis. Typically, 5 μl of sample (theoretical total: 25 μg) was loaded and captured 
on a home-made capillary pre-column (Magic C18; 3 μm-200Å; 2 cm × 250 μm) prior to analytical 
LC separation (nanoACQUITY UPLC, Waters). Samples were separated using a 90-minute biphasic 
gradient starting from 100% A solvent (2% acetonitrile, 0.1% formic acid) to 90% B solvent (100% 
acetonitrile, 0.1% formic acid) on a Nikkyo (Nikkyo Technologies) nano-column (C18; 3 μm-100 Å; 
15 cm length and 100 μm inner diameter, at a flow of 1 μl/min). The gradient was followed by a wash 
for 8 min at 90% solvent B and column re-equilibration of 12 min at 100% solvent A.   
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Selected reaction monitoring (SRM) of TFs 
All samples were analyzed on a TSQ-Vantage triple-quadrupole mass spectrometer (Thermo Fisher, 
Scientific). A 0.7 FWHM resolution window for both Q1 and Q3 was set for parent- and product-ion 
isolation. Fragmentation of parent-ions was performed in Q2 at 1.5 mTorr, using collision energies 
calculated with the Pinpoint software (v1.1). Parent-ion selection was set for fully digested peptides on 
the doubly charged ion for both SH-Quant tags and target proteins. Generally, singly charged peptide 
fragment ions ranging from y’’3 to y’’n-1 were preferably monitored, unless otherwise stated. A 
complete list of all monitored transitions is provided in Supplementary Table 5. A parent-ion 
retention time target window of 2 min (single quantification of RXRα and PPARγ) and 5 min 
(multiplexed quantification of ten TFs) was set for Q1 during a scheduled SRM run. A total of 
respectively 88 and 76 transitions were monitored for RXRα and PPARγ in the single protein 
quantification strategy, whereas a total of 492 transitions were typically monitored during a multiplex 
run. A cycle time of 0.5 s and 2 s was used for single and multiplex SRM runs respectively. A 
minimum dwell time of 10 ms or more was set for both single and multiplex SRM assays. Samples 
were analyzed as three biological and three technical replicates (n=3) in RXRα and PPARγ single 
protein quantification assays. One biological replicate was analyzed in 6 technical replicates as a 
proof-of-concept of the multiplex SRM assay. 
 
Data analysis and absolute quantification of TFs 
Calculation of absolute levels of TFs was performed using a two-step procedure as outlined in Figure 
2. All data analyses were carried out using Pinpoint software (v.1.1). Peptide identification and peak 
area integration of all SH-Quant tags and targeted peptides as well as their transitions were verified 
manually in Pinpoint. Ten individual standard curves were established for all SH-Quant tags using a 
concentration range of six values recorded in three technical replicates (Supplementary Fig. 10). The 
performance-based definitions of lower limits of quantification (LLOQ) were applied as defined by the 
FDA (Guidance for Industry: Bioanalytical Method Validation: 
http://www.fda.gov/cder/guidance/index.htm). Briefly, the threshold for the limit of detection (LOD) 
was set at 20% of the CV, whereas the LLOQ was set at 15% of the CV using three technical 
replicates for single- and six technical replicates for multiplex quantification approaches. An example 
of the LLOQ found for an SH-Tag is provided in Supplementary Figure 11. An analysis of variance 
(ANOVA) coupled with a Neuwman-Keuls post-hoc test was applied for calculating the differences in 
endogenous levels of TFs between different differentiation time points, where the level of P<0.05 was 
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considered as statistically significant. The calculation steps to derive absolute copy numbers per cell 
(nucleus) are presented in Supplementary Table 3.  
 
Motif Analysis 
Regions enriched with H3K27ac as determined by Mikkelsen et al.,
37
 were scanned with FIMO
47
 
allowing for a P value of 10
-3
. Each match in those regions was then scored for log-likelihood given by 
the position weight matrix of the PPARγ motif from the JASPAR CORE database48, assuming uniform 
background. 
 
PPARγ ChIP-seq data reanalysis 
ChIP-seq data from Nielsen et al. (
34
) was processed as in Raghav et al.
23
. 
 
Quantitative model of genome-wide TF DNA binding 
The estimation of the PPARγ DNA binding profile is based on equilibrium thermodynamics and is 
described in detail in the Supplementary Note.  
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SUPPLEMENTARY INFORMATION 
 
 
 Absolute copy number analysis of transcription factors during cellular differentiation 
using a multiplex, targeted proteomics approach  
 
 
 
Supplementary Figures 
 
 
 
Supplementary Figure 1.  Diagram representing the 3 shotgun MS pipelines tested utilizing 3T3-
L1 total nuclear protein extract at Day 4 of differentiation.  
Each pipeline employs a different peptide separation technique in the first dimension: SAX (strong 
anion exchange, 6 fractions), SCX (strong cation exchange, 20 fractions), and separation of peptides 
by their isoelectric point using an “Off-gel” electrophoretic system (24 fractions). The peptides were 
subsequently submitted to LC-MSMS for identification. The two adipogenic master regulators PPARγ 
and RXRα were specifically targeted. A maximum of only 2 peptides per TF were ultimately 
observed. 
 
 
PPARγ 0 1 1
RXRα 2 0 0
Detection of PPARγ and RXRα peptides by 3 shotgun MS pipelines 
MSMS MSMS MSMS
3T3-L1 total nuclear protein 
extract at Day 4
SAXSCXOff-gel 1st dimension of separation
LC LC LC 2nd dimension of separation
Peptide detection and 
identification
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Supplementary Figure 2. 10 in vitro-expressed GST-tagged TFs.   
The 10 in vitro-expressed TFs were run on a denaturing SDS-PAGE gel stained with silver nitrate. 
The molecular weights of the TF constructs (molecular weight of the TF + molecular weight of the 
GST-tag (26 kDa)) are presented in parentheses and their respective bands are indicated by an arrow. 
Peptide detection and protein identification for each TF construct was performed by in-gel digestion 
and LC-MS analysis. 
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Supplementary Figure 7. Immunoblotting analysis of PPARγ and RXRα expression levels found 
in 3T3-L1 nuclear extracts.  
(a) Validation of nuclear levels of PPARγ (left panel: isoform II on top at 57.6 kDa, isoform I on the 
bottom at 54.5 kDa) and RXRα (right panel: 51,2 kDa) expression by Western blot using TF-specific 
primary antibodies in 3T3-L1 cells during 6 time points of terminal differentiation. PARP-1 was used 
as a nuclear loading control.  
(b) Densitometric analysis was performed for both PPARγ (left) and RXRα (right). Values were 
normalized against PARP-1 and Day 0 was taken as reference. Values of the subsequent days are 
represented in terms of fold changes. 
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Supplementary Figure 8. PPARγ and RXRα protein copy number versus the number of detected 
binding sites. 
(a) Graph showing the PPARγ protein copy number profile during terminal adipogenesis as detected 
by SRMs in relation to its binding site profile. A sharp increase in detected binding sites can be 
observed after Day 4, despite a saturation in PPARγ protein copy numbers. 
(b) Graph showing the RXRα protein copy number profile during terminal adipogenesis as detected by 
SRMs in relation to its binding site profile. A sharp increase in detected binding sites can be observed 
after Day 4, despite a decrease in RXRα protein copy numbers. 
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Supplementary Figure 9. Establishment of standard curves for all ten SH-Quant tags used for 
multiplex SRM analysis. 
(a) All ten SH-Quant tags were spiked into nuclear extracts and analyzed in triplicates. Standard 
curves were established covering an on-column tag concentration range from 2.5 fmol to 15.0 fmol in 
a complex matrix. Top panels: linear regression analysis (R
2
 = 0.960 – 0.997) for all ten SH-Quant 
tags. Bottom panel: graphical representation of the variation found within all technical replicates (2.5 - 
15 fmol) as well as the calculated value of an unknown treated sample (positive control) spiked into 
nuclear extract at 1.25 fmol.  
(b) Top panel: example of the calculated peak areas of two isobaric tags (tags 1 and 9), with slightly 
modified sequences, analyzed in three technical replicates at a concentration range of 1.25 – 15 fmol. 
Bottom panel: the table provides a summary of the calculated CV for all ten SH-Quant tags spiked at 
different concentrations (1.25 – 15 fmoles) into nuclear extracts. All samples were analyzed in 
triplicates.  
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Supplementary Methods 
 
3T3-L1 protein extraction 
3T3-L1 cells were collected at 6 different differentiation time points (0h, 2h, 24h or Day 1, 
Day 2, Day 4, and Day 6). At each time-point, petri-plates were rinsed twice with 1X PBS, 
after which cells were trypsinized, rinsed once with cold 1X PBS, and centrifuged and the 
pellets were then stored at -80°C. Cells were lysed in cold lysis buffer (10mM HEPES-NaOH 
at pH 7.9, 1.5mM MgCl2, 10mM KCl, 1mM DTT, 0.5% NP-40, 0.1mM EDTA, 0.1mM 
EGTA) containing protease inhibitors and phosphates inhibitors (Roche) for 15 min and 
centrifuged for 10 min at 6,000 rpm (at 4°C) to sediment the nuclei. The pellet was washed 
twice to remove non-nuclear particles. The cytosolic fraction was collected and stored at -
80°C. The isolated nuclei were then washed using protein extraction buffer (20mM HEPES-
NaOH at pH 7.9, 25% glycerol, 1.5mM MgCl2, 420mM NaCl, 0.1mM EDTA, 0.1mM EGTA) 
after adding protease inhibitor and phosphatase inhibitor cocktail tablets (Roche) at 4°C for 
30 min and centrifuged for 10 min at 6,000 rpm (at 4°C). Protein concentration was measured 
for each time point utilizing the Quick Start Bradford Dye Reagent (Bio-Rad). The 
supernatant containing nuclear proteins was collected and stored at -80 °C.  
 
In vitro protein expression and purification, gel staining, and immunoblotting 
For selection of optimal TF transitions: to purify in vitro-expressed TFs, proteins were mixed 
with glutathione sepharose 4B beads (GE Healthcare) and incubated overnight at 4°C on a 
rotator to enrich for the GST-fusion proteins. The beads were washed 3 times with a saline 
buffer (50 mM tris-HCl pH 8.0, 150 mM NaCl, 2mM EDTA, 0.1% NP-40, 10% glycerol) and 
boiled at 95°C for 5 min in protein loading buffer (1-3x depending on expression yield) to 
release the fusion proteins. The protein-bead mixture was centrifuged at 6’000 rpm for 30 s to 
sediment the beads. The supernatant fraction was separated by SDS-PAGE in a 10% resolving 
gel (Tris-Glycine) and stained either with silver nitrate or with Coomassie blue (SimplyBlue 
Safestain, Invitrogen) for band visualization. Validation of in vitro-expressed proteins was 
performed by Western blot using rabbit anti-GST primary antibodies (Cell signalling) and 
goat anti-rabbit coupled to HRP secondary antibodies (Santa Cruz) on a nitrocellulose 
membrane. Validation of PPARγ and RXRα expression was performed again by Western blot 
using rabbit anti-PPARγ (Santa Cruz, SC-7196) and rabbit anti-RXRα (Santa Cruz, SC-553) 
primary antibodies, using PARP-1 as a nuclear control (Santa Cruz, SC-1561). Densitometric 
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quantitation analyses were performed using the AlphaDigiDoc 1201 software (Alpha 
Innotech). 
 
In vitro-expressed TF identification 
Samples were prepared for liquid chromatography/tandem mass spectrometry (LC-MS-MS) 
analysis as indicated in the Online Methods section. A mass spectrometer (LTQ Orbitrap XL 
(Thermo Fisher Scientific) equipped with an ultraperformance LC (UPLC) system 
(nanoACQUITY; Waters) was used. Peptides were trapped in a custom-made precolumn 
(Magic C18 AQ stationary phase, 5 μm diameter, 200Å pore, 0.1 × 20 mm, Michrom 
Bioresource) and separated in a custom-made main column (Magic C18 AQ, 3 μm diameter, 
100Å pore, 0.75 × 150 mm), using a run of 53 minutes and a gradient of H2O:ACN:FA 
98%:2%:0.1% (solvent A) and ACN:H2O:FA 98%:1.9%:0.1% (solvent B). The gradient of 
the run was set at a flow rate of 250 nl/min as follows: 100% A for 3 min, 30% B within 36 
min, 47% B within 14 min, 90% B within 5 min and held for 5 min and 100% A for 17 min. 
The MS/MS was operated in an information-dependent mode, in which each full MS analysis 
was followed by 10 MS/MS acquisitions, during which the most abundant peptides were 
selected for collision-induced dissociation (CID) to generate tandem mass spectra. The 
normalized collision energies were set to 35% for CID. Data search was performed using 
Mascot software (v. 2.3; Matrix Science) and Proteome Discoverer (v.1.3; Thermo Fisher 
Scientific). The sequences were searched against a concatenated database consisting of a 
Triticum aestivum (wheat) database created from Uniprot database version 12.02 (4,684 
sequences), the sequences of the TF constructs expressed complemented with a set of 
common contaminant proteins sequences. Finally, the results were imported into Scaffold (v. 
3.3; Proteome Software) for validation of protein identification, normalization, and 
comparison of spectral counts. Peptide identifications were accepted if they could be 
established at a probability of greater than 95% as determined by the PeptideProphet 
algorithm
1
. Protein identifications were accepted if they were assigned at least two unique 
validated peptides, and could be established with at least 99% probability as determined by 
the ProteinProphet algorithm
2
. 
 
Proteotypic peptides selection 
Peptide proteotypicity: candidate proteotypic peptides were selected using Pinpoint (v.1.1; 
Thermo Fischer Scientific) and their fragmentation spectra visually checked in Skyline
3
 using 
the spectral library inspection function. The following rules were applied in Pinpoint and 
128 
 
Skyline to the tryptic peptides detected to ensure that only high quality peptides were retained 
for the analysis: 
Peptide uniqueness: As a general rule, the TF-specific peptides selected here were uniquely 
representative of the TF of interest. In some instances however, empirically observed best-
flying candidates were shared among two or more TF isoforms or TF subfamily members and 
were included in the assay. Discarding such candidates for less-than-optimal ones could 
compromise detectability. Therefore, the precision of absolute measurements accomplished 
utilizing such non-unique TF-specific peptides may be affected to a certain extent by TF 
isoform(s) or/and subfamily counterpart(s). The following non-unique peptides were utilized 
in the multiplexed assay: 
ARID3a: peptide GLNLPTSITSAAFTLR is shared with ARID3b; NFIB: peptide 
EDFVLTVTGK is shared with NFIA, and GIPLESTDGER is shared with NFIA and NFIC; 
PIAS3: peptide VSELQVLLGFARG is shared with PIAS2; RXRα: peptide VLTELVSK is 
shared with RXRβ and ILEAELAVEPK is shared with RXRγ; SMAD2: peptide 
VETPVLPPVLVPR is shared with SMAD3. 
Peptide detectability: only peptides spanning 7-25 amino-acids and falling within a mass 
range of 700 to 3,000 Da were used. N- or C-terminal peptides which could be degraded or 
modified in the protein of interest were excluded. The sequences immediately flanking the N- 
and C-terminal peptides of the target sequence were also excluded from the evaluation (the 
sequence linking the SH-Quant tag to the N-terminus and the sequence linking the C-terminal 
peptide and the GST-tag sequence). 
Peptide digestability: as the whole methodology is peptide-centric and thus dependent on the 
completeness and specificity of the digestion step, special care was taken to ensure that only 
end-product peptides would be selected for the assay. This was especially true for the SH-
Quant tag construction which contains a [KK] dibasic sequence at its C-terminal part which 
could lead to miscleavages. The SH-Quant tag configuration was however retained as 
systematic attempts to detect miscleavage products originating from the [KK] dibasic 
sequence using either accurate mass inclusion mass spectrometry or targeted SRM detection 
were negative (i.e. only the SH-Quant tag end-product was detected). For all the other 
peptides, only fully tryptic peptides with no miscleavage other than [KP] and [RP] were 
considered. N- or C- terminal dibasic residues ([KK], [KR], [RK], [RR]) as well as 
surrounding acidic residues (E, D) in position P’1 and P’2 potentially leading to miscleavages 
were excluded. 
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Peptide stability: peptide sequences containing oxidation-sensitive residues, methionine only 
in this case, were excluded. These peptides which usually ionize well were however kept as 
secondary choices in case no usable sequences would remain after the selection
4
. Peptides 
containing potential imide forming residues, [NG], potential deamidating residue, [DP], or N-
terminal glutamine (Q) were excluded as well. 
Peptide selection: A first manual ranking of the proteotypic peptides was performed using 
peptide intensities extracted from the MS1 stage with the intention of selecting the best 
“flyers”. This ranking was complemented by a manual evaluation of the tandem MS spectral 
quality aimed at not excluding low intensity MS1 peaks with intense selective fragment ions 
(TIC MS2 in Supplementary Table 2). Specifically, tandem MS spectra presenting high 
intensity singly charged y’’ ions above the m/z of the parent ion were included in the second 
screen performed on the triple quadrupole instrument (TSQ Vantage, Thermo Fisher 
Scientific). In a preliminary SRM run, all selected peptides were targeted. The final best-
responding candidates were selected by performing a pilot SRM analysis targeting the heavy 
labeled versions of the peptides selected in the previous screen spiked in a nuclear extract 
digest prepared in the same way as for the real experiment. A minimum of two peptides per 
TF was finally selected for the multiplex assay.   
 
Evaluation of heavy TF isotope incorporation and miscleavage during SRM  
All in vitro-expressed heavy TFs were assessed for light isotope (K & R) misincorporation 
prior to SRM quantification. The amounts of isotope misincorporation (usually ≤ 5%) were 
corrected in the final calculations of absolute endogenous concentrations. In addition, all SH-
Quant tags were monitored for trypsin miscleavage during a dedicated LC-MS run targeting 
the SH-Quant tag and its potential miscleavage products to assess the extent of digestion 
completeness. 
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Future work: 
Decoding the adipogenic gene regulatory network using 
quantitative targeted proteomics 
INTRODUCTION 
Adipogenesis is probably one of the best characterized cell differentiation processes in biology as it 
has been subject to great attention primarily because of the vital role that the adipose tissue has in 
energy homeostasis and because excessive fat storage leading to obesity can be directly linked to a 
plethora of diseases (E.Calle and R.Kaaks, Nature Reviews Cancer, 2004). This extensive knowledge 
is in large part due to the availability of immortalized cell lines that faithfully mimic what happens in 
vivo (Rosen et al., Genes dev., 2000). As a result, key players involved in the adipogenic 
transcriptional network have been identified (Figure 1) although this has so far only yielded a rather  
qualitative picture of the mechanisms at play. 
 
 
Figure 1: Transcriptional cascade regulating adipogenesis. (Rosen and MacDougald, Nature Reviews Molecular 
Cell Biology, 2006) 
 
AIMS OF THE PROJECT: QUANTIFICATION OF ADIPOGENIC KEY PLAYERS VIA 
TARGETED PROTEOMICS  
Building upon the development of our targeted quantitative approach aimed at quantifying lowly 
abundant TFs, we decided to expand the analytical capabilities of our methodology by integrating into 
the workflow a series of consecutive SRM runs (each able of measuring the abundance of 10 TFs at 
the time maximum), with the aim of increasing the number of proteins that can be scrutinized in one 
study. As often biological processes are rather complex, involving the interplay of many proteins (e.g. 
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signaling pathways), it would be extremely useful to devise a quantitative approach that can be 
adapted to cover a larger number of participant (a prerequisite in the majority of systems biology 
investigations). In our case, since we are interested in the study of adipogenesis, it would be of utmost 
importance to be able to measure fluctuations in the abundance of the many TFs involved in this 
process of cell differentiation. To this end, we aim to quantify in absolute amounts the TFs that lie at 
the core of the adipogenic gene regulatory network (12 proteins, therefore 2 SRM assays) (the 
complete list is presented in Table 1) and possibly increase the number of selected proteins in a second 
phase. Since the regulatory capabilities of TFs are largely dictated by their cellular abundance, the 
quantitative data obtained will be of utmost importance to understand the gene regulatory mechanisms 
at play. In order to better understand the fine-tuning mechanisms that take place in the nucleus upon 
changes in the external or internal environment, comparative quantitative studies can be envisaged. In 
particular, we aim at perturbing the regulatory network by knocking down an important adipogenic co-
repressor such as SMRT (Raghav et al., Molecular Cell, 2012) and explore the concurrent changes in 
adipogenic TF copy number. This will allow us to study the dynamic characteristics of the underlying 
regulatory machinery during terminal differentiation of 3T3-L1 cells by comparing knock-down 
versus wild-type. The copy per cell counts obtained will be used to develop a computational model 
that will elucidate or predict the dynamic properties of gene regulatory mechanisms underlying 
adipogenesis. Ultimately, the same methodology could be utilized to investigate in a comprehensive 
manner gene regulatory networks involved in other cellular processes of choice, including those 
involving a large number of players. 
 
 
TF SwisssProt ID TF Swissprot ID 
Cebpα P53566 Klf5 Q9Z0Z7 
Cebpβ P28033 Klf15 Q9EPW2 
Cebpδ Q00322  Krox20 P08152 
Cebpγ P53568  Pparγ P37238 
Gata3 P23772 Srebp1 Q9WTN3 
Klf2 Q60843 Chop P35639 
 
Table 1: List of transcription factors involved in the core adipogenic gene regulatory network. 
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 III. CONCLUSIONS 
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Regulation of gene expression, which is orchestrated in cells by gene regulatory networks, is the result 
of a complex interplay between genes and their DNA-binding partners, transcription factors. Due to 
their vital role in most cellular processes, understanding the mechanisms by which transcription 
factors regulate gene expression is of crucial importance in biology. Thanks to their particularly high 
sensitivity and specificity, MS-based proteomics is quickly becoming the gold standard in the 
characterization and quantification of DNA binding TFs.  
Originally, we aimed to develop a gene-centered proteomic platform to capture TFs and co-
TFs in the form of functional complexes in a systematic manner utilizing a novel technique called 
PICh (Proteomics of Isolated Chromatin segments), targeting β-globin-like gene regulatory elements 
in an immortalized human myelogenous leukaemia cell line. Although extensive work has been 
accomplished in characterizing the key players (in terms of TFs) involved in many biological 
processes, including the one controlling β-globin gene switching (depicting a rather comprehensive 
qualitative picture of the major GRNs), almost no quantitative information was available in the 
literature. Thus, while our efforts were initially calibrated towards dissecting TF-complex formation to 
elucidate novel mechanisms of gene regulation, we became soon aware of the importance of 
accurately quantifying DNA-binding proteins. Moreover, deriving TF copy numbers has been of 
longstanding interest in regulatory biology since the DNA binding ability and thus the regulatory 
capabilities of these proteins strongly depends on their cellular concentration
5-7
. To date, only a 
handful of studies have so far provided estimates on the absolute in vivo abundance of animal TFs. 
These measurements were achieved with indirect, immuno-based methods though (which thanks to 
signal amplification are still considered to be the gold standard in the quantification of low-abundant 
proteins), whose additional drawbacks include the dependence on antibodies which are available for 
only a limited number of TFs. Our intent was to propose a viable option to such alternative 
methodologies, since they ultimately prove to be too time-consuming and impractical at large scale.  
We focused on Selected Reaction Monitoring (SRM), which appeared to be particularly well 
suited for targeting low abundant proteins such as TFs, which are difficult to identify and considerably 
more difficult to quantify with standard shotgun LC-MS-based approaches. Together with our 
difficulties to implement the PICh approach, which seemed to be shared and acknowledged by many 
colleagues (thus raising doubts about the reproducible nature of the PICh method), we therefore 
decided to put the original project on hold and focus instead fully on the problem of TF quantification. 
Specifically, we aimed to establish a novel analytical platform that focuses on the use of spectral 
libraries of TF peptide libraries, based on in vitro protein expression proteomic parameter selection, 
for the high-throughput development of SRM assays in an adipogenic model. In particular, we 
intended to exploit the TF proteotypic peptide library that we had already started populating with the 
previous project as to obtain the parameters needed for the implementation of such assays (e.g. elution 
time and charge state of the peptides). With parameter selection being a crucial aspect, a variety of 
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predictive tools had been appositely developed. Unfortunately, predictions tend to fail to fully capture 
the peculiar behavior of peptides in a mass spectrometer, therefore have to be utilized with care. We 
found out that by utilizing experimental data we obtain better peptide candidates, improving thereby 
the assay as a whole (choosing inadequate peptides may prevent quantification). In this regard, starting 
from our vast murine TF ORF collection, we were able to create a peptide Atlas that contains more 
than 1000 TF peptide spectra, representing some 800 unique peptides belonging to approximately 100 
TFs. This vast effort was the first of its kind; we aimed at creating a comprehensive TF-specific 
spectral repository to make available to the public. TF-specific data can be utilized as a guide for 
future SRM assays or to improve protein identification. Although a significant effort has been devoted 
since the beginning of our project to address TF-specific peptide information paucity, reliable TF 
peptide data is still lacking in the majority of databases. 
Hence, capitalizing on the TF-specific data acquired, we developed a state-of-the-art, targeted 
SRM-based assay, which combines high sensitivity and technological innovation to enable the 
monitoring of absolute copy number changes of TFs of interest during specific biological processes 
using in vitro-expressed, isotopically-labelled protein standards. Our pipeline significantly extends 
recent efforts to specifically tailor MS methodologies to quantify low-abundant proteins such as TFs, 
by offering several advantages. First, the use of full-length protein standards allow us to bypass the use 
of expensive, accurately quantified synthetic peptide standards. Second, current absolute protein 
quantification methodologies relying on full-length protein internal standards currently require that the 
latter are quantified in a separate experiment, thus limiting the measurements to one standard at a time. 
We significantly simplify the internal protein standard quantification step, which, in our assay, is 
performed in situ along with the quantification of its endogenous counterpart (two quantification steps 
are collapsed into one unique assay). This in turn circumvents the need for intermediate protein 
storage as well as separate quantification procedures, effectively eliminating two significant sources of 
measurement variation. Third, the use of a proteotypic-peptide tag previously employed for 
quantitative interaction studies, the SH-Quant tag, allowed us to design and validate 9 additional 
quantotypic peptide-tag variants, simply by changing at the most by one or two amino acids within the 
original tag sequence at selected positions. We used the tag variants to develop a multiplex SRM-
based assay that allows the in situ quantification of up to 10 proteins in one single assay. Importantly, 
we were able to demonstrate that the upscale features the same overall accuracy and sensitivity 
compared to the single protein analysis. In conclusion, the multiplexing of the assay provides a 
sensitive, cost-effective, and rapid strategy to simultaneously quantify small sets of proteins in one 
unique integrated assay. The multiplexing capability constitutes an important step towards addressing 
the need for assay upscaling, which remains one of the main limitations in current SRM-based assays. 
Moreover, our quantification methodology therefore constitutes a powerful and even cost-effective 
alternative to quantitative immunoassays to determine fluctuations in protein abundance by presenting 
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the additional advantage of being amicable to multiplexing. The expanded analytical capabilities 
offered by the multiplexed workflow should be of great value in the modeling of absolute, dynamic 
changes of entire pathways as well as in the field of biomarker discovery.  
Once the workflow had been established and extensively tested, we applied it to uniquely assess the in 
vivo expression changes of the adipogenic master regulators PPARγ and RXRα as well as eight other 
TFs during the terminal phase of adipogenesis. We found that the absolute abundance of TFs differs 
quite substantially, but that their dynamic range during fat cell differentiation is limited, varying at 
most five-fold. Finally, we illustrated the importance of deriving this type of data in building a 
quantitative model of genome-wide TF DNA binding by focusing on the adipogenic master regulator 
PPARγ. Specifically, we sought to mechanistically explain the paradoxical finding of a significantly 
increased number of PPARγ binding sites during the final stage of differentiation despite a concurrent 
saturation in the number of PPARγ molecules. The ensuing model provided unique, quantitative 
insights into TF DNA binding. Whereas it had previously been suggested that other factors may 
contribute to binding site selectivity, we revealed that the DNA binding profile of PPARγ can be 
faithfully modeled by considering its own copy number, simple thermodynamic principles, and 
chromatin accessibility, thus emphasizing the importance of both protein copy number and chromatin 
remodeling in dictating TF DNA binding behavior during adipogenesis.  
 
To conclude, the work accomplished during my PhD thesis, the development of the SRM-based 
methodology for the quantification of low-abundant protein species in particular, represents an 
important effort to expand the analytical and practical capabilities of targeted proteomics approaches 
while preserving measurement accuracy. Possible improvements would include the further expanding 
the number of reference-peptide variants to increase the assay’s upscale capacity. The resulting 
increase in throughput capabilities will allow the elucidation and dynamic modeling of entire 
biological processes or networks under different experimental conditions. 
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DNA and protein gel electrophoresis, Immunoassays  
Mass Spectrometry-based techniques (including SRM/MRM) 
Genetic analysis tools (Cloning, mutagenesis) 
Cell culture (including murine 3T3-L1 and human HEK293, K562 cell lines) 
 
LANGUAGES 
 
Fluent: English, French, Italian, Serbian. Good knowledge: German, Spanish. 
 
PERSONAL INTERESTS 
 
 
Surfing, Waterpolo, Swimming, Golf, History, Anthropology, Economics, Political Science. 
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PUBLICATIONS AND PRESENTATIONS 
 
Imaging mass spectrometry using peptide isoelectric focusing   
Ali R. Vaezzadeh, Jovan Simicevic, Alexis Chauvet, Patrice François, Catherine G. Zimmermann-Ivol, Pierre 
Lescuyer, Jacques P. M. Deshusses, Denis F. Hochstrasser, Rapid Communications in Mass Spectrometry, 
Volume 22 Issue 17 (2008), Pages 2667 – 2676 
 
DNA-centered approaches to characterize regulatory protein-DNA interaction complexes Molecular 
Biosystems, 2010  
J. Simicevic, B. Deplancke, Molecular Biosystems, 2010, 6, 462-468. 
 
Decoding Absolute copy number analysis of transcription factors during cellular differentiation using a 
multiplex, targeted proteomics approach  (submitted) 
Jovan Simicevic, Adrian W. Schmid, Benjamin Zoller, Sunil K. Raghav
 
,Irina Krier, Carine Gubelmann, 
Frédérique Lisacek, Felix Naef, Marc Moniatte, Bart Deplancke, submitted
 
 
 
 “Swiss Proteomics Society 2007 scientific meeting”, Lausanne (Switzerland): 
-  Pushing the limits of the Shotgun IPG-IEF workflow 
  “3rd All-SystemsX.ch-Day 2009”, Bern (Switzerland)  
-  Development of a gene-centered proteomic platform for the systematic identification of DNA binding proteins 
and complexes 
 “4th EUPA Meeting 2010”, Estoril (Portugal) + oral presentation: 
-  Novel proteomic approach for the absolute quantification of transcription factors controlling adipogenesis 
 “4th All-SystemsX.ch-Day 2010”, Geneva (Switzerland) + oral presentation: 
-  Novel proteomic approach for the absolute quantification of transcription factors controlling adipogenesis 
 “SPS PhD Student Symposium 2010”, Basel (Switzerland) + oral presentation: 
-  Novel proteomic approach for the absolute quantification of transcription factors controlling adipogenesis 
 “HUPO 10th World Congress 2011”, Geneva (Switzerland): 
-  Absolute quantification of a large set of transcription factors involved in the adipogenic gene regulatory 
network via a mass spectrometry-based approach 
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ANNEX 
Supplementary Table 1: list of the 10 selected TFs
Gene symbol Name DNA-binding domain IPI 
RXRa Retinoic acid receptor RXR-alpha zf-C4 P28700
Nfib Nuclear factor 1 B-type MH1 P97863
Pias3 E3 SUMO-protein ligase PIAS3 SAP O54714
Pias4 E3 SUMO-protein ligase PIAS4 SAP Q9JM05
Fosl2 Fos-related antigen 2 bZIP_1 P47930
Rarg Retinoic acid receptor gamma zf-C4 P18911
PPARg Peroxisome proliferator-activated receptor gamma zf-C4 P37238
Arid3a AT-rich interactive domain-containing protein 3A ARID Q62431
Nr2c1 Nuclear receptor subfamily 2 group C member 1 zf-C4 Q0VGP8
Smad2 Mothers against decapentaplegic homolog 2 MH1 Q62432
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Supplementary Table 3: calculations of PPARγ and RXRα copy-number per cell (1 TF per assay)
MS intensity # cells ug ugNE/cell copies/cell*
1st bio.repl. 
PPARγ Day 0 0.039 21825000 2025 9.27835E-05 2179
2h 0.037 26475000 1876 7.08593E-05 1579
Day1 0.028 36150000 2048 5.66528E-05 955
Day2 0.069 39375000 2104 5.34349E-05 2220
Day4 0.153 61125000 4227 6.91534E-05 6372
Day6 0.072 56486250 3809 6.74323E-05 2924
RXRα Day 0 0.33 21825000 2025 9.27835E-05 18438
2h 0.252 26475000 1876 7.08593E-05 10753
Day1 0.518 36150000 2048 5.66528E-05 17672
Day2 1.399 39375000 2104 5.34349E-05 45018
Day4 0.883 61125000 4227 6.91534E-05 36772
Day6 0.357 56486250 3809 6.74323E-05 14497
2nd bio.repl. 
PPARγ Day 0 0.049 24975000 1380 5.52553E-05 1630
2h 0.04 24450000 1420 5.80777E-05 1399
Day1 0.092 29287500 1532 5.2309E-05 2898
Day2 0.281 42000000 2036 4.84762E-05 8203
Day4 0.303 48000000 2819 5.87292E-05 10716
Day6 0.299 43950000 3174 7.22184E-05 13003
RXRα Day 0 0.245 24975000 1380 5.52553E-05 8152
2h 0.314 24450000 1420 5.80777E-05 10982
Day1 0.627 29287500 1532 5.2309E-05 19751
Day2 0.945 42000000 2036 4.84762E-05 27587
Day4 0.468 48000000 2819 5.87292E-05 16552
Day6 0.281 43950000 3174 7.22184E-05 12221
3rd bio.repl. 
PPARγ Day 0 0.108 24900750 1270 5.10025E-05 3317
2h 0.074 29025000 1260 4.34109E-05 1935
Day1 0.182 45234000 1500 3.31609E-05 3634
Day2 0.342 53700000 2050 3.8175E-05 7862
Day4 0.308 56212500 2500 4.44741E-05 8249
Day6 0.235 57412500 2620 4.56347E-05 6458
RXRα Day 0 0.191 24900750 1270 5.10025E-05 5866
2h 0.321 29025000 1260 4.34109E-05 8392
Day1 0.459 45234000 1500 3.31609E-05 9166
Day2 1.099 53700000 2050 3.8175E-05 25265
Day4 0.646 56212500 2500 4.44741E-05 17301
Day6 0.445 57412500 2620 4.56347E-05 12229
calculations of 10 TFs copy-number per cell (multiplex)
4th bio.repl. 
RXRα Day 0 0.174 22650000 1264 5.58057E-05 5847
Day 2 0.551 20175000 1466 7.26642E-05 24111
Day4 0.307 37275000 2249 6.03353E-05 11155
PPARγ Day 0 0.07 22650000 1264 5.58057E-05 2352
Day 2 0.194 20175000 1466 7.26642E-05 8489
Day4 0.176 37275000 2249 6.03353E-05 6395
Pias3 Day 0 0.023 22650000 1264 5.58057E-05 773
Day 2 0.011 20175000 1466 7.26642E-05 481
Day4 0.007 37275000 2249 6.03353E-05 254
Pias4 Day 0 0.172 22650000 1264 5.58057E-05 5780
Day 2 0.174 20175000 1466 7.26642E-05 7614
Day4 0.136 37275000 2249 6.03353E-05 4941
NFIB Day 0 5.659 22650000 1264 5.58057E-05 190178
Day 2 6.984 20175000 1466 7.26642E-05 305608
Day4 4.703 37275000 2249 6.03353E-05 170879
SMAD2 Day 0 0.431 22650000 1264 5.58057E-05 14484
Day 2 0.341 20175000 1466 7.26642E-05 14922
Day4 0.32 37275000 2249 6.03353E-05 11627
RARg Day 0 0.129 22650000 1264 5.58057E-05 4335
Day 2 0.106 20175000 1466 7.26642E-05 4638
Day4 0.104 37275000 2249 6.03353E-05 3779
NR2C1 Day 0 0.043 22650000 1264 5.58057E-05 1445
Day 2 0.041 20175000 1466 7.26642E-05 1794
Day4 0.037 37275000 2249 6.03353E-05 1344
FOSL2 Day 0 0.077 22650000 1264 5.58057E-05 2588
Day 2 0.093 20175000 1466 7.26642E-05 4070
Day4 0.073 37275000 2249 6.03353E-05 2652
ARID3a Day 0 0.015 22650000 1264 5.58057E-05 504
Day 2 0.013 20175000 1466 7.26642E-05 569
Day4 0.013 37275000 2249 6.03353E-05 472
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Supplementary Table 5 - 10TF transitions monitored
Transcription Factor Sequence Parent ion mass Product ion mass Transition
m/z [M+2H]2+ m/z [M+H]+ y-ion
RXR VLTELVSK 444.7736 333.2127 y3
RXR VLTELVSK 444.7736 446.2968 y4
RXR VLTELVSK 444.7736 575.3394 y5
RXR VLTELVSK 444.7736 676.387 y6
RXR VLTELVSK 444.7736 789.4711 y7
RXR VLTELVSK[HeavyK] 448.7807 341.2269 y3
RXR VLTELVSK[HeavyK] 448.7807 454.311 y4
RXR VLTELVSK[HeavyK] 448.7807 583.3536 y5
RXR VLTELVSK[HeavyK] 448.7807 684.4012 y6
RXR VLTELVSK[HeavyK] 448.7807 797.4853 y7
RXR AIVLFNPDSK 552.3084 349.1712 y3
RXR AIVLFNPDSK 552.3084 446.224 y4
RXR AIVLFNPDSK 552.3084 560.2669 y5
RXR AIVLFNPDSK 552.3084 707.3353 y6
RXR AIVLFNPDSK 552.3084 820.4194 y7
RXR AIVLFNPDSK 552.3084 919.4878 y8
RXR AIVLFNPDSK 552.3084 1032.572 y9
RXR AIVLFNPDSK[HeavyK] 556.3155 357.1854 y3
RXR AIVLFNPDSK[HeavyK] 556.3155 454.2382 y4
RXR AIVLFNPDSK[HeavyK] 556.3155 568.2811 y5
RXR AIVLFNPDSK[HeavyK] 556.3155 715.3495 y6
RXR AIVLFNPDSK[HeavyK] 556.3155 828.4336 y7
RXR AIVLFNPDSK[HeavyK] 556.3155 927.502 y8
RXR AIVLFNPDSK[HeavyK] 556.3155 1040.586 y9
RXR ILEAELAVEPK 606.3477 373.2076 y3
RXR ILEAELAVEPK 606.3477 472.276 y4
RXR ILEAELAVEPK 606.3477 543.3131 y5
RXR ILEAELAVEPK 606.3477 656.3972 y6
RXR ILEAELAVEPK 606.3477 785.4398 y7
RXR ILEAELAVEPK 606.3477 856.4769 y8
RXR ILEAELAVEPK 606.3477 985.5195 y9
RXR ILEAELAVEPK 606.3477 1098.604 y10
RXR ILEAELAVEPK[HeavyK] 610.3548 381.2218 y3
RXR ILEAELAVEPK[HeavyK] 610.3548 480.2902 y4
RXR ILEAELAVEPK[HeavyK] 610.3548 551.3273 y5
RXR ILEAELAVEPK[HeavyK] 610.3548 664.4114 y6
RXR ILEAELAVEPK[HeavyK] 610.3548 793.454 y7
RXR ILEAELAVEPK[HeavyK] 610.3548 864.4911 y8
RXR ILEAELAVEPK[HeavyK] 610.3548 993.5337 y9
RXR ILEAELAVEPK[HeavyK] 610.3548 1106.618 y10
RXR GLSNPAEVEALR 628.3356 359.2396 y3
RXR GLSNPAEVEALR 628.3356 488.2822 y4
RXR GLSNPAEVEALR 628.3356 587.3506 y5
RXR GLSNPAEVEALR 628.3356 716.3932 y6
RXR GLSNPAEVEALR 628.3356 787.4303 y7
RXR GLSNPAEVEALR 628.3356 884.483 y8
RXR GLSNPAEVEALR 628.3356 998.526 y9
RXR GLSNPAEVEALR 628.3356 1085.558 y10
RXR GLSNPAEVEALR 628.3356 1198.642 y11
RXR GLSNPAEVEALR[HeavyR] 633.3398 369.2479 y3
RXR GLSNPAEVEALR[HeavyR] 633.3398 498.2904 y4
RXR GLSNPAEVEALR[HeavyR] 633.3398 597.3589 y5
RXR GLSNPAEVEALR[HeavyR] 633.3398 726.4014 y6
RXR GLSNPAEVEALR[HeavyR] 633.3398 797.4385 y7
RXR GLSNPAEVEALR[HeavyR] 633.3398 894.4913 y8
RXR GLSNPAEVEALR[HeavyR] 633.3398 1008.534 y9
RXR GLSNPAEVEALR[HeavyR] 633.3398 1095.566 y10
RXR GLSNPAEVEALR[HeavyR] 633.3398 1208.65 y11
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Supplementary Table 5 - 10TF transitions monitored
Transcription Factor Sequence Parent ion mass Product ion mass Transition
m/z [M+2H]2+ m/z [M+H]+ y-ion
Pparg HLYDSYIK 519.7663 423.2596 y3
Pparg HLYDSYIK 519.7663 510.2917 y4
Pparg HLYDSYIK 519.7663 625.3186 y5
Pparg HLYDSYIK 519.7663 788.382 y6
Pparg HLYDSYIK[HeavyK] 523.7734 431.2738 y3
Pparg HLYDSYIK[HeavyK] 523.7734 518.3058 y4
Pparg HLYDSYIK[HeavyK] 523.7734 633.3328 y5
Pparg HLYDSYIK[HeavyK] 523.7734 796.3961 y6
Pparg VEPASPPYYSEK 683.8298 363.1869 y3
Pparg VEPASPPYYSEK 683.8298 526.2502 y4
Pparg VEPASPPYYSEK 683.8298 689.3135 y5
Pparg VEPASPPYYSEK 683.8298 786.3663 y6
Pparg VEPASPPYYSEK 683.8298 883.4191 y7
Pparg VEPASPPYYSEK 683.8298 970.4511 y8
Pparg VEPASPPYYSEK 683.8298 1041.488 y9
Pparg VEPASPPYYSEK 683.8298 1138.541 y10
Pparg LNHPESSQLFAK 685.8567 365.2178 y3
Pparg LNHPESSQLFAK 685.8567 478.3018 y4
Pparg LNHPESSQLFAK 685.8567 606.3604 y5
Pparg LNHPESSQLFAK 685.8567 693.3925 y6
Pparg LNHPESSQLFAK 685.8567 780.4245 y7
Pparg LNHPESSQLFAK 685.8567 909.4671 y8
Pparg LNHPESSQLFAK 685.8567 1006.52 y9
Pparg LNHPESSQLFAK 685.8567 1143.579 y10
Pparg VEPASPPYYSEK[HeavyK] 687.8369 371.2011 y3
Pparg VEPASPPYYSEK[HeavyK] 687.8369 534.2644 y4
Pparg VEPASPPYYSEK[HeavyK] 687.8369 697.3278 y5
Pparg VEPASPPYYSEK[HeavyK] 687.8369 794.3805 y6
Pparg VEPASPPYYSEK[HeavyK] 687.8369 891.4333 y7
Pparg VEPASPPYYSEK[HeavyK] 687.8369 978.4653 y8
Pparg VEPASPPYYSEK[HeavyK] 687.8369 1049.502 y9
Pparg VEPASPPYYSEK[HeavyK] 687.8369 1146.555 y10
Pparg LNHPESSQLFAK[HeavyK] 689.8638 373.232 y3
Pparg LNHPESSQLFAK[HeavyK] 689.8638 486.316 y4
Pparg LNHPESSQLFAK[HeavyK] 689.8638 614.3746 y5
Pparg LNHPESSQLFAK[HeavyK] 689.8638 701.4067 y6
Pparg LNHPESSQLFAK[HeavyK] 689.8638 788.4387 y7
Pparg LNHPESSQLFAK[HeavyK] 689.8638 917.4813 y8
Pparg LNHPESSQLFAK[HeavyK] 689.8638 1014.534 y9
Pparg LNHPESSQLFAK[HeavyK] 689.8638 1151.593 y10
Pparg SVEAVQEITEYAK 733.8722 381.2127 y3
Pparg SVEAVQEITEYAK 733.8722 510.2553 y4
Pparg SVEAVQEITEYAK 733.8722 611.303 y5
Pparg SVEAVQEITEYAK 733.8722 724.387 y6
Pparg SVEAVQEITEYAK 733.8722 853.4296 y7
Pparg SVEAVQEITEYAK 733.8722 981.4882 y8
Pparg SVEAVQEITEYAK 733.8722 1080.557 y9
Pparg SVEAVQEITEYAK 733.8722 1151.594 y10
Pparg SVEAVQEITEYAK 733.8722 1280.636 y11
Pparg SVEAVQEITEYAK[HeavyK] 737.8793 389.2269 y3
Pparg SVEAVQEITEYAK[HeavyK] 737.8793 518.2695 y4
Pparg SVEAVQEITEYAK[HeavyK] 737.8793 619.3171 y5
Pparg SVEAVQEITEYAK[HeavyK] 737.8793 732.4012 y6
Pparg SVEAVQEITEYAK[HeavyK] 737.8793 861.4438 y7
Pparg SVEAVQEITEYAK[HeavyK] 737.8793 989.5024 y8
Pparg SVEAVQEITEYAK[HeavyK] 737.8793 1088.571 y9
Pparg SVEAVQEITEYAK[HeavyK] 737.8793 1159.608 y10
Pparg SVEAVQEITEYAK[HeavyK] 737.8793 1288.651 y11
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Supplementary Table 5 - 10TF transitions monitored
Transcription Factor Sequence Parent ion mass Product ion mass Transition
m/z [M+2H]2+ m/z [M+H]+ y-ion
PIAS3 VSSIVAPGSSLR 586.8353 375.2345 y3
PIAS3 VSSIVAPGSSLR 586.8353 462.2665 y4
PIAS3 VSSIVAPGSSLR 586.8353 519.288 y5
PIAS3 VSSIVAPGSSLR 586.8353 616.3408 y6
PIAS3 VSSIVAPGSSLR 586.8353 687.3779 y7
PIAS3 VSSIVAPGSSLR 586.8353 786.4463 y8
PIAS3 VSSIVAPGSSLR 586.8353 899.5303 y9
PIAS3 VSSIVAPGSSLR 586.8353 986.5624 y10
PIAS3 VSSIVAPGSSLR 586.8353 1073.594 y11
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 385.2428 y3
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 472.2748 y4
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 529.2963 y5
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 626.349 y6
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 697.3861 y7
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 796.4545 y8
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 909.5386 y9
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 996.5706 y10
PIAS3 VSSIVAPGSSLR[HeavyR] 591.8394 1083.603 y11
PIAS3 VSELQVLLGFAGR 694.8984 303.177 y3
PIAS3 VSELQVLLGFAGR 694.8984 450.2454 y4
PIAS3 VSELQVLLGFAGR 694.8984 507.2668 y5
PIAS3 VSELQVLLGFAGR 694.8984 620.351 y6
PIAS3 VSELQVLLGFAGR 694.8984 733.435 y7
PIAS3 VSELQVLLGFAGR 694.8984 832.5034 y8
PIAS3 VSELQVLLGFAGR 694.8984 960.562 y9
PIAS3 VSELQVLLGFAGR 694.8984 1073.646 y10
PIAS3 VSELQVLLGFAGR 694.8984 1202.689 y11
PIAS3 VSELQVLLGFAGR 694.8984 1289.721 y12
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 313.1852 y3
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 460.2537 y4
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 517.2751 y5
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 630.3592 y6
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 743.4432 y7
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 842.5117 y8
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 970.5703 y9
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 1083.654 y10
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 1212.697 y11
PIAS3 VSELQVLLGFAGR[HeavyR] 699.9025 1299.729 y12
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Supplementary Table 5 - 10TF transitions monitored
Transcription Factor Sequence Parent ion mass Product ion mass Transition
m/z [M+2H]2+ m/z [M+H]+ y-ion
PIAS4 SYSVALYLVR 585.8295 387.2709 y3
PIAS4 SYSVALYLVR 585.8295 550.3342 y4
PIAS4 SYSVALYLVR 585.8295 663.4183 y5
PIAS4 SYSVALYLVR 585.8295 734.4554 y6
PIAS4 SYSVALYLVR 585.8295 833.5238 y7
PIAS4 SYSVALYLVR 585.8295 920.5558 y8
PIAS4 SYSVALYLVR 585.8295 1083.619 y9
PIAS4 SYSVALYLVR[HeavyR] 590.8336 397.2791 y3
PIAS4 SYSVALYLVR[HeavyR] 590.8336 560.3425 y4
PIAS4 SYSVALYLVR[HeavyR] 590.8336 673.4265 y5
PIAS4 SYSVALYLVR[HeavyR] 590.8336 744.4637 y6
PIAS4 SYSVALYLVR[HeavyR] 590.8336 843.532 y7
PIAS4 SYSVALYLVR[HeavyR] 590.8336 930.5641 y8
PIAS4 SYSVALYLVR[HeavyR] 590.8336 1093.627 y9
PIAS4 LDPDSEIATTGVR 687.3489 331.2083 y3
PIAS4 LDPDSEIATTGVR 687.3489 432.256 y4
PIAS4 LDPDSEIATTGVR 687.3489 533.3036 y5
PIAS4 LDPDSEIATTGVR 687.3489 604.3408 y6
PIAS4 LDPDSEIATTGVR 687.3489 717.4248 y7
PIAS4 LDPDSEIATTGVR 687.3489 846.4674 y8
PIAS4 LDPDSEIATTGVR 687.3489 933.4995 y9
PIAS4 LDPDSEIATTGVR 687.3489 1048.526 y10
PIAS4 LDPDSEIATTGVR 687.3489 1145.579 y11
PIAS4 LDPDSEIATTGVR 687.3489 1260.606 y12
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 341.2166 y3
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 442.2642 y4
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 543.3119 y5
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 614.349 y6
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 727.4331 y7
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 856.4757 y8
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 943.5077 y9
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 1058.535 y10
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 1155.587 y11
PIAS4 LDPDSEIATTGVR[HeavyR] 692.3531 1270.614 y12
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Supplementary Table 5 - 10TF transitions monitored
Transcription Factor Sequence Parent ion mass Product ion mass Transition
m/z [M+2H]2+ m/z [M+H]+ y-ion
RARG GLGQPDLPK 462.761 357.2491 y3
RARG GLGQPDLPK 462.761 472.276 y4
RARG GLGQPDLPK 462.761 569.3288 y5
RARG GLGQPDLPK 462.761 697.3874 y6
RARG GLGQPDLPK 462.761 754.4088 y7
RARG GLGQPDLPK 462.761 867.4929 y8
RARG GLGQPDLPK[HeavyK] 466.7681 365.2633 y3
RARG GLGQPDLPK[HeavyK] 466.7681 480.2902 y4
RARG GLGQPDLPK[HeavyK] 466.7681 577.343 y5
RARG GLGQPDLPK[HeavyK] 466.7681 705.4016 y6
RARG GLGQPDLPK[HeavyK] 466.7681 762.423 y7
RARG GLGQPDLPK[HeavyK] 466.7681 875.5071 y8
RARG LQEPLLEALR 591.348 359.2396 y3
RARG LQEPLLEALR 591.348 488.2822 y4
RARG LQEPLLEALR 591.348 601.3662 y5
RARG LQEPLLEALR 591.348 714.4503 y6
RARG LQEPLLEALR 591.348 811.5031 y7
RARG LQEPLLEALR 591.348 940.5457 y8
RARG LQEPLLEALR 591.348 1068.604 y9
RARG VQLDLGLWDK 593.8269 448.2185 y3
RARG VQLDLGLWDK 593.8269 561.3026 y4
RARG VQLDLGLWDK 593.8269 618.324 y5
RARG VQLDLGLWDK 593.8269 731.4081 y6
RARG VQLDLGLWDK 593.8269 846.4351 y7
RARG VQLDLGLWDK 593.8269 959.5191 y8
RARG VQLDLGLWDK 593.8269 1087.578 y9
RARG LQEPLLEALR[HeavyR] 596.3521 369.2479 y3
RARG LQEPLLEALR[HeavyR] 596.3521 498.2904 y4
RARG LQEPLLEALR[HeavyR] 596.3521 611.3745 y5
RARG LQEPLLEALR[HeavyR] 596.3521 724.4586 y6
RARG LQEPLLEALR[HeavyR] 596.3521 821.5114 y7
RARG LQEPLLEALR[HeavyR] 596.3521 950.554 y8
RARG LQEPLLEALR[HeavyR] 596.3521 1078.613 y9
RARG VQLDLGLWDK[HeavyK] 597.834 456.2327 y3
RARG VQLDLGLWDK[HeavyK] 597.834 569.3168 y4
RARG VQLDLGLWDK[HeavyK] 597.834 626.3383 y5
RARG VQLDLGLWDK[HeavyK] 597.834 739.4223 y6
RARG VQLDLGLWDK[HeavyK] 597.834 854.4492 y7
RARG VQLDLGLWDK[HeavyK] 597.834 967.5333 y8
RARG VQLDLGLWDK[HeavyK] 597.834 1095.592 y9
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Supplementary Table 5 - 10TF transitions monitored
Transcription Factor Sequence Parent ion mass Product ion mass Transition
m/z [M+2H]2+ m/z [M+H]+ y-ion
FOSL2 GTGSAVGPVVVK 535.8138 345.2491 y3
FOSL2 GTGSAVGPVVVK 535.8138 444.3175 y4
FOSL2 GTGSAVGPVVVK 535.8138 541.3702 y5
FOSL2 GTGSAVGPVVVK 535.8138 598.3917 y6
FOSL2 GTGSAVGPVVVK 535.8138 697.4601 y7
FOSL2 GTGSAVGPVVVK 535.8138 768.4973 y8
FOSL2 GTGSAVGPVVVK 535.8138 855.5293 y9
FOSL2 GTGSAVGPVVVK 535.8138 912.5507 y10
FOSL2 GTGSAVGPVVVK 535.8138 1013.598 y11
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 353.2633 y3
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 452.3317 y4
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 549.3845 y5
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 606.4059 y6
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 705.4744 y7
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 776.5115 y8
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 863.5435 y9
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 920.5649 y10
FOSL2 GTGSAVGPVVVK[HeavyK] 539.8209 1021.613 y11
FOSL2 LQAETEELEEEK 724.3435 405.1974 y3
FOSL2 LQAETEELEEEK 724.3435 534.2401 y4
FOSL2 LQAETEELEEEK 724.3435 647.3241 y5
FOSL2 LQAETEELEEEK 724.3435 776.3667 y6
FOSL2 LQAETEELEEEK 724.3435 905.4093 y7
FOSL2 LQAETEELEEEK 724.3435 1006.457 y8
FOSL2 LQAETEELEEEK 724.3435 1135.5 y9
FOSL2 LQAETEELEEEK 724.3435 1206.537 y10
FOSL2 LQAETEELEEEK 724.3435 1334.595 y11
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 413.2116 y3
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 542.2542 y4
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 655.3383 y5
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 784.3809 y6
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 913.4235 y7
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 1014.471 y8
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 1143.514 y9
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 1214.551 y10
FOSL2 LQAETEELEEEK[HeavyK] 728.3506 1342.609 y11
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Supplementary Table 5 - 10TF transitions monitored
Transcription Factor Sequence Parent ion mass Product ion mass Transition
m/z [M+2H]2+ m/z [M+H]+ y-ion
Smad2 GWGAEYR 419.6957 338.1817 y2
Smad2 GWGAEYR 419.6957 467.2243 y3
Smad2 GWGAEYR 419.6957 538.2614 y4
Smad2 GWGAEYR 419.6957 595.2829 y5
Smad2 GWGAEYR 419.6957 781.3622 y6
Smad2 GWGAEYR[HeavyR] 424.6998 348.19 y2
Smad2 GWGAEYR[HeavyR] 424.6998 477.2326 y3
Smad2 GWGAEYR[HeavyR] 424.6998 548.2697 y4
Smad2 GWGAEYR[HeavyR] 424.6998 605.2912 y5
Smad2 GWGAEYR[HeavyR] 424.6998 791.3705 y6
Smad2 VETPVLPPVLVPR 708.4346 371.2396 y3
Smad2 VETPVLPPVLVPR 708.4346 583.392 y5
Smad2 VETPVLPPVLVPR 708.4346 680.4448 y6
Smad2 VETPVLPPVLVPR 708.4346 777.4976 y7
Smad2 VETPVLPPVLVPR 708.4346 890.5817 y8
Smad2 VETPVLPPVLVPR 708.4346 989.6501 y9
Smad2 VETPVLPPVLVPR 708.4346 1086.703 y10
Smad2 VETPVLPPVLVPR 708.4346 1187.75 y11
Smad2 VETPVLPPVLVPR[HeavyR] 713.4388 381.2479 y3
Smad2 VETPVLPPVLVPR[HeavyR] 713.4388 494.3319 y4
Smad2 VETPVLPPVLVPR[HeavyR] 713.4388 593.4003 y5
Smad2 VETPVLPPVLVPR[HeavyR] 713.4388 690.4531 y6
Smad2 VETPVLPPVLVPR[HeavyR] 713.4388 787.5059 y7
Smad2 VETPVLPPVLVPR[HeavyR] 713.4388 900.5899 y8
Smad2 VETPVLPPVLVPR[HeavyR] 713.4388 999.6583 y9
Smad2 VETPVLPPVLVPR[HeavyR] 713.4388 1096.711 y10
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Supplementary Table 5 - 10TF transitions monitored
Transcription Factor Sequence Parent ion mass Product ion mass Transition
m/z [M+2H]2+ m/z [M+H]+ y-ion
Nr2C1 AYVEFQDYITR 702.8433 389.2502 y3
Nr2C1 AYVEFQDYITR 702.8433 552.3135 y4
Nr2C1 AYVEFQDYITR 702.8433 667.3404 y5
Nr2C1 AYVEFQDYITR 702.8433 795.399 y6
Nr2C1 AYVEFQDYITR 702.8433 942.4674 y7
Nr2C1 AYVEFQDYITR 702.8433 1071.51 y8
Nr2C1 AYVEFQDYITR 702.8433 1170.578 y9
Nr2C1 AYVEFQDYITR 702.8433 1333.642 y10
Nr2C1 AYVEFQDYITR[HeavyR] 707.8474 399.2584 y3
Nr2C1 AYVEFQDYITR[HeavyR] 707.8474 562.3217 y4
Nr2C1 AYVEFQDYITR[HeavyR] 707.8474 677.3487 y5
Nr2C1 AYVEFQDYITR[HeavyR] 707.8474 805.4073 y6
Nr2C1 AYVEFQDYITR[HeavyR] 707.8474 952.4757 y7
Nr2C1 AYVEFQDYITR[HeavyR] 707.8474 1081.518 y8
Nr2C1 AYVEFQDYITR[HeavyR] 707.8474 1180.587 y9
Nr2C1 AYVEFQDYITR[HeavyR] 707.8474 1343.65 y10
Nr2C1 SPLAATPTFVTDSETAR 882.4441 347.2032 y3
Nr2C1 SPLAATPTFVTDSETAR 882.4441 476.2458 y4
Nr2C1 SPLAATPTFVTDSETAR 882.4441 563.2778 y5
Nr2C1 SPLAATPTFVTDSETAR 882.4441 678.3047 y6
Nr2C1 SPLAATPTFVTDSETAR 882.4441 779.3524 y7
Nr2C1 SPLAATPTFVTDSETAR 882.4441 878.4208 y8
Nr2C1 SPLAATPTFVTDSETAR 882.4441 1223.59 y11
Nr2C1 SPLAATPTFVTDSETAR 882.4441 1395.675 y13
Nr2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 573.2861 y5
Nr2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 789.3607 y7
Nr2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 888.4291 y8
Nr2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 1136.545 y10
Nr2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 1233.598 y11
Nr2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 1334.646 y12
Nr2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 1405.683 y13
Nr2C1 SPLAATPTFVTDSETAR[HeavyR] 887.4482 1476.72 y14
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Supplementary Table 5 - 10TF transitions monitored
Transcription Factor Sequence Parent ion mass Product ion mass Transition
m/z [M+2H]2+ m/z [M+H]+ y-ion
Nfib EDFVLTVTGK 554.7978 305.1814 y3
Nfib EDFVLTVTGK 554.7978 404.2498 y4
Nfib EDFVLTVTGK 554.7978 505.2975 y5
Nfib EDFVLTVTGK 554.7978 618.3815 y6
Nfib EDFVLTVTGK 554.7978 717.45 y7
Nfib EDFVLTVTGK 554.7978 864.5184 y8
Nfib EDFVLTVTGK 554.7978 979.5453 y9
Nfib EDFVLTVTGK[HeavyK] 558.8049 313.1956 y3
Nfib EDFVLTVTGK[HeavyK] 558.8049 412.264 y4
Nfib EDFVLTVTGK[HeavyK] 558.8049 513.3117 y5
Nfib EDFVLTVTGK[HeavyK] 558.8049 626.3958 y6
Nfib EDFVLTVTGK[HeavyK] 558.8049 725.4642 y7
Nfib EDFVLTVTGK[HeavyK] 558.8049 872.5326 y8
Nfib EDFVLTVTGK[HeavyK] 558.8049 987.5595 y9
Nfib GIPLESTDGER 587.2909 304.161 y2
Nfib GIPLESTDGER 587.2909 361.1825 y3
Nfib GIPLESTDGER 587.2909 476.2094 y4
Nfib GIPLESTDGER 587.2909 577.2571 y5
Nfib GIPLESTDGER 587.2909 664.2891 y6
Nfib GIPLESTDGER 587.2909 793.3317 y7
Nfib GIPLESTDGER 587.2909 906.4158 y8
Nfib GIPLESTDGER 587.2909 1003.469 y9
Nfib GIPLESTDGER[HeavyR] 592.295 314.1693 y2
Nfib GIPLESTDGER[HeavyR] 592.295 371.1907 y3
Nfib GIPLESTDGER[HeavyR] 592.295 486.2177 y4
Nfib GIPLESTDGER[HeavyR] 592.295 587.2654 y5
Nfib GIPLESTDGER[HeavyR] 592.295 674.2974 y6
Nfib GIPLESTDGER[HeavyR] 592.295 803.34 y7
Nfib GIPLESTDGER[HeavyR] 592.295 916.424 y8
Nfib GIPLESTDGER[HeavyR] 592.295 1013.477 y9
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Transcription Factor Sequence Parent ion mass Product ion mass Transition
m/z [M+2H]2+ m/z [M+H]+ y-ion
ARID GGVSSIGTNTTTGSR 697.8471 319.1719 y3
ARID GGVSSIGTNTTTGSR 697.8471 420.2196 y4
ARID GGVSSIGTNTTTGSR 697.8471 521.2673 y5
ARID GGVSSIGTNTTTGSR 697.8471 622.3149 y6
ARID GGVSSIGTNTTTGSR 697.8471 736.3578 y7
ARID GGVSSIGTNTTTGSR 697.8471 837.4055 y8
ARID GGVSSIGTNTTTGSR 697.8471 894.427 y9
ARID GGVSSIGTNTTTGSR 697.8471 1007.511 y10
ARID GGVSSIGTNTTTGSR 697.8471 1094.543 y11
ARID GGVSSIGTNTTTGSR 697.8471 1181.575 y12
ARID GGVSSIGTNTTTGSR 697.8471 1280.644 y13
ARID GGVSSIGTNTTTGSR 697.8471 1337.665 y14
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 329.1802 y3
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 430.2278 y4
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 531.2755 y5
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 632.3232 y6
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 746.3661 y7
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 847.4138 y8
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 904.4352 y9
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 1017.519 y10
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 1104.551 y11
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 1191.583 y12
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 1290.652 y13
ARID GGVSSIGTNTTTGSR[HeavyR] 702.8512 1347.673 y14
ARID GLNLPTSITSAAFTLR 831.4646 389.2502 y3
ARID GLNLPTSITSAAFTLR 831.4646 536.3185 y4
ARID GLNLPTSITSAAFTLR 831.4646 607.3557 y5
ARID GLNLPTSITSAAFTLR 831.4646 678.3928 y6
ARID GLNLPTSITSAAFTLR 831.4646 765.4248 y7
ARID GLNLPTSITSAAFTLR 831.4646 866.4725 y8
ARID GLNLPTSITSAAFTLR 831.4646 979.5566 y9
ARID GLNLPTSITSAAFTLR 831.4646 1066.589 y10
ARID GLNLPTSITSAAFTLR 831.4646 1167.636 y11
ARID GLNLPTSITSAAFTLR 831.4646 1264.689 y12
ARID GLNLPTSITSAAFTLR 831.4646 1377.773 y13
ARID GLNLPTSITSAAFTLR 831.4646 1491.816 y14
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 399.2584 y3
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 546.3268 y4
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 617.364 y5
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 688.4011 y6
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 775.4331 y7
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 876.4808 y8
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 989.5648 y9
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 1076.597 y10
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 1177.645 y11
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 1274.697 y12
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 1387.781 y13
ARID GLNLPTSITSAAFTLR[HeavyR] 836.4688 1501.824 y14
Supplementary Note
Absolute copy number analysis of transcription factors during
cellular differentiation using a multiplex, targeted proteomics
approach
1 Statistical Modeling of protein binding
1.1 Statistical Mechanics Approach
The first question we want to address is how many protein molecules on average are bound to
specific sites in a given cell. The approach used to compute the occupancy of the different specific
sites is based on statistical mechanics. The main idea consists in enumerating all the different
configurations by which one can place N proteins on the accessible genome weighted by the
Boltzmann factor exp (−βE), which determines the likelihood of a configuration depending on its
energy E. Typically, this is achieved by means of the partition function which describes the statis-
tical properties of the system at thermodynamical equilibrium.
For the sake of simplicity, we made the following assumptions regarding our system: 1) we
considered only one species of protein, 2) all the proteins are assumed to be on the DNA [1, 2]
(either at specific sites or non-specific sites), 3) we do not consider hindrance between possibly
(but very unlikely) overlapping sites, 4) we model k categories of specific sites of different affinity
and all of these sites are assumed to be stronger than non-specific sites. Consequently, the system
can be parametrized in the following way. N is the total number of proteins in the nucleus, M the
size of the accessible genome, mi the number of specific sites of category i, ni the number of
proteins bound to sites of category i and the energy Ei associated with each category of sites i.
Therefore, the partition function Z of the system can be written as:
Z(N) =
N∑
n1,n2,...,nk=0
(
M −m
N − n
)
exp (−β(N − n)E0)
{
k∏
i=1
(
mi
ni
)
exp (−βniEi)
}
with m =
∑k
i=1mi the total number of specific sites, n =
∑k
i=1 ni the number of proteins bound
to specific sites and E0 the energy of an non-specific site. We can compute the average number
of proteins n¯i which are bound to specific sites of category i, with the derivative of the log of the
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partition function with respect to the energy Ei:
n¯i = − 1
β
∂
∂Ei
logZ(N)
It follows that the mean occupancy pi of a site i is given by:
pi =
n¯i
mi
In the following, it is convenient to rewrite the partition function in term of the affinities Xi =
exp (−β(Ei − E0)) of the different sites where the reference energy is chosen as the energy of
the non-specific sites E0. Consequently, the affinity of a non-specific site is X0 = 1 and the parti-
tion function is now given by:
Z(N) =
N∑
n1,n2,...,nk=0
(
M −m
N − n
){ k∏
i=1
(
mi
ni
)
Xnii
}
(1)
It is possible to compute an approximate expression for the average number of occupied specific
sites n¯i and their occupancy pi in two different regimes: either the number of proteins is in excess
compared to number of specific sites, or the number of specific sites is much larger than the
number of proteins.
1.2 Regime 1: Excess of Proteins over Specific Sites
In this first regime, we assume that the number of proteins N is much larger than the total number
of specific sites m but that N is still small compared to the size of the accessible genome M ,
namely:
M  N  m =
k∑
i=1
mi with mi ≥ ni ∀i ∈ {1, 2, ..., k}
The average number of occupied sites and the mean occupancy of a site can be derived rigorously
from the partition function by approximating the binomial coefficients. Here, we present a more
intuitive approach leading to the same results. By setting mi = 1 and mj = 0 ∀j 6= i in the partition
function (1), we can compute the probability P (b|N,m = 1) that a specific site i is bound given that
we have only one specific site in the genome and N proteins. We find that:
P (b|N,m = 1) =
N
MXi
M−N
M +
N
MXi
'
N
MXi
1 + NMXi
which is the famous Hill function where the occupation of the site depends on the concentration
of proteins N/M and the affinity of the site Xi. Since there are many proteins compared to the
number of specific sites, each site can be seen as independent from others, namely we neglect
the depletion of the protein pool due to binding at specific sites. Therefore, the average number of
specific sites which are occupied n¯i is given by P (b|N,m = 1) multiplied by the number of sites mi:
n¯i = mi
N
MXi
1 + NMXi
2
The mean occupancy pi = n¯i/mi of a site of category i is then identical to P (b|N,m = 1):
pi =
N
MXi
1 + NMXi
1.3 Regime 2: Excess of Specific Sites over Proteins
In the second regime, we assume that the number of specific sites mi and the number of non-
specific sites m0 = M − m are much larger than the number of proteins N . This can be stated
as:
M =
k∑
i=0
mi with mi  N ≥ ni ∀i ∈ {0, 1, ..., k}
From the partition function (1), one can compute the probability P (b|N = 1, {mi}) that one protein
is bound to a specific site given the set of specific sites {mi} and that the total number of proteins
is one, this probability is given by:
P (b|N = 1, {mi}) =
mi
M Xi
m0
M +
∑k
i=1
mi
M Xi
The probability that one protein is bound to a specific site now depends on the concentrations of
sites mi/M and the affinities Xi of the different sites. Since the number of sites is much larger than
the number of proteins, each protein can be considered as being independent from each other. The
average number of proteins n¯i which are bound to specific site i is then given by P (b|N = 1, {mi})
times the number of proteins N :
n¯i = N
mi
M Xi
m0
M +
∑k
i=1
mi
M Xi
Thus, the expression for the mean occupancy pi = n¯i/mi of a site of category i is similar that in
the first regime except that the denominator now depends on the concentrations of sites mi/M :
pi =
N
MXi
m0
M +
∑k
i=1
mi
M Xi
In the above expression, since X0 = 1, the denominator can be expressed in term of the average
affinity of the sites X¯ which depends on the distribution of affinities in the accessible genome
P (Xi) = mi/M , therefore we obtain:
pi =
N
MXi∑k
i=0
mi
M Xi
=
N
MX¯
Xi
1.4 Typical Parameters
The size of the accessible mice genome is typically less than 10% of the full genome, consequently
M ∼ 108 bp. Regarding the number of proteins, the measured number for PPARγ and RXRα were
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approximately in the range of N ∼ 103 proteins. The number of binding sites which were detected
is approximately m ∼ 103 sites [3], it is important to realize that those represent the stronger sites,
weaker sites are most likely not detected. Finally, the dissociation constant Kd is typically in the
order of µM for a non-specific site and nM for a strong site, consequently we can assume that a
strong site has an affinity roughly 103 times larger than a non-specific one [2].
Given those numbers, the first regime (Section 1.2) where the proteins are assumed to be in
excess is clearly not adequate, since the number of detected binding sites is in the range of the
number of proteins 103. Despite the fact that in our case the strongest sites might be fewer than the
number of proteins N , most of the sites will actually be in large excess compared to N , therefore
the second regime (Section 1.3) is appropriate to describe the occupancies of the different sites
in our ChIP-seq experiments. In fact, it also predicts very well the behavior of the strongest sites
(cf. Supplementary Fig. 15), because the strongest sites are not saturated due to the competition
with the very large number of less favorable sites. Consequently, we expect a linear relationship
between the occupancy and the affinity of the sites.
pi =
N
MX¯
Xi (2)
If the non-specific sites dominate, namely the affinities Xi decrease fast enough compared to the
increase in number of sites mi, then the mean affinity of the sites will be close to one X¯ ' 1. This
might not be true in practice, we will see later how to estimate the coefficient X¯ (Section 2.4).
2 Link between ChIP-seq signal and affinity
2.1 Simple ChIP-seq Model
In a ChIP-seq experiment, the signal, i.e. the average number of fragments Si for any sites of type
i, should reflect the mean occupancy of the sites pi. Of course, the occupancy is not the only
contribution to the signal, the efficiency and specificity of the antibody as well as the number of
cells play an important role, but those effects can be implicitly included in a simple model:
Si = Api +B
where as a first approximation the signal Si is proportional to the occupancy pi plus some back-
ground B [4]. Since in our case the occupancy goes as pi ' NMX¯Xi, we expect a correlation
between the affinity Xi and the mean signal Si:
Si =
AN
MX¯
Xi +B (3)
2.2 Link between Energy and PWM Log-likelihood
In practice, one does not necessarily know the binding energy of the sites of interest, but if we know
the position weight matrix (PWM), it is then possible to make the link between each sequence and
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its binding energy [4, 5]. In the PWM framework the binding energy of the site ε = −βE is assumed
to be the sum of independent contributions of each base εk(b). If the binding sites are characterized
by an average energy ε¯, one can express the likelihood q(s) that a randomly chosen binding sites
of length L will have sequence s:
q(s) =
L∏
k=1
exp (λεk(sk))∑
b exp (λεk(b))
=
L∏
k=1
fk(sk)
where the selection parameter λ ensures that ε¯ =
∑
s ε(s)q(s) and fk(b) is the frequency of obser-
vation of base b at position k. Therefore, the log-likelihood z(s) = log (q(s)) is related to energy by
the factor λ plus a constant:
z = log (q) = λε+ cst
We can express the energy of the sites with respect to the consensus sequence which is assumed
to be the best sequence with the largest log-likelihood zmax = log (qmax):
−β(Ei − Ec) = 1
λ
(zi − zmax)
where Ec is the energy of the consensus. Finally the affinities Xi in term of the log-likelihood are
given by:
Xi = Xmax exp
(
1
λ
(zi − zmax)
)
(4)
where Xmax = exp (−β(Ec − E0)) is the affinity of the consensus sequence. In the following we
will assume that Xmax = 103 which is the typical magnitude for the strongest sites compared to
non-specific ones [2].
2.3 Estimating the Parameter λ
Using our simple model for the ChIP-seq signal, we can now relate the log-likelihood score zi of
the different sites with the signal. Indeed, from equation (3) and (4), the signal is given by:
Si = A′ exp
(
1
λ
zi
)
+B (5)
where A′ is a new proportionality constant. Therefore, it is possible to estimate the λ parameter of
the PPARγ motif from the ChIP-seq signal. This enables us to make the link between the energy
scale and the log-likelihood score.
We focused on PPARγ at day 0, day 2 and day 6, we used the motif from the JASPAR CORE
database [6] and we screened the accessible genome with FIMO [7] from the MEME suite for all
the sequences which had a p-value < 10−3. Due to limited sequencing depth of available DHS
data, we used the H3K27ac regions from Tarjei et al. [8] as a proxy for the accessible genome. We
verified that these regions cover most of the reported PPARγ sites. The size of these regions were
similar between the three time points, M0 = 5.97 · 107 bp, M2 = 6.99 · 107 bp and M6 = 6.76 · 107
bp. For each of those three time points, we estimated the parameter λ using the mean ChIP-seq
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signal for different category of sites, namely we separated the sequences in 6 bins of log-likelihood
covering the range obtained with FIMO (cf. Supplementary Fig. 16). We estimated the background
level for the three time points by taking a window of 200 bp shifted by 1000 bp from each peak, we
obtained B0 = 1.273, B2 = 1.146 and B6 = 2.004. Since there is not much ChIP signal at day 0
(very few PPARγ proteins before induction), we estimated the λ parameter as the average of day
2 and 6, we obtained λ ' 3.36.
2.4 Estimating X¯
In the second regime, where the specific sites are in excess compared to proteins, we showed in
Section 1.3 that the occupancy can be expressed as follows:
pi =
N
MXi∑k
i=0
mi
M Xi
=
N
MX¯
Xi
where X¯ is actually the average affinity of the sites X¯ =
∑k
i=0XiP (Xi). We estimated X¯ using the
theoretical distribution of sites with respect to the log-likelihood ρ(z) given by the PWM of PPARγ:
X¯ =
∫ zmax
zmin
X(z)ρ(z)dz (6)
where X(z) is given by equation (4) above the non-specific threshold z? = zmax − λ log (Xmax)
which corresponds to the limit where non-specific binding starts to dominate. Therefore, X(z) can
be expressed as:
X(z) =
{
Xmax exp
(
1
λ(z − zmax)
)
z > z?
X0 = 1 z ≤ z?
(7)
We approximated the probability density distribution ρ(z) as a normal distribution N (z; z¯, σz). We
sampled the distribution from the PWM in order to estimate the mean z¯ = −32.69 and the standard
deviation σz = 5.33. Performing the integral (6), we obtained X¯ ' 1.93. A correction to the normal
distribution based on the saddle-point approximation [9] did not change much the result (X¯ ' 1.97).
3 Predicting the number of binding sites
3.1 Occupancy Threshold
In order to predict the number of binding sites that should be detected in our ChIP-seq data, we
assume that there is a certain occupancy threshold pt above which we will start detecting the sites.
We can now express this threshold in term of the log-likelihood. Indeed, from equation (2) and (4)
the occupancy can be expressed as :
pt =
NXmax
MX¯
exp
(
1
λ
(zt − zmax)
)
(8)
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Inverting this relation gives the log-likelihood threshold zt:
zt = λ log
(
MX¯pt
NXmax
)
+ zmax (9)
Given this threshold zt and the density of sites with respect to the log-likelihood, we will be able
to predict the number of binding sites Nsites(zt), by counting how many sites in the accessible
genome (section 2.3) have a log-likelihood larger than zt.
3.2 Number of Binding Sites
We used the same approach than the previous section 2.3 to screen the accessible genome in
order to model the cumulative number of sites Nsites(z) with respect to the log-likelihood z. In
order to obtain a smooth representation, it is convenient to parametrize the tail of Nsites(z) as a
power-law:
Nsites(z) = C(z0 − z)k (10)
where k is the power law exponent, C and z0 are constants. We estimated the parameters C, k
and z0 for PPARγ at day 0, day 2 and day 6 using non-linear least squares, this representation
gives excellent results (cf. Supplementary Fig. 17). Knowing the log-likelihood threshold zt above
which we should start to detect sites, we can predict the number of sites by evaluating (10) in zt:
Nsites(zt) = C(z0 − zt)k with zt = λ log
(
MX¯pt
NXmax
)
+ zmax
We determined the log-likelihood threshold zt for the three different time points using equation (9)
and the measured proteins copy number N0 = 2376, N2 = 6095, N6 = 7462 which were average
over the three biological replicates. The occupancy threshold pt is a free parameter which was
assumed to be the same between each time points, it was chosen so that the squared error be-
tween the detected number of sites and the predicted one is minimized, we obtained pt ' 1.35%
(cf. Supplementary Fig. 18) which is comparable to % input values in a good ChIP experiment
[10]. We remind the reader that % input would correspond to occupancy in the case of an ideal
ChIP (100% efficient antibody).
3.3 Independent Validation
We tested our model with a different set of ChIP-seq data provided by Siersbaek et al. [11] al-
though they only performed ChIP-seq on PPARγ at day 2 and 6 after induction. Following a similar
approach than in section 2.3 and using the same DNA accessibility marks, we fitted the selection
parameter and obtained λ ' 2.69. Using the measured copy number as in section 3.2 and as-
suming no detected PPARγ binding site at day 0, we then minimized the squared error between
the detected and predicted number of binding sites for the three time points, and we obtained an
occupancy threshold of pt ' 0.98% (cf. Supplementary Fig. 18) which is in the same range as the
value we obtained in the previous section (section 3.2). Despite the new selection parameter, the
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prediction for both data set are in good agreement. If we average both the selection parameter and
the number of detected binding sites from [3] and [11], the model is then in excellent agreement
with the average detected binding sites (cf. Supplementary Fig. 18).
3.4 Discussion
Our model makes a few assumptions that merit discussions. First, since we did not know the affin-
ity of the best sites in vivo, we assumed that the strongest sites, namely sites corresponding to the
consensus sequence, were 1000 fold stronger than non-specific sites (Xmax = 103), which is real-
istic [2]. In addition, we computed how the predicted occupancies pi depend on this number trough
the ratio Xi/X¯ (cf. Supplementary Fig. 19). We observe two regimes: one when Xmax > 103
where Xi/X¯ becomes insensitive to Xmax. Secondly when Xmax < 103 (which is unlikely biologi-
cally), the predicted occupancies would decrease, but this could be compensated by lowering the
occupancy threshold pt. Thus, our conclusions on the behavior of the number of sites vs proteins
number do not strongly depend on the presumed value of Xmax.
As a second assumption, we did not model explicitly the dimer between PPARγ and RXRα,
which is justified since PPARγ is in limiting amounts. Moreover, we neglected the hindrance due
to other protein species which could distort the predicted occupancies. Indeed, many proteins are
interacting with DNA and thereby obstruct the accessible sites [12]. In particular, this might reduce
the size of the genomic regions that are effectively accessible for PPARγ and consequently the
occupancy of the sites might be higher. Nevertheless, the values derived for the occupancy (2) will
not be strongly affected since the product MX¯ would only be mildly changed if we assume that
additional proteins would essentially deplete non-specific or weak PPARγ binding sites. Indeed, if
we assume that one third of the transcription factors of the mouse (∼ 850 TFs) are expressed at an
average level of 104 copies [13], we would obtain NTF ' 8.5 · 106 molecules in the nucleus which
is still small compared to the measured accessible genome size M ' 6.8 · 107.
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Supplementary Figure 15. Top: site occupancy p with respect to affinity X, computed with the
approximate expression (2) and exactly from the partition function (1), for a reduced system with
comparable concentration of proteins than PPARγ at day 6 (cf. Section 2.3). The theoretical
distribution of sites with respect to the affinity given by the PWM of PPARγ was discretized in
k = 20 categories, covering the range of affinities [X0 = 1, Xmax = 1000]. Bottom: comparison
between the approximate and exact occupancy for the same system. Even if the stronger sites are
in low amount compared to the number of proteins (m19 = 1, m18 = 2, ..., m14 = 80 < N = 100),
the approximation (2) still predicts very well their occupancy.
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Supplementary Figure 16. Left column: fitting of the selection parameter λ from the mean ChIP-
seq signal at day 0, day 2 and day 6 in log-space. Right column: representation of expression (5)
in real space, using the estimated parameters on the left.
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Supplementary Figure 17. Left: cumulative number of sites found in H3K27ac regions with FIMO
[7] at day 0, day 2 and day 6. Right: cumulative number of sites approximated as a power law, this
representation gives excellent results R2 > 0.99.
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Supplementary Figure 18. Left: predicted number of PPARγ binding sites based on Nielsen et
al. ChIP-seq data [3]. Right: predicted number of PPARγ binding sites based on Siersbaek et
al. ChIP-seq data. [11] Bottom: predicted number of PPARγ binding sites compared to average
number of detected sites in both [3] and [11].
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Supplementary Figure 19. Effect of Xmax on the ratio Xmax/X¯ which appears in the occupancy
expression (8). If Xmax > 103, the ratio becomes insensitive to Xmax. On the other hand, if
Xmax < 103, the occupancy will decrease.
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